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ABSTRACT 
 
The complex process by which cancer cells invade local tissue and metastasise is 
responsible for approximately 90% of cancer related deaths. The cell biological 
events that underlie this transition to malignancy are driven by invariable alterations 
within the genome, however relatively little is known about the genetic determinants 
involved. If identified, novel genes which perturb the rate of tumour progression 
could become potential targets for future therapeutic intervention.  
Using a novel in vivo system, it is possible to characterise the behaviour of 
transformed cells during the early stages of tumour development and follow these 
cells in real time, thus improving our understanding of the critical events that initiate 
cell proliferation, tumour cell invasion and metastasis. Using Drosophila as a model 
organism it is possible to generate neoplastic tumours within the dorsal thorax 
whereby clones of transformed cells are homozygous mutant for a specific tumour 
suppressor gene. By specifically labelling these transformed cells with GFP, their 
behaviour can be observed in high temporal and spatial resolution within the living 
epithelium. RNAi technology can also be employed to simultaneously knock-down 
expression of an additional gene specifically within the mutant tissue. This forms the 
basis of a large-scale screen for novel genes that may promote tumour progression in 
this epithelium.  
The screen is now almost complete and so far we have screened through almost 500 
genes, the majority of which have previously been implicated in cancer but remain 
uncharacterised. We have observed a wide range of phenotypes, with genes affecting 
cell proliferation, invasion, cell shape, actin organisation, junction integrity and 
epithelial multilayering. By setting ‘thresholds’ for particular phenotypes ‘hits’ have 
been identified which drastically enhance tumour progression, and these genes are in 
the process of being fully characterised to further our understanding of their role in 
tumour progression. 
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Chapter 1 Introduction 
Recent statistics suggest that 1 in 2 people will be affected by cancer during the 
course of their lifetime, with someone being diagnosed with the disease every 2 
minutes ("Cancer Research UK," 2016) . There are more than 200 different types of 
cancer arising from a multitude of various cell types within the body which acquire 
the ability to grow in an uncontrolled manner, forming tumour masses. As a result of 
extensive cancer research using both human and animal models, the diagnosis and 
treatment of the disease has improved significantly in the last 40 years ("Cancer 
Research UK," 2016). However at a biological level our knowledge of the genes 
involved and pathways implicated during tumour progression remain poorly 
understood. 
 
1.1 Tumour Formation 
The focus of my PhD research is on understanding the molecular basis of tumour 
progression, and more specifically invasion. Therefore in my introduction I will give a 
brief overview of the molecular basis of tumourigenesis and tumour progression, 
with a more detailed focus of cancer cell invasion.  
 
The human genome is organised into 23 pairs of chromosomes consisting of large 
strands of DNA, found in the nucleus of all cells. Genes define the protein-coding 
segments of chromosomal DNA, and ultimately determine cell fate and maintain 
tissue homeostasis (Fraser & Bickmore, 2007). Cancer arises through a succession of 
invariable alterations in the genome, capable of driving the progressive transition of 
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cells to malignancy. Genetic alterations in 2 distinct classes of genes responsible for 
tightly regulating progression through the cell cycle can result in uncontrolled 
proliferation and cellular transformation (Bishop, 1996; Hanahan & Weinberg, 2000; 
Vogelstein & Kinzler, 2004). In normal cell cycle control, proto-oncogenes and tumour 
suppressor genes act at checkpoints to respectively stimulate or inhibit cellular 
growth, or promote differentiation.  Dominant gain-of-function mutations in proto-
oncogenes therefore drive continuous cell division, whilst the recessive inactivation 
of tumour suppressor genes prevents differentiation, thus leading to hyper-
proliferation and a sustained growth advantage over neighbouring wild-type cells 
(Hanahan & Weinberg, 2000; Lodish, 2000). Tumour progression in humans is a multi-
step process in which malignant growth is dictated by the manifestation of various 
modifications to cell physiology. As first described by Hanahan and Weinberg (2000), 
the ‘hallmarks of cancer’ propose that cancer cells must acquire at least six essential 
biological capabilities (Fig. 1.1) for the efficient conversion of normal cells into 
malignant derivatives. In 2011, Hanahan and Weinberg proposed an additional four 
essential hallmarks. Acquisition of these vital hallmarks ensures that incipient cancer 
cells are not eliminated through the cells natural defence mechanisms. 
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Figure 1.1 Hanahan and Weinberg’s ‘Hallmarks of Cancer’ 
The diagram illustrates the essential capabilities that cancer cells must acquire in 
order to form, survive, grow and progress into highly malignant tumours. The image 
also depicts some of the key regulators and pathways involved in tumour 
progression.  
 
1.1.1 Mitogenic signalling 
Mitogens convey signals to cells in order for them to progress through the cell cycle 
and proliferate in a controlled manner (Alberts, 2002). During the intricately 
regulated cell cycle chromosomal DNA is duplicated and precisely segregated into 
two daughter cells which are genetically identical (Fig. 1.2) (Morgan, 2006). In order 
to sustain continuous growth, cancer cells can adopt autocrine signalling whereby 
they are able to synthesise and respond to their own mitogenic growth factors 
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(Sporn, 1996). This generates a positive feedback loop which enables cancer cells to 
progress through the cell cycle and grow without extracellular stimulation. 
Additionally, tyrosine-kinase receptors which are usually responsible for conveying 
mitogen signals are often overexpressed in cancer cells, such that even with ambient 
levels of growth factors the cell is hyper-responsive and continues to proliferate 
(Hanahan & Weinberg, 2000). 
 
One of the main regulators of cell cycle progression is a family of serine/threonine 
proteins called cyclin-dependent kinases (CDKs) (Malumbres & Barbacid, 2009). As 
their name suggests the kinase activity of these proteins is controlled by another 
family of proteins called cyclins. CDKs comprise two subunits: the catalytic core and 
cyclin-binding site. The catalytic subunit contains an ATP-binding pocket and 
activating T-loop motif. In its inactivated state the T-loop blocks the catalytic domain 
preventing substrate activation. However, when the appropriate cyclin binds to the 
CDK the T-loop becomes displaced which in turn exposes the catalytic site allowing 
CDK-cyclin complexes to actively regulate the cell cycle (Lim & Kaldis, 2013). The role 
of CDKs is to phosphorylate and activate specific proteins which are required for 
various phases in the cell cycle, which, until activated or synthesised prevents the cell 
from progressing through the cell cycle. While CDKs are present throughout the 
process of cell replication and division, temporal regulation is determined by cyclins 
which are synthesised and degraded at different points throughout the cell cycle. 
During early G1 phase, cells are mitogen-dependent, requiring extracellular growth 
factors for progression past the ‘Restriction point’ which defines entry into S phase. 
During G1 cyclin E must be synthesised in order for cells to be committed to S phase, 
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for this several biochemical reactions take place which are tightly regulated. The 
transcription factor E2F binds to the promoter of cyclin E to regulate its transcription. 
However, retinoblastoma (Rb) in turn determines the activity of E2F (Weinberg, 
1995). In its hypophosphorylated state Rb binds to E2F which prevents downstream 
transcription of cyclin E. The G1-CDK complex, which comprises cyclin D with either 
CDK4 or CDK6, controls synthesis of cyclin E by regulating the phosphorylation state 
of Rb. When activated, the G1-CDK complex phosphorylates Rb causing it to 
dissociate from E2F, enabling the transcription of cyclin E. Once cyclin E is abundant 
in the cell it can bind to CDK2 forming the G1/S CDK complex and allowing cells to 
irreversibly pass through the ‘Restriction point’ (Dyson, 1998; Harbour & Dean, 2000; 
Ohtani, DeGregori, & Nevins, 1995). In this way CDK/cyclin complexes regulate a cells’ 
progression through the cell cycle and are in turn tightly regulated. 
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Figure 1.2 Cell Cycle 
The diagram illustrates the eukaryotic cell cycle, including stages of mitosis, 
checkpoints and cell cycle regulators. 
 
Extracellular mitogens can regulate the cell cycle in early G1 phase only; however 
they can also permit cells to enter the cell cycle from a quiescent state (G0), while 
anti-mitogenic signals can cause cell cycle arrest and entry into G0 (Alberts, 2002). 
Epidermal growth factor (EGF) signalling provides a good example of the complexity 
of signalling pathways and how extracellular mitogenic signals can influence cell cycle 
progression (Normanno et al., 2006). When EGF binds to cell surface EGF-receptors 
(EGFR) a cascade of biochemical reactions take place. Initially, the receptor dimerises 
which results in transphosphorylation of a cytoplasmic tyrosine residue on one of the 
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receptor subunits. Phosphorylated tyrosines specifically bind to proteins containing 
src-homology 2 (SH2) domains, such as the growth factor receptor bound protein 2 
(Grb2) (Lowenstein et al., 1992). The guanine-nucleotide exchange factor (GEF) Son 
of Sevenless (SOS) is then recruited to the plasma membrane where it activates Ras 
(Margolis & Skolnik, 1994). Ras is a small GTPase with central roles in signalling 
cascades associated with the cell cycle, growth and survival (Coleman, Marshall, & 
Olson, 2004). Once activated, Ras activates the mitogen-activated-protein-kinases 
(MAPK) signalling pathway which leads to the transcription of various proteins, 
including Myc, a transcription factor which regulates the transcription of cyclin D 
(Zhang & Liu, 2002). Synthesis of cyclin D promotes progression from G1 to S, and 
therefore cell proliferation (Daksis, Lu, Facchini, Marhin, & Penn, 1994). This 
signalling pathway demonstrates the complexity of cell cycle regulation and the sheer 
number of different protein complexes involved.  
 
Equally, as well as sustaining continuous mitogenic growth promoting signals, cancer 
cells must be able to avoid anti-proliferative signals, thus preventing them from 
entering a quiescent or post-mitotic state (Hanahan & Weinberg, 2000). Inhibitors of 
cell cycle transition act primarily to prevent G1 to S transition and typically converge 
on the Rb pathway. There are several ways that cancer cells elicit their insensitivity to 
growth signals via the Rb pathway. Firstly, loss of or mutations in TGF-βR, or loss of 
Smad4 (see below), block TGF-β signalling which in turn promotes the 
phosphorylation of Rb. This causes Rb to release E2F enabling the transcription of 
various proteins required for transition through the ‘Restriction point’ in the cell 
cycle. Cells are particularly sensitive to a defective Rb pathway and increased E2F 
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activity. High E2F activity drives expression of genes involved in the apoptotic 
program, including p14 ARF (an Mdm2 inhibitor) (Weinberg, 1995). Additionally, loss 
of TGF-β prevents inhibition of the proto-oncogene c-myc and upregulation of CDK 
inhibitors (Fynan & Reiss, 1993; Moses, Yang, & Pietenpol, 1990). Due to its direct 
effects on cell proliferation, de-regulation of Rb signalling is a major contributor to 
human cancer with Rb seen to be downregulated in approximately 80% of human 
cancers (Weinberg, 1995). Additionally cancer cells can avoid entering post-mitotic 
states, through the over-expression of Myc. Abundant Myc results in the formation of 
Myc:Max heterodimers. This dimerisation prevents Max forming its normal complex 
with Mad which functions to induce differentiation signals (Foley & Eisenman, 1999; 
Grinberg, Hu, & Kerppola, 2004; Nair & Burley, 2003). To summarise, by sustaining 
growth signals and evading anti-proliferative signals cancer cells are able to 
continuously proliferate in an uncontrolled manner.  
 
As their name suggests CDK inhibitors negatively regulate the activity of CDKs. The 
two main classes of inhibitors are the Ink4 family (p16INK4a, p15INK4b, p18INK4c, p19INK4d) 
and Cip/Kip family (p21CIP1, p27KIP1, p57KIP2) which inhibit cyclin-CDK complexes (Sherr 
& Roberts, 1999). Transforming growth factor β (TGF-β) signalling is a prime example 
of extracellular signalling which activates CDK inhibitors to block the transition from 
G1 to S phase. Similar to EGF signalling, TGF-β binds to the serine/threonine kinase 
transmembrane receptor TGF-β-receptor (TGFβR) which phosphorylates cytoplasmic 
Smad proteins (Heldin, Miyazono, & ten Dijke, 1997). Once phosphorylated Smads 
are able to translocate into the nucleus where they act as transcription factors. One 
of the proteins that is transcribed following Smad activation is the CDK inhibitor p21, 
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resulting in the cell cycle arrest (Pardali, Kowanetz, Heldin, & Moustakas, 2005). Cell 
cycle arrest can also be initiated when cells contain damaged DNA. Following DNA 
damage (including UV and ionising radiation) the transcription factor p53 becomes 
phosphorylated (Siliciano et al., 1997). Normally p53 is present in low levels and 
quickly turned over in the cell. This is due to its binding with the E3 ubiquitin protein 
ligase mouse double minute-2 (Mdm2) which sequesters in the transactivation 
domain of P53 (between Glutamate17 and Proline27) (Meek, 1998). Mdm2 binding 
results in the degradation of p53. However, under stress p53 becomes 
phosphorylated by DNA dependent protein kinase (DNA-PK) at sites within the 
transactivation domain, this prevents Mdm2 binding and thus the abnormal 
accumulation of p53 in the nucleus (Mayo, Turchi, & Berberich, 1997). Abundant p53 
can transcriptionally activate p21 to initiate cell cycle arrest, and when sustained for 
a longer period of time p53 can activate the Bcl-2 associated protein (Bax) which 
induces the release of cytochrome c from the mitochondria which initiates the 
apoptotic cascade (Fridman & Lowe, 2003; Miyashita et al., 1994). (Section 1.1.2). 
 
1.1.2  Apoptotic signalling 
Programmed cell death (apoptosis) is a homeostatic energy dependent mechanism 
which is essential for tissue development and cell turnover (Alberts, 2002). It can also 
be initiated in times of stress, such as DNA damage, hypoxia and prolonged oncogene 
activation. For this reason, it is essential that cancer cells prevent activation of the 
apoptotic cascade (Fig. 1.3) if they are to survive (Hanahan & Weinberg, 2000). The 
apoptotic cascade is a complex succession of biochemical reactions resulting in cell 
shrinkage, pyknosis, cytosolic extrusion, nuclear fragmentation, cell budding and 
26 
 
phagocytosis (Wyllie, Kerr, & Currie, 1980). Both extrinsic and intrinsic signalling 
pathways can signal apoptotic machinery, both of which converge on the execution 
pathway and ultimately result in cell death. The extrinsic apoptotic pathway involves 
a host of proteins belonging to the tumour necrosis factor receptor (TNFR) family 
which comprises a group of death receptors with homologous ‘death domains’ 
including FasR and TNFR-1 (Ashkenazi & Dixit, 1999). Upon binding its ligand (Fas L), 
FasR recruits the cytoplasmic Fas associated protein with death domain (FADD) an 
adaptor protein which in turn cleaves pro-caspase 8 also known as a gatekeeper 
caspase. Caspases are a family of cysteine proteases existing as proenzymes, which, 
until cleaved remain inactive (Thornberry & Lazebnik, 1998). Unlike the extrinsic 
pathway, the intrinsic pathway mediates apoptotic signalling via mitochondria. A 
variety of signals induced by cell stress or lack of sufficient hormones and cytokines 
impinge on the mitochondria and as a result alter the mitochondrial membrane 
potential (Brenner & Mak, 2009). This causes the mitochondrial permeability 
transition pore (MPT) to open, releasing cytochrome c which is a key regulator in the 
apoptotic cascade. Once released cytochrome c forms the apoptosome, a complex 
consisting of Apaf-1 and pro-caspase 9. Formation of the apoptosome results in 
cleavage of caspase 9, another gatekeeper caspase, which in turn initiates the 
execution pathway (Cain, Bratton, & Cohen, 2002). The apoptotic pathway is 
stringently regulated by pro-apoptotic (Bcl-2, Bcl-XL, Bcl-W) and anti-apoptotic (Bax, 
Bak, Bid, Bim) proteins. These B-cell lymphoma 2 (Bcl-2) family proteins largely 
mediate apoptosis by regulating mitochondrial permeability (Chipuk, Moldoveanu, 
Llambi, Parsons, & Green, 2010). One of the most notable regulators of apoptosis is 
p53 which responds to stress signals to induce cell death by upregulating anti-
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apoptotic genes including Bax to stimulate the release of cytochrome c. Functionally 
inactivated p53 is detected in more than 50% of human cancers, rendering cells 
insensitive to stress signals, and able to evade apoptosis (Levine, 1997). Additionally, 
overexpression of Bcl-2 promotes cancer cell survival via cooperative effects with c-
myc and through the concerted inhibition of cytochrome c release (Vaux, Cory, & 
Adams, 1988). Anti-apoptotic proteins also include the inhibitor of apoptosis (IAP) 
family which includes XIAP, C-IAP1, c-IAP2, NAIP and survivin. These proteins 
preferentially bind to procaspase -3 and -7 which prevent cleavage and subsequent 
initiation of apoptosis. Moreover, these proteins are commonly overexpressed in 
human cancer to prolong the life of cancer cells (Tamm et al., 1998). Therefore, by 
preventing apoptosis cancer cells are able to continue proliferating, bypassing one of 
the body’s natural defence programmes.  
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Figure 1.3 Apoptotic cascade 
The extrinsic pathway is initiated by extracellular signals leading to cleavage of pro-
caspase 8. Alternatively the intrinsic pathway responds to cell stress or other factors 
and impinges on the mitochondria. Release of cytochrome c ultimately leads to the 
cleavage of pro-caspase 9. Both caspase 8 and 9 cleave several execution caspases 
leading to cell death.  
 
1.1.3  Replicative potential 
In 1965 Hayflick demonstrated that in culture, normal cells exhibit a limited 
replicative potential, whereby human fibroblasts ceased growing over many rounds 
of cell replication. For normal tissue homeostasis this replicative potential is essential 
in preventing cancer in renewable tissues which undergo many rounds of replication 
(Shay & Wright, 2000). Telomeric DNA protectively caps the ends of chromosomes 
and consists of multiple 5’ –TTAGGG- 3’ sequence repeats (Moyzis et al., 1988). 
During each succession of the cell cycle 50-100bp are lost as a result of inefficient 
replication of the 3’ end by DNA polymerase. In normal cells, single stranded G-rich 
tails left at the ends of telomeres can protect itself by generating ‘T-loops’ in which 
the telomere folds back on itself, this leads to the single stranded tail invading the 
double stranded telomeric DNA (Griffith et al., 1999). The 6 subunit shelterin complex 
then binds to T-loops and protects the DNA from being recognised and treated as 
‘damaged DNA’ by the double –stranded-DNA repair machinery (de Lange, 2005). 
However, due to the successive loss of telomeric DNA following each round of cell 
division, eventually telomeric DNA becomes too short and the unprotected 
chromosomal ends fuse together in karyotypic disarray through breakage-fusion-
bridge cycles, resulting in chromosomal instability, senescence and cell death 
(Counter et al., 1992). Most cancer calls are considered to be ‘immortal’ due to their 
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ability to replicate without restriction, and in most cases this is due to increased 
expression of telomerase. Telomerase, a reverse transcriptase, maintains telomeric 
DNA by adding hexanucleotides to the chromosomal ends, and in this way cells can 
continue to proliferate uncontrollably. In a small percentage of cancer cells, unlimited 
replication is achieved through an alternative telomere lengthening (ALT) 
mechanism, which involves the homologous recombination of adjacent telomeres 
(Bryan, Englezou, Gupta, Bacchetti, & Reddel, 1995; Cesare & Reddel, 2010).  
 
1.1.4 Angiogenesis  
Another key hallmark that cancer cells must overcome in their transition to 
malignancy is angiogenesis (Hanahan & Weinberg, 2000). Angiogenesis defines the 
process in which new blood vessels are formed in order to provide a tissue with 
essential nutrients and oxygen. In normal tissues, angiogenesis is tightly regulated by 
maintaining a balance between activating or inhibitory angiogenic signals (Bergers & 
Benjamin, 2003; Duffy, 1996). A prerequisite to neoplastic tissue growth is the ability 
of tumours to mediate the ‘angiogenic switch’, resulting in the upregulation of pro-
angiogenic factors and down-regulation of anti-angiogenic factors (Hanahan & 
Folkman, 1996). For example, loss of p53 in many cancers results in decreased 
expression of the angiogenic inhibitor thrombospondin-1, while activated oncogenic 
Ras in tumours leads to the upregulation of vascular endothelial growth factor (VEGF) 
which promotes growth of neo-vasculature (Dameron, Volpert, Tainsky, & Bouck, 
1994; Rak et al., 2000; Volpert, Dameron, & Bouck, 1997). As well as providing the 
growing tumour with essential nutrients, this novel vasculature also provides a direct 
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route for cancer cells to spread to other parts of the body (Zetter, 1998) (Section 
1.2). 
 
1.1.5 Genomic Instability 
Hanahan and Weinberg (2011) later proposed additional hallmarks that must be 
overcome during tumour progression including cancer genomic instability. As 
discussed, tumour progression is defined by the accumulation of more than one 
genetic alteration and the concerted co-operation between up-regulated oncogenes 
and down-regulated tumour suppressor genes. Additionally, genome instability 
within cancer cells is generated through the down-regulation of so called ‘caretaker 
genes’ which detect DNA damage and activate appropriate repair machinery (Ciccia & 
Elledge, 2010; Kinzler & Vogelstein, 1997; Negrini, Gorgoulis, & Halazonetis, 2010). 
This renders cancer cells hypersensitive to mutagenic agents and unable to detect 
and repair genomic alterations. One of the most common forms of genomic 
instability: chromosomal instability (CIN) sees the rate of accumulated chromosomal 
alterations increase over time. A common example in human cancer involves 
mutations in the breast cancer (BRCA1) gene which regulates DNA homologous 
recombination repair. Mutations in this gene force cells to adopt non-homologous 
end joining repair machinery which is highly error prone, resulting in the 
accumulation of more mutations (Powell & Kachnic, 2003). Genomic instability is also 
a key factor in hereditary cancers, such that all cells within a patient present germline 
mutations for a gene – such as BRCA1 – making the patient more susceptible to 
additional mutations, where a single event could drive tumour progression (Deng, 
2006; Narod et al., 1993). Additionally, as telomerase protects cancer cells from 
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limited replication, it is also considered a regulator of genome instability (Hanahan & 
Weinberg, 2011). Figure 1.4 shows a karyotype taken from normal cells and cancer 
cells where genomic instability- aneuploidy and hybrid chromosomes can be easily 
visualised.  
 
Figure 1.4 Chromosomes from a karyotype of normal and cancer cells 
Comparison of a few chromosomes taken from a karyotype of (A) normal cells and 
(B) cancer cells. These images (taken from (Weinberg, 2014)) were generated using 
multi-coloured FISH which labels chromosomes with different fluorescent dyes. 
Cancer cells (B) are often aneuploidy with chromosomal aberrations, and 
chromosomal translocations (multi-coloured). Adapted from (Weinberg, 2014). 
 
1.1.6  Tumour associated inflammation 
The identification of immune cells within tumour lesions adds an additional layer of 
complexity to tumour progression and the tumour microenvironment. Tumour-
associated inflammation and the innate immune response have been shown to 
enhance tumour progression by promoting many of the other hallmarks of cancer 
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(Dvorak, 1986). Chronic inflammation is a result of a variety of factors including 
infection and environmental toxins. Inflammation due to environmental factors such 
as smoking, obesity and alcohol therefore link these to higher risks of cancer. 
Examples of inflammatory induced tumours include bladder carcinomas which can be 
caused by chronic cystitis, Hepatocellular carcinoma caused by Hepatitis B/C and 
colorectal carcinoma which can be caused by inflammatory bowel disease (Weinberg, 
2014). 
 
Up to 50% of tumour masses can comprise immune cells including tumour-associated 
macrophages (TAMs). Immune cells within a tumour promote tumour progression 
through the secretion of mitogens, survival and pro-angiogenic factors as well as 
matrix metalloproteases (MMPs) which facilitate epithelial-mesenchymal transition 
(EMT) (Section 1.2) (DeNardo, Andreu, & Coussens, 2010; Grivennikov, Greten, & 
Karin, 2010). In many cancers the protein nuclear factor kappa B (NF-κB) is 
constitutively activated or activated by inflammatory cells secreted by TNF-α. This 
transcription factor orchestrates a tumour-promoting inflammatory response by 
activating cytokines such as interleukin 6 (IL6) (Hoesel & Schmid, 2013). Additionally 
cancer cells may present immune-evasion whereby regulators of immune 
surveillance are suppressed. As demonstrated in transgenic mice, tumours developed 
more readily in mice with deficiencies in CD8+ cytotoxic T lymphocytes and CD4+ 
helper cells compared to control immune-competent mice. In human cancers, 
secretion of immune-suppressors such as TGF-β eliminates CD8+ cells (M. Y. Kim et 
al., 2009; Teng, Swann, Koebel, Schreiber, & Smyth, 2008).  
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Additionally, the tumour microenvironment adds layers of complexity to the process 
of tumour progression (Hanahan & Weinberg, 2011). As mentioned, various other 
molecules have been shown to elicit tumour promoting effects and are recruited to 
the tumour environment, forming the tumour microenvironment. These non-
transformed cells include members of the immune system, lymphatic system and 
surrounding stromal cells, all of which can aid tumour growth. The complex tumour 
microenvironment therefore presents a problem with regards to cancer therapy 
across patients (Junttila & de Sauvage, 2013; Singh & Settleman, 2010).  
 
1.1.7  Tumour energy metabolism 
One of the more recently defined hallmarks of cancer indicates that developing 
tumours are capable of reprogramming their energy metabolism, initiating a 
‘metabolic switch’ (Hanahan & Weinberg, 2011; Hsu & Sabatini, 2008). Tumour cells 
favour the less efficient aerobic glycolysis over normal respiration in order to produce 
energy at a faster rate and generate a host of biosynthetic molecules for tumour 
growth. Glycolytic fuelling in cancer cells is typically associated with the upregulation 
of the glucose transporter (GLUT1) which encourages aerobic glycolysis. Oncogenes 
such as Ras and Myc, along with p53 have also been linked to increased glycolysis 
which can act pleiotropically along with hypoxic tumour conditions (DeBerardinis, 
Lum, Hatzivassiliou, & Thompson, 2008; Jones & Thompson, 2009). Additionally, 
upregulation of phosphionostide-3-kinase in cancer cells leads to increased hypoxia 
inducible factors (HIF) which promote aerobic glycolysis, fuelling growing tumours 
(Semenza, 2010).  
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1.2 Invasion and Metastasis 
The final ‘hallmark of cancer’ depicts the progression of solid tumours into aggressive 
metastatic tumours (Hanahan & Weinberg, 2000). Despite the increasing trend in 
cancer survival rates, patients with locally advanced cancers have a reduced 
prognosis compared to those with primary tumours alone; with the formation of 
secondary metastases in distant anatomical sites being accountable for more than 
90% of deaths in cancer patients (Gupta & Massague, 2006; Sporn, 1996). Sometimes 
certain primary tumours have a tendency to form secondary metastases in particular 
organs/tissues.  For example, cancers originating in the ovaries tend to metastasise to 
the peritoneum (abdomen lining) whilst breast and colorectal cancers commonly 
spread to the liver (Hess et al., 2006). The invasion-metastasis cascade is an elaborate 
multi-step process comprising a succession of complex cell-biological changes which 
facilitate the dissemination of cancer cells from a primary tumour to distant sites 
(Valastyan & Weinberg, 2011).  
 
Initial stages of the cascade include the local invasion and migration of cancer cells 
away from the primary tumour mass. Should migrating cancer cells encounter the 
vasculature, their subsequent intravasation into the blood and/or lymphatic vessels 
would allow their transportation and dissemination around the body. Surviving 
cancer cells extravasate at secondary sites to form small tumorous nodules, known as 
micrometastases, which have the potential to colonise into fatal secondary tumours 
(Fidler, 2003). However these micrometastases usually remain dormant for many 
years due to the inefficiency of colonisation and formation of macroscopic metastatic 
tumours (Aguirre-Ghiso, 2007). This metastatic cascade of events results in dramatic 
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changes in cell shape, cell polarity, cytoskeletal organisation, cell-cell junctions and 
focal contacts. The complex metastatic cascade can be broadly divided into three 
events: invasion, intravasation and extravasation (Hanahan & Weinberg, 2000).  
 
1.2.1 Invasion and Epithelial – Mesenchymal Transition (EMT) 
The vast majority of cancers originate from epithelial cells, which are specialised cells 
organised into adherent sheets. These epithelial sheets form a closed epithelium 
found lining most body organs, as well as the skin, and provide protection from the 
external environment. There are various types of epithelial cells, classified primarily 
by their site of origin, and cancers arising from these cells are known as carcinomas 
(Valastyan & Weinberg, 2011). These specialised cells are highly polarised with a 
distinct planar polarity and apicobasal polarity, which defines separate domains along 
the apical-basal axis. This polarity and organisation of epithelial sheets is maintained 
by various signalling networks involving polarity complexes, adhesion molecules and 
the actin cytoskeleton (Fristrom, 1988). The physiological function of epithelial cells is 
partly regulated by various adhesive junctions connecting neighbouring epithelial 
cells (Ebnet, 2008). In vertebrates, tight junctions (TJs) are found on the apical 
membrane, above the adherens junction (AJ) and are composed of transmembrane 
claudins which regulate the permeability of the cell and govern the passage of 
various molecules between adjacent cells (Anderson & Van Itallie, 2009). Instead of 
TJs, invertebrates possess septate junctions, which are functionally similar but 
molecularly distinct and are located below the AJ. AJs, located apically on the lateral 
membrane, are an essential feature of the epithelium in both vertebrates and 
invertebrates, defining the apical-basal axis and connecting neighbouring epithelial 
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cells (Fig. 1.5) (W. Meng & Takeichi, 2009). Desmosomes, which are composed of 
glycoproteins and intermediate filaments, are located beneath the AJs and function 
to maintain adhesion between cells (Alberts, 2002).  
 
Mature AJs are formed by an E-cadherin-catenin complex that binds to cytoskeletal 
components along with various regulatory and signalling molecules (Gumbiner, 2005) 
(Fig. 1.5). E-cadherin is a calcium-dependent glycoprotein which is characterised by 
three distinct domains: a long extracellular domain with five cadherin repeats (EC1-
EC5) which establishes trans- and cis-homophillic interactions, a single 
transmembrane domain and a cytoplasmic tail, which associates with various 
intracellular proteins (Hartsock & Nelson, 2008; Patel et al., 2006). The extracellular 
domain forms trans-cadherin bonds with adjacent cells via histidine-alanine-valine 
(HAV) domains located on EC1 and requires calcium for correct cadherin 
conformation (Pokutta, Herrenknecht, Kemler, & Engel, 1994). The cytoplasmic tail 
contains a catenin binding domain and juxtamembrane domain which enables the 
important interactions with p120-catenin and β-catenin which is pivitol to the 
adhesive properties of the AJs (Yap, Niessen, & Gumbiner, 1998). While β-catenin 
binds to the cytoplasmic domain of E-cadherin with high affinity, it in turns binds to 
α-catenin which regulates actin filaments (Aberle et al., 1994). α-catenin has been 
described as an allosteric protein that exists either as a monomer or homodimer. The 
different conformation states of α-catenin define its affinity to bind to either β-
catenin or actin filaments. High concentrations of α-catenin which tend to form 
clustered pools at the plasma membrane around E-cadherin force its monomeric 
state and high affinity binding to β-catenin. Meanwhile dimeric α-catenin is found in 
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cytoplasmic pools allowing it to interact with actin filaments (Drees, Pokutta, 
Yamada, Nelson, & Weis, 2005; Huber, Stewart, Laurents, Nelson, & Weis, 2001; 
Pokutta & Weis, 2000). This ‘catenin molecular switch’ indicates the dynamic nature 
of junctional adhesion and its interactions with the actin cytoskeleton. Additionally, 
α-catenin dimers drive the formation of bundle actin filaments while repressing the 
actin-related protein 2/3 (Arp2/3) complex and subsequent branching actin 
networks; Arp2/3 is an actin nucleator complex which initiates actin polymerisation 
leading to branched actin filaments (Drees et al., 2005; Pollard & Beltzner, 2002). 
Branched actin networks are associated with lamellipodia and leading edge extension 
seen commonly in mesenchymal migratory cells (Pollard & Borisy, 2003). As shown, 
the vast network of cadherins, catenins and associated signalling pathways link 
cellular adhesion, epithelial polarity and the actin cytoskeleton to one another. 
Additionally, the binding of various proteins to the E-cadherin cytoplasmic tail 
regulates the processes of recycling and endocytosis for essential turnover of E-
cadherin and junctional material (Georgiou, Marinari, Burden, & Baum, 2008; Le, Yap, 
& Stow, 1999).  
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Figure 1.5 E-cadherin and EMT signalling 
Diagram shows E-cadherin at the AJ of epithelial cells and the associated signalling 
networks linking E-cadherin to the actin cytoskeleton and transcription. E-cadherin 
binds β-catenin and p120, which interacts with the microtubule cytoskeleton and α-
catenin which in turn interacts with actin filaments. Loss of E-cadherin results in 
abundant cytoplasmic β-catenin which translocates to the nucleus and induces 
transcription of cancer-associated genes. Additionally WNT signalling prevents 
degradation of β-catenin by inhibiting GSK-3β/axin/APC complex which normally 
targets β-catenin for ubiquitination and degradation. Signalling pathways associated 
with E-cadherin, such as PI3K regulates Rho family GTPases which mediate 
membrane actin protrusions which when mis-regulated can contribute to EMT and 
mesenchymal cell morphology. (A) Septate junction and adherens junction in 
Drosophila epithelial cells compared to (B) adherens junction and tight junction in 
vertebrate.  
 
The process of invasion is typically defined by the loss of adhesion between cells, 
thus allowing cells to dissociate from the epithelium and spread. In particular, the 
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loss of E-cadherin and adhesion junction regulators is associated with invasion and 
metastasis of cancer cells (Cavallaro & Christofori, 2004). There are various 
mechanisms by which E-cadherin-mediated adhesion is abolished in invasive 
tumours, for example, at a transcriptional level, E-cadherin expression can be 
repressed by the transcription factors Snail and Twist which are known repressors of 
the E-cadherin promoter (Batlle et al., 2000). Additionally, the E-cadherin protein can 
undergo proteolytic degradation by secreted MMPs (Werb, 1997). The loss of E-
cadherin disrupts cell-cell adhesion, cell polarity and cell shape, thereby facilitating 
the detachment of tumour cells from the epithelium. Moreover, downregulation of E-
cadherin in cancer triggers various downstream signalling pathways which contribute 
to tumour progression (Christofori & Semb, 1999). For example, in the absence of E-
cadherin, β-catenin is liberated from the adhesive junctional Cadherin/Catenin 
complex. Normally, non-sequestered β-catenin would be phosphorylated by the 
APC/axin/GSK3β complex which subsequently results in its degradation. However, in 
many cancers (notably colon carcinomas) accumulation of β-catenin in the cytoplasm 
occurs due to inactivated mutant APC or increased WNT signalling which prevents 
the targeting of β-catenin for degradation (Brabletz et al., 2001; Kishida et al., 1998). 
Translocation of β-catenin to the nucleus and its subsequent binding to Tcf and Lef 
transcription factors results in the expression of specific genes implicated in hyper-
proliferation and tumour progression (Christofori & Semb, 1999). Loss of E-cadherin 
function is also associated with Rho signalling leading to reorganisation of the actin 
cytoskeleton (Christofori, 2006). The Rho-GTPases Rac1, RhoA and Cdc42 function to 
regulate the formation of lamellipodia, contractile forces in migratory cells and 
formation of actin-rich filopodia respectively (Etienne-Manneville & Hall, 2002; Nobes 
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& Hall, 1995). In normal cells E-cadherin is able to suppress RhoA and subsequent 
migratory behaviour by recruiting p190 Rho-GAP, as well as regulating actin assembly 
by recruiting phosphoinositide 3 kinase (PI3K). PI3K signalling in turn recruits the 
protein T-cell lymphoma invasion and metastasis 1 (TIAM1) which results in the 
activation of Rac1 and Cdc42 which regulates the actin cytoskeleton (Arthur & 
Burridge, 2001; Christofori, 2006).  
 
In order for cancer cells to invade and spread they must lose their specialised 
characteristics including apical-basal polarity and cell-cell adhesion. EMT is the 
process in which highly differentiated epithelial cells become motile and invasive by 
adopting mesenchymal characteristics (Klymkowsky & Savagner, 2009; Polyak & 
Weinberg, 2009). Normally EMT acts as an essential regulatory program implicated 
during gastrulation and wound healing, however tumour cells have been shown to 
‘hijack’ this cellular program during tumour progression (Thiery, Acloque, Huang, & 
Nieto, 2009) (Hanahan & Weinberg, 2011). Unlike epithelial cells, mesenchymal cells 
are solitary cells with a front-rear polarity making them capable of migrating. The 
process of EMT is accompanied by a host of physiological changes from the 
dissolution of adhesive junctional complexes, the switch between apical-basal and 
front-rear polarity, reorganisation of the actin cytoskeleton and subsequent change 
in cell shape (Nelson, 2009; Ridley et al., 2003; Yilmaz & Christofori, 2009). 
Furthermore, at a transcriptional level EMT is associated with the downregulation 
and upregulation of epithelial and mesenchymal genes respectively. As mentioned 
previously, the loss of AJ integrity is defined by the dissolution of E-cadherin-
mediated adhesion between neighbouring cells (Cavallaro & Christofori, 2004; 
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Gumbiner, 1996). Additionally, decreases in occludin and claudin along with the loss 
of zonula occludens 1 (ZO1) at cell contacts impair TJ integrity (R. Y. Huang, Guilford, 
& Thiery, 2012). Section 1.3 describes the various polarity protein complexes which 
localise along the apical-basal axis defining specific apical, lateral and basal domains. 
De-regulation or mis-localisation of these polarity regulators results in the loss of 
epithelial apical-basal polarity. Additionally, re-organisation of the actin cytoskeleton 
facilitates the switch between apical-basal polarity and front-rear polarity which 
enables directional movement of mesenchymal cells (Christofori, 2006; Nelson, 
2009). Rho-GTPases regulate reorganisation of the cortical actin cytoskeleton 
producing membrane extensions at the leading edge, while Rho activated stress 
fibres drive cell contractility for motility and directed mesenchymal-like migration 
(Fig. 1.5) (Nobes & Hall, 1995). 
 
The most recognised switch in gene expression during EMT is the ‘cadherin switch’ 
where E-cadherin is down-regulated and expression of N-cadherin is upregulated (J. 
P. Johnson, 1991). This switch in cadherin expression along with the upregulation of 
EMT transcription factors evokes the loss of AJs, allowing tumour cells to subvert 
their differentiated polygonal characteristics and adopt a fibroblastic morphology for 
enhanced cell motility (Nelson, 2009; Polyak & Weinberg, 2009). These gene 
expression changes are often regulated by various transcription factors associated 
with early EMT, such as Snail and Twist (Fig. 1.6). Snail regulates transcription by 
specifically binding to E-box domains in target gene promoters (such as E-cadherin) 
(Batlle et al., 2000). Snail then recruits polycomb repressive complex 2 (PRC2) which 
drives a host of histone modifications which are capable of activating or repressing 
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transcription of the target gene (Herranz et al., 2008). In this way Snail can drive 
transcription of mesenchymal cell components whilst suppressing epithelial markers. 
Similarly, Twist drives histone modifications on target genes by binding to DNA 
recognition sites and recruiting SET8 (Yang et al., 2012). Various signalling pathways, 
including TGF-β, WNT and Notch, can regulate the expression of these transcription 
factors and ultimately promote EMT. For example, under hypoxic conditions HIF1α 
signalling activates Twist. In addition to Snail and Twist, Zeb, Fox and Sox 
transcription factors are also associated with EMT (Lamouille, Xu, & Derynck, 2014).  
 
 
Figure 1.6 EMT transcription factors 
Activators and transcriptional targets of the transcription factors Snail and Twist, 
which regulate EMT by initiating the ‘cadherin switch’. 
 
To summarise, by breaking adhesive interactions between neighbouring cells, altering 
the actin cytoskeleton and initiating EMT, tumour cells are able to break away from 
each other and exchange their epithelial characteristics for a mesenchymal-like 
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morphology, allowing them to invade and metastasise.  It is important to note 
however, that whilst EMT serves as the predominant method enabling epithelial cells 
to invade and metastasise, there are several additional discrete modes of invasion 
that have been implicated in metastatic cancers. For example, ‘collective invasion’ 
describes the advancement of cancer cells into adjacent tissue en- masse, whilst 
‘amoeboid invasion’ sees individual cancer cells escaping through interstices pre-
existing in the extracellular matrix (ECM), by acquiring a morphological plasticity 
phenotype (Hanahan & Weinberg, 2011; Sabeh, Shimizu-Hirota, & Weiss, 2009). 
During amoeboid invasion, increased Rho signalling leads to actomyosin contractility 
and subsequent cell cortex remodelling (Sahai & Marshall, 2003). In some cases, 
inflammatory cells assembling at tumour boundaries have also been shown to aid 
invasion by secreting enzymes to degrade the ECM (Joyce & Pollard, 2009).  
 
1.2.2 Intravasation and Extravasation 
For cancer cells to spread from the primary tumour to distant sites they must first 
break through the basement membrane (BM) and enter the blood and lymphatic 
system (Fig. 1.7). Both tumour cells and neighbouring stromal cells release MMPs 
which are zinc-dependent endopeptidases released to facilitate degradation of the 
basement membrane and remodelling of collagen fibres within the ECM. By releasing 
extracellular MMPs, which are normally required for tissue morphogenesis, growth 
and repair, cancer cells are able to invade through the basement membrane (Kleiner 
& Stetler-Stevenson, 1999; Werb, 1997). 
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A prerequisite for metastatic dissemination is the formation of immature neo-
vasculature, which supplies oxygen and nutrients to the growing tumour (Bergers & 
Benjamin, 2003; Duffy, 1996). The release of pro-angiogenic and pro-inflammatory 
cytokines such as VEGF from tumour cells and stromal cells in the surrounding 
microenvironment stimulate tumour angiogenesis (Bergers & Benjamin, 2003). 
Cytokines, MMPs and hypoxic conditions at the tumour site initiate migration of 
endothelial cells up a chemoattractant gradient towards the tumour to establish the 
novel, albeit leaky vascular network (Carmeliet & Jain, 2000). To metastasise, locally 
invaded cancer cells must enter this novel neo-vasculature along with the bodies’ 
blood and lymphatic vessels (Hanahan & Weinberg, 2011). This process of 
intravasation is considered to be the rate limiting step of invasion and metastasis as 
circulating cancer cells are often unable to overcome the challenges they face in the 
circulatory system. For example, circulatory cancer cells often have to rely on anti-
apoptotic proteins such as bcl-2 to protect them from anoikis, which occurs due to 
the loss of matrix and stromal interactions (Guo & Giancotti, 2004). Additionally, 
platelets are often recruited to shield cancer cells from immune cells and shearing 
forces present in the circulatory vessels (Gay & Felding-Habermann, 2011; Joyce & 
Pollard, 2009). Furthermore, cancer cells typically get lodged in the first capillary they 
enter due to geometric constraints, unless they can enter the larger venous system 
first, enabling them to travel further (Gupta & Massague, 2006). Once cancer cells 
have become stuck in a capillary they form adhesive interactions with the endothelial 
wall via interactions with various integrins and chemokine receptors. These 
interactions facilitate the extravasation of cancer cells into secondary tissues. Cancer 
cells achieve trans-endothelial migration by either breaking through endothelial 
45 
 
junctions or mechanically bursting through the endothelial wall (Valastyan & 
Weinberg, 2011). Successfully extravasated cancer cells undergo mesenchymal-
epithelial transition (MET) and form micro-metastases in the new location. MET 
simply defines the process of metastasised cancer cells regaining their epithelial 
characteristics so they can colonise in the new tissue, and is achieved by reversing 
the reactions performed during EMT. These cells usually enter G0 phase of the cell 
cycle remaining quiescent and dormant for many years. Eventually, macromastatic 
growth and colonisation is achieved with interplay from the microenvironment which 
releases growth factors such as TGF-β and IL-6 (Tsai & Yang, 2013). Additionally, it has 
been hypothesised that a pre-metastatic niche contributes to successful colonisation 
in which migrating cancer stem cells and bone marrow derived cells facilitate growth 
of tumours at the new site (Qian & Pollard, 2010). Colonisation and remodelling of 
the secondary tumour site is achieved through complex heterotypic signalling 
between cells in the tumour microenvironment. Paracrine signalling, secretion of 
cytokines and increased tumour associated fibroblasts contribute to the 
premetastatic niche making it susceptible to colonisation. For example, breast cancer 
cells have been shown to induce secretion of periostin which promotes WNT 
signalling and cell growth at the secondary site (Malanchi et al., 2012).  
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Figure 1.7 Intravasation and Extravasation 
The process in which motile cancer cells metastasise from the primary tumour and 
form macro-metastases in new locations, and some of the dangers they must 
overcome.   
 
1.3 Epithelial Cell Polarity 
Cell polarity is a fundamental characteristic of all epithelial cells, defining distinct 
apical, lateral and basal domains for the asymmetric organisation of cell components, 
essential for normal cell physiology and tissue homeostasis. Tumour progression is 
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largely associated with the loss of this epithelial cell polarity. A distinct apical-basal 
axis of polarity enables the exchange of ions and solutes across the epithelium and is 
required for regulating asymmetric cell division as well as maintaining the apical 
junctional complex (Fristrom, 1988; Januschke & Gonzalez, 2008). The apical 
junctional complex consists of TJs (SJs in Drosophila) and AJs, which are structurally 
dependent on the integrity of several polarity complexes (Fig. 1.8). These polarity 
complexes which make up the epithelial polarity programme (EPP) localise separately 
along the apical-basal axis for tight coordination of cell polarity, cell-cell junctions and 
cytoskeletal organisation (Januschke & Gonzalez, 2008; Rodriguez-Boulan & Macara, 
2014).  
 
Epithelial cell polarity is established through the generation of apical and basolateral 
domains which defines asymmetry along the apical-basal axis. These domains are 
generated through mutually exclusive interactions formed between distinct polarity 
proteins. The apical Par and Crumbs complex and basolateral Scribble and 
Yurt/Coracle complex interact with one another generating zones of mutual exclusion 
surrounding the mature epithelial junctions (Fig. 1.8) (Assemat, Bazellieres, Pallesi-
Pocachard, Le Bivic, & Massey-Harroche, 2008).  
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Figure 1.8 Epithelial polarity complexes 
Interactions between polarity complexes which are mutually antagonistic define the 
apical and basolateral domains. The Crumbs and Par complex are restricted to the 
apical domain whilst the Scribble complex localises to the basolateral domain to 
maintain apical-basal polarity. (A) Adherens junction and septate junction in 
Drosophila compared to (B) Tight junctions and adherens junctions in vertebrate 
epithelial cells.  
 
1.3.1 Apical Par and Crumbs complexes 
The apical Par complex was first characterised in 1988 in C.elegans and was closely 
linked to asymmetric cell division (Nance, Munro, & Priess, 2003). There is a host of 
Par family proteins including the Par kinases (Par1, Par4) and scaffold PDZ-containing 
proteins (Par3/bazooka, Par6). The Par complex itself is formed by the interactions 
between Par3 and Par6 along with atypical protein kinase C (aPKC) and the small 
GTPase cdc42 (Bilder, 2003; Joberty, Petersen, Gao, & Macara, 2000; D. I. Johnson, 
1999; Lin et al., 2000). The Par complex plays an important role in regulating spatial 
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restriction of the actin cytoskeleton, spindle orientation during asymmetric cell 
division and driving epithelial polarity through its adverse effects at epithelial TJs 
(Suzuki & Ohno, 2006). Par3 binds to TJs (AJs in Drosophila) through adhesion 
proteins associated with mature junctions; this anchorage to the apical-lateral border 
allows Par3 to recruit the remaining members of the Par complex. Par6 initially binds 
to Par3 and subsequently recruits aPKC to the complex. Cdc42 is the last member of 
the Par complex to join, and binds directly to Par6 (Joberty et al., 2000). GTP bound 
cdc42 interacts directly with Par6 which changes the conformation of the Par 
complex, leading to aPKC activation and subsequent phosphorylation of target 
proteins (Yamanaka et al., 2001). aPKC is pivotal in the maintenance of polarity by 
generating feedback loops and mutually exclusive interactions. The first feedback 
loop initiated is between aPKC and Par3 (Baz). As shown in Drosophila, the Baz/aPKC 
interaction is inhibited when Baz is phosphorylated on serine 980 by aPKC. In 
addition, Crumbs prevents the interaction between Baz with Par6, maintaining its 
localisation to the apical lateral border. Localisation of Baz is also restricted basally by 
the Scribble complex which regulates Par1 localisation which subsequently results in 
phosphorylation of Baz at serine 151 or 1085. (Morais-de-Sa, Mirouse, & St Johnston, 
2010; Suzuki & Ohno, 2006).  
 
The Crumbs complex (Crumbs, PALS/Stardust and PATJ) is also found in the apical 
domain and is important in the establishment of AJs and apical-basal polarity. 
Crumbs was first identified in Drosophila (Tepass, Theres, & Knust, 1990) but has 
since been widely studied in other organisms. The crumbs complex regulates 
formation of the apical membrane and forms feedback loops with the Par complex to 
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restrict apical proteins to the apical-lateral domain whilst restricting the third polarity 
complex (Scribble) to the basolateral domain. Apical restriction is achieved through 
interactions between crumbs and Par6 which subsequently upregulates aPKC (Suzuki 
& Ohno, 2006; Tanentzapf & Tepass, 2003).  
 
1.3.2 The Scribble complex 
The scribble complex consists of Scribble, discs large (dlg) and lethal giant larvae (lgl) 
and localises to the basolateral domain. These polarity proteins are all capable of 
recruiting a variety of different protein networks due to their highly conserved 
guanylate kinase, PDZ and SH3 domains (Bilder, 2003). Lgl was the first recognised 
member of the scribble complex, being identified in Drosophila in 1930, although it 
wasn’t until the 1980’s that it was fully sequenced and characterised (Mechler, 
McGinnis, & Gehring, 1985). Dlg was also first discovered in Drosophila in 1972 and 
was quickly identified as an essential regulator of epithelial structure and 
development. Dlg belongs to the membrane-associated guanylate kinase (MAGUK) 
family and localises at septate junctions in flies. There are 5 Dlg human homologues 
all of which consist of conserved PDZ and SH3 domains (Woods & Bryant, 1991; 
Woods, Hough, Peel, Callaini, & Bryant, 1996). Finally, Scribble was identified in 
Drosophila in 2000 (Bilder & Perrimon, 2000) as a key regulator of epithelial 
morphogenesis. Scrib specifically regulates positioning of AJs and restriction of apical 
determinants from the basolateral domain which defines epithelial polarisation. 
 
The Scribble complex establishes the basolateral domain through a number of 
antagonistic interactions which inhibit lateral localisation of the Par complex. Apical 
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localisation of Lgl is inhibited by a phosphorylation event mediated by aPKC 
(Betschinger, Mechtler, & Knoblich, 2003). Additionally, lgl prevents Par6 from 
localising to the cell cortex. Moreover the scribble complex regulates Par1 
localisation which inhibits basolateral localisation of Par3 (Assemat et al., 2008). 
Importantly, components of the Scribble complex have been linked to cell migration 
events. Functional alterations to members of the protein networks responsible for 
orchestrating cell polarity is thought to be crucial to the pathology of cancer (Royer & 
Lu, 2011). 
 
The genes coding these polarity proteins, lethal(2)giant larvae (lgl), discs large (dlg) 
and scribble (scrib) also act as neoplastic tumour suppressors which were first 
identified in Drosophila melanogaster, and along with other functionally related 
genes have been shown to play a role in human cancers (Bilder, 2004; Gateff, 1978; 
Schneiderman & Gateff, 1967). In the imaginal discs loss of these genes results in 
neoplastic overgrowth, however, when clones are introduced these mutant cells are 
outcompeted through cell competition (Section 3.1) (Brumby & Richardson, 2003; C. 
L. Chen, Schroeder, Kango-Singh, Tao, & Halder, 2012; Pagliarini & Xu, 2003). It has 
also been shown that these tumour suppressors act together through a common 
pathway to regulate epithelial cell polarity and growth (Bilder & Perrimon, 2000). 
Additionally, direct interactions have been observed between the mammalian 
homologues of Drosophila Scrib and Lgl (Lg1-2) (Kallay, McNickle, Brennwald, 
Hubbard, & Braiterman, 2006). Cortical localisation of Lgl, a membrane-associated 
protein, has also been shown to facilitate formation of the cytoskeletal network. All 
three members of the scribble complex have been shown to interact genetically and 
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the concerted activity of these genes regulates polarity and cytoskeletal organisation 
(Bilder & Perrimon, 2000).  
 
Mutations resulting in the loss of function in these polarity complexes results in 
apical-basal polarity defects, however these defect phenotypes can be compensated 
by reducing expression of the unaffected complex. This demonstrates that the apical-
basal axis is defined by the mutual exclusion of these polarity complexes to their 
apical/basolateral domains (Bilder, 2003; Tanentzapf & Tepass, 2003). 
 
1.4 Drosophila as a genetic model organism for tumour 
progression 
For over a century, Drosophila melanogaster has been used as a genetic tool for 
developing our understanding of genetics, development, ageing and various 
signalling cascades. The American geneticist Thomas Hunt Morgan is undoubtedly the 
most recognised scientist in Drosophila history, popularising the fruit fly as a model 
organism for genetic studies and developing ‘classical’ Drosophila genetics. He 
studied white eyed mutant flies and their pattern of inheritance. He was awarded the 
Nobel Prize in 1933 for his earlier work on the chromosome theory of inheritance and 
evidence that some genes are linked such that they are inherited together. 
Additionally, Morgan’s students Muller and Bridges produced ground-breaking 
research in genetics. In 1918, Muller developed the use of balancer chromosomes to 
stably maintain homozygous lethal mutations, a genetic tool which is still extremely 
important in Drosophila genetics today. Furthermore, Bridges produced an array of 
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incredibly accurate polytene and cytogenetic maps between 1935 and 1938. 
Drosophila has since become a very popular model to carry out large genetic screens 
for various diseases and processes (Rubin & Lewis, 2000). One of the first and most 
famous screens was carried out by Volhard and Wieschaus and was awarded the 
Nobel Prize in 1980. They carried out a mutagenesis screen studying developmental 
and patterning defects in the embryo. From this they identified a host of ‘classic’ 
genes required during embryogenesis, including hedgehog and Krüppel (Nusslein-
Volhard & Wieschaus, 1980).  
 
Additionally, Drosophila has become an increasingly popular model organism for 
studying tumour progression, allowing research on many cancer pathways, due to 
high conservation of the human genome and preservation of more than 60% of 
cancer proteins (Potter, Turenchalk, & Xu, 2000). Due to the vast complexity of 
cancer and the number of molecules and pathways implicated, Drosophila has 
become an ideal tool for studying the mechanisms and genes involved, as many of 
the same pathways and genes found in Drosophila are found in humans (Bernards & 
Hariharan, 2001; Dahman, 2008; Potter et al., 2000). Chapter 3 outlines some of the 
important cancer research and loss of function screens that have been carried out in 
Drosophila over the years.  
 
There are many reasons why Drosophila has become such a popular model organism. 
For example, compared to other model organisms Drosophila is relatively cheap and 
easy to use. With a short life cycle (Fig. 1.9) and simple maintenance, experiments 
can be performed quickly and cheaply. Additionally, with the developing and 
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excelling fly community a wide range of genetic tools are available, including large 
RNA interference (RNAi) stock centres and online resources such as flybase (Attrill et 
al., 2016). Genetically, Drosophila is easy to manipulate, with reduced redundancy 
and a lack of recombination in males. Meanwhile the use of balancer chromosomes 
prevents random meiotic recombination in females and allows stocks to be kept 
which carry homozygous lethal mutations (Bernards & Hariharan, 2001; Dahman, 
2008; Potter et al., 2000). 
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Figure 1.9 Drosophila Life Cycle 
The different stages of the Drosophila life cycle when kept at 25oC and the time scale 
of development. The Drosophila life cycle is approximately doubled in time when flies 
are kept at 18oC. 
 
1.5 Research Aims 
To characterise the critical cell biological events underlying tumour cell invasion, the 
notum of Drosophila was used as a model system in a genetic screen, combining 
sophisticated Drosophila genetics with cell biology.  The notum (the dorsal thorax of 
the fly) is a well-organised, columnar, monolayered epithelium, which is formed 
during pupal development. Through a succession of morphogenic events at early 
pupal stages, lateral epithelial sheets approach and meet at the midline where they 
fuse together to form the dorsal thorax (Zeitlinger & Bohmann, 1999).  
 
Clones of transformed cells labelled with GFP can be visualised within the living 
epithelium of Drosophila, where the shape, dynamics and behaviour of transformed 
cells can be followed in high resolution over time as the tissue becomes neoplastic. 
Significantly this novel genetic system is one of the few able to characterise the 
precise molecular and cell biological events during early tumourigenesis (Cohen, 
Georgiou, Stevenson, Miodownik, & Baum, 2010).  
 
By inducing small mutant clones, which are homozygous mutant for a specific tumour 
suppressor gene, it is possible to generate neoplastic tumours in the notum of the fly 
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These tumours show overgrowth, loss of apical-basal polarity and cells that undergo 
EMT which can survive beneath the epithelial sheet (Georgiou & Baum, 2010; 
Georgiou et al., 2008).  
 
Using this system it is possible to generate clones of transformed cells homozygous 
mutant for lgl (see Chapter 3), allowing an enhancer-suppressor screen to be carried 
out for genes that either promote or inhibit tumour progression. For the screen, 
transformed cells, homozygous mutant for the tumour suppressor lgl, will 
simultaneously express a GFP reporter (allowing us to observe tumour size, shape 
and behaviour) and an RNAi transgene that knocks down the expression of an 
additional gene in the Drosophila genome. Importantly, using the MARCM technique 
(see Section 2.2.2.3) the expression of both the GFP reporter and the RNAi transgene 
will be specific to the homozygous mutant tissue, so only the developing tumour will 
be labelled in the notum and only the developing tumour will have knockdown of the 
target gene expression. In this way, genes will be identified that promote or inhibit 
tumour progression by affecting tumour size, cell morphology, cell behaviour and/or 
the number of invading cells.  
 
The overall aim of my PhD was to optimise and set up a large-scale genetic screen 
using RNAi to identify novel genes involved in tumour progression. From this, I hoped 
to characterise these genes in more detail to try to further our understanding of their 
biological role in cancer.  
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One of the initial aims of my research was to carry out a preliminary pilot screen 
which would be used to ensure the system was working efficiently in the notum, 
determine ideal conditions and identify which mutant background was most suitable 
for the main screen. The aim of the main candidate screen was to study 
approximately 700 RNAi transgenes targeting 500 different genes over 3 years. Then 
once specific genes that perturb tumour progression had been identified, I would be 
able to study in more detail the role of these genes in tumour progression. 
 
Targeted cancer therapy has become of particular interest to cancer researchers, 
whereby drugs are strategically targeted to specific genes directly linked to cell 
growth and proliferation. Current targeted therapeutics aim to specifically attack 
cancer cells with minimal damage to normal tissue in the tumour microenvironment. 
With this in mind, high relapse rates associated with current therapies such as 
chemotherapy are hoped to be significantly reduced. The anti-cancer drug avastin for 
example specifically prevents endothelial cell recruitment during angiogenesis, an 
essential step in the metastasis cascade (Cappuzzo et al., 2003; Miller et al., 2007; 
Savage & Antman, 2002). It is hoped that novel genes implicated during the invasion-
metastatic cascade will be identified through the in vivo genetic screen and by 
investigating how oncogenes and tumour suppressor genes cooperate to affect 
epithelial cell morphology and invasion; the results obtained will be of great 
significance to human health. Therefore the overall aim of my research was to 
identify genes that affect tumour progression from over-proliferation to invasion and 
metastasis.  
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Materials and Methods 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Drosophila stocks 
Table 2.1 contains a list of all the Drosophila stocks used and where they originated. 
The majority of stocks were made in the Georgiou Lab, while the rest are available 
publicly. A full list of all the RNAi lines used can be found in Appendix B-C. 
Table 2.1 Drosophila Stocks 
Stock Genotype Source 
M383 w,P[mw,Ubx-flp]; IF/P[CyO-GFP]; P[mw,GAL4][Pnr], 
P[mw,UAS-Moe-GFP]/TM6b 
Georgiou Lab 
8217 ;P[FRT][40A], P[FRT][G13]/CyO Bloomington 
M413 w, P[mw, Ubx-flp]; P[FRT][40A],P[FRT][G13]/P[CyO-GFP]; 
P[mw,GAL4][Pnr], P[mw,UAS-Moe-GFP]/TM6b 
Georgiou Lab 
M380 w;P[mw,Tub-GAL80], P[FRT][40A]; MKRS/TM6b Georgiou Lab 
M442 
 
w, P[mw, Ubx-FLP];lgl[4], P[FRT][40A]/P[CyO-GFP];P[mw, 
GAL4][Pnr], P[mw,UAS-Moe-GFP]/TM6b 
Georgiou Lab 
M471 P[mw,Ubx-flp]; P[mw,GAL4][Act], P[mw,UAS-Moe-GFP]/ 
P[CyO-GFP]; P[FRT][82b], scrib/TM6b 
Georgiou Lab 
M485 IF/ P[CyO-GFP];; P[mw,Tub-GAL80], P[FRT][82b]/TM6b Georgiou Lab 
M371 
 
P[mw,Ubx-flp], dlg, P[FRT][19A]/FM7, P[Kr-GFP];; 
P[mw,GAL4][Pnr], P[mw,UAS-Moe-GFP]/TM6b 
Georgiou Lab 
M382 P[mw,Tub-GAL80], P[FRT][19A]; MKRS/TM6b Georgiou Lab 
M59 ;; P[GAL4][Neu], P[mw,UAS-Moe-GFP]/TM6b Georgiou Lab 
M147 w;;; Bloomington 
M520 P[mw,Ubx-flp]; IF/ P[CyO-GFP];MKRS/TM6b Georgiou Lab 
5626 W; P[FRT][42D], P[Uni-GFP.nls]/CyO Bloomington 
M530 P[mw,Tub-GAL80], P[FRT][42D]/ P[CyO-GFP]; 
P[GAL4][Neu]/TM6b 
Georgiou Lab 
M288 w;; P[mw,GAL4][Pnr], P[mw,UAS-Moe-GFP]/TM6b Georgiou Lab 
32123 w;; P[UAS-Apoliner]/TM3, sb Bloomington 
 w; P[FRT][42D], dscam21/23/CyO Gift from Dr. 
Larry Zipursky 
V51247 Lgl-RNAi (III) VDRC 
58742 w; P[FRT][42D], shg/CyO; P[Ubi-p63E-shg.GFP]  Bloomington 
35496 y, w;  P[FRT][42D],  P[Ubi-mRFP.nls]  Bloomington 
6298 P[UAS-p35];; Bloomington 
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3703 w; P[CyO-GFP]/Sco; MKRS/TM6B Bloomington 
54591 y1 P(nos-cas9, w+) M(3xP3-RFP.attP)ZH-2A w* Bloomington 
 
2.1.2 Chromosome balancers, markers and genetic constructs 
Chromosome balancers (homozygous lethal alleles with a dominant visible 
phenotype) were used to suppress meiotic recombination that naturally occurs in 
females and to track progeny genotype through multiple genetic cross schemes. 
Table 2.2 contains all the balancers and genetic markers used. 
 
Table 2.2 Balancers and genetic markers 
Name Chromosome Type Phenotype 
CyO (Curley of Oster) 2  Balancer Curly Wings  
FM7 (ln(1)FM7) 1 Balancer Kidney-shaped eyes 
TM3 (ln(3LR)TM3) 3 Balancer Stubble (shortened bristles) 
or serrate wings 
TM6b (ln(3LR)TM6) 3 Balancer Tubby (short, fat body), 
Humeral (extra 
macrochaetes), and stubble 
IF (Irregular facets) 2 Marker Small ‘rough’ eyes with 
irregular ommatidia. 
MKRS 3 Marker Stubble  
Sco (Scutoid) 2 Marker Loss of bristles 
 
Table 2.3 Genetic constructs 
Table outlining the function of genetic constructs incorporated into the Drosophila 
genome. 
Genetic construct Function 
Pnr-GAL4 GAL4 expression is driven by the pannier promoter which 
restricts expression to the central region of the notum.  
Act-GAL4 GAL4 is expressed ubiquitously under control of Actin5C 
promoter. 
Neu-GAL4 GAL4 is expressed specifically in the sensory organ precursor 
cells and their progeny. 
Tub-GAL80 The tubulin promoter ubiquitously drives expression of GAL80 
which represses GAL4 activity. 
FRT Flippase Recognition Target (FRT) sites are located at various 
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positions along chromosomes (40A, 19A, G13, 82b, 42D) and 
are the site of flp induced post-mitotic recombination.  
UAS-Moe-GFP The actin-binding domain of Moesin (Moe) is tagged to GFP 
which is under the control of UAS. GFP therefore localises to 
actin filaments.  
Kr-nls-GFP GFP expression is driven by the Kruppel (kr) promoter and the 
nuclear localisation sequence (nls) restricts GFP localisation to 
the nucleus.  
Ubx-flp The Ultrabithorax (Ubx) promoter drives expression of flippase 
(flp) in the nucleus.  
UAS-RNAi Various RNAi constructs under the control of UAS.  
CyO-GFP GFP expression in the abdomen is under the control of the 
Curley of Oster promoter. 
Ubi-nls-GFP The ubiquitous (Ubi) promoter expresses GFP in the nucleus. 
UAS-Apoliner Genetic construct consisting of GFP and RFP separated by a 
caspase recognition site. Used as a marker for apoptosis. 
UAS-p35 Expression of p35 under UAS control. P35 blocks apoptosis. 
Ubi-nls-RFP The ubiquitous (Ubi) promoter expresses RFP in the nucleus. 
Ubi-shg.GFP The ubi promoter drives expression of E-cadherin (shg) tagged 
at the C-terminus with GFP (live cadherin) 
 
2.1.3 Mutagenesis and cloning oligonucleotides 
For mutagenesis using CRISPR/Cas technology, oligos (Table 2.4) were designed using 
CRISPR optimal target finder and ordered (desalted, dried) from Sigma-Aldrich®  
Table 2.4 CRISPR/Cas oligonucleotides 
Name Primer sequence 5’-3’ 
CG10600 Target 2 sense GTCGGTCGCGCTCCCGCTCCCTAT 
CG10600 Target 2 anti-sense AAACATAGGGAGCGGGAGCGCGAC 
 
Table 2.5 Plasmids 
Plasmid Source 
pCFD3-dU6:3gRNA gift from Simon Bullock (Addgene plasmid # 49410) 
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2.1.4 Primers for PCR and Sanger Sequencing 
Sanger sequencing was used to confirm DNA plasmid sequences and verify CRISPR 
mutants. Sequencing was carried out by the DNA sequencing facility in the School of 
Life Sciences, at the University of Nottingham. Non-universal primers were designed 
using primer 3. 
Table 2.6 Primers 
Name Primer Sequence 5’-3’ Supplier 
T3 CAATTAACCCTCACTAAAGG Universal primer supplied by DNA Seq 
facility, University of Nottingham. 
CG1 AAGAAGAGAGACAGGGAGCG Sigma-Aldrich® 
CG2 CGTTCTGCACTTTCGAAACG Sigma-Aldrich® 
CG3 CGATAAGGTGAACGCGAGAC Sigma-Aldrich® 
RSB1 GCAGCTTTCTACGTGATGGG Eurofins 
RSB2 ATTGGGCCAGCTCTCTGTAAGT Eurofins 
ING1 TACTGTCTGTGCAACCAGGT Eurofins 
ING2 TTCTCCAGGGCTTTGTCCAT Eurofins 
GAP F ATGTTCGTCATGGGTGTGAA Thermofisher Scientific 
GAP R GTCTTCTGGGTGGCAGTGAT Thermofisher Scientific 
 
2.1.5 siRNAs 
Table 2.6 lists all the ON-TARGET plus siRNAs used for targeting human genes as well 
as scrambled siRNA control and siGLO for optimisation experiments. SMARTpool (a 
mix of 4 different siRNAs targeting the same gene) were ordered to improve 
specificity.  
Table 2.7 siRNA 
siRNA target Oligo Sequence Supplier 
ING1 AGAGAGGGCUUACAACAGG 
CGAGAAGACCAUGGACAAA 
CCACGUACUGUCUGUGCAA 
GCGUGGGGCUCAAUCAUAA 
Dharmacon 
RSBN1L GAUAUAGAGACAACGACUA 
UAGAAGUAGUUCAACGAAU 
GUGUGGUAUUGUAGUGCAA 
Dharmacon 
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UCUAGUUGAUACAAGGCAA 
Non-targeting control  Dharmacon 
SiGLO Cyclophilin B 
control 
GGAAAGACUGUUCCAAAAA Dharmacon 
 
2.1.6 Antibodies  
Table 2.8 Primary Antibodies 
List of primary antibodies and corresponding supplier. Target epitopes and dilution 
for immunofluorescence (IF) shown.  
Primary Antibody Dilution for 
IF 
Supplier 
Mouse anti-GFP 1:300 Roche  
Rabbit anti-GFP 1:1000 Molecular Probes  
Rabbit anti-PKC zeta 1:50 Santa Cruz (California, USA) 
Rat anti-DE cadherin 1:100 Developmental studies hybridoma bank 
(DSHB) (Iowa, USA) 
Guinea Pig anti-
Bazooka 
1:1000 Prof. Andreas Wodarz 
Mouse anti-Fasciclin III 1:400 DSHB (Iowa, USA) 
Mouse anti-Dscam 1:250 Gift from  Larry Zipursky 
Mouse anti-Armadillo 1:100 DSHB (Iowa, USA) 
 
Table 2.9 Secondary Antibodies 
List of secondary antibodies with supplier and dilution for IF.  
Secondary Antibody Dilution (IF) Supplier 
Alexa Fluor ® 488 goat anti-mouse  1:300 Molecular Probes 
Alexa Flour ® 546 goat anti-rabbit 1:300 Molecular Probes 
Alexa Flour ® 546 goat anti-rat 1:300 Molecular Probes 
Alexa Flour ® 488 goat anti-rabbit 1:300 Molecular Probes 
Alexa Flour ® 546 goat anti-mouse 1:300 Molecular Probes 
Alexa Flour ® 546 goat anti-guinea 
pig 
1:300 Molecular Probes 
Alexa Flour ® 546 goat anti-Rat 1:300 Molecular Probes 
DAPI 25mg/ml Thermofisher Scientific 
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Table 2.10 General Reagents 
Reagent Supplier 
Agarose Life Technologies 
Alkaline Phosphatase, Calf Intestinal (CIP) NEB 
Ampicillin Sigma 
BbsI NEB 
BSA Sigma 
Chloroform Sigma 
CIP NEB 
DEPC Thermofisher Scientific 
Dharmafect Reagent Dharmacon 
DMEM Thermofisher Scientific 
DMSO Thermofisher Scientific 
DNase 1 Invitrogen 
10X DNase 1 Buffer Invitrogen 
dNTP Mix Thermofisher Scientific 
EDTA Invitrogen 
Ethanol Sigma 
Foetal bovine serum (FBS) Thermofisher Scientific 
Fetal calf serum (FCS) Thermofisher Scientific 
Glycerol Sigma 
Glycogen Sigma 
Hanks balanced salt solution (HBSS) Thermofisher Scientific 
HEPES Thermofisher Scientific 
Isopropyl alcohol Sigma 
iQ SYBR Master Mix BioRad, UK 
LB agar Sigma 
LB broth Sigma 
L-Glutamine Thermofisher Scientific 
NEBuffer 2.1 NEB 
Non-essential amino acids Thermofisher Scientific 
N-Propyl galate (anti-fade) Sigma 
Nuclease-free water Thermofisher Scientific 
Oligo(dT)18 Primer Thermofisher Scientific 
Paraformaldehyde (PFA) Thermofisher Scientific 
PBS Sigma 
Penicillin/Streptomycin (P/S) Thermofisher Scientific 
Proteinase K Thermofisher Scientific 
5X Reaction Buffer Thermofisher Scientific 
RevertAid Reverse Transcriptase Thermofisher Scientific 
RiboLock RNase Inhibitor Thermofisher Scientific 
5x siRNA buffer Dharmacon 
sybersafe Invitrogen 
50x TAE GeneFlow 
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TRIzol Reagent Ambion, Life Technologies 
Trypsin Thermofisher Scientific 
T4 DNA ligase  New England Biolabs (NEB) 
T4 DNA Ligase Reaction Buffer (10X) NEB 
T4 Polynucleotide Kinase NEB 
Tween 20 Sigma 
 
Table 2.11 Cells  
Cells Source 
U87 (adult human glioblastoma) Gift from Dr Ruman Rahman 
MDA-MB-231 (human breast 
adenocarcinoma) 
Gift from Dr Sally Wheatley 
Chemically competent DH5alpha cells  Gift from Dr Jen Patel 
 
2.2 Methods  
2.2.1 Drosophila Husbandry 
Drosophila stocks were maintained at 25oC and 18oC (where the life cycle of the fly is 
10 and 21 days respectively (Dahman, 2008)) and raised on a standard cornmeal 
medium made as follows (8L batch): 7340mlH20, 565ml golden syrup, 127g yeast, 
73g soya flour, 536g cornmeal, 42g agar, 35.4ml propanoic acid.  Stocks were flipped 
every 2-3 days at 25oC or once a month when stored at 18oC.  
 
Flies were anaesthetised using a CO2 porous polyeythylene gas diffuser and viewed 
under a Leica M60 or fluorescence microscope (Leica MZ10F) for virgin collections 
and analysis. Flies were sexed based on the identification of ventrally located claspers 
on the posterior abdomen of males and virgin females were collected every 8 hours 
when stored at 25oC or 16 hours when stored at 18oC (as females will not mate 
within the first 8 hours of adulthood (Ashburner, 1989). Genetic crosses were set up 
with approximately 20 females and 5-10 males and kept at 25oC.  F1 flies and pupae 
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were then screened against appropriate genetic markers and balancers to ensure the 
inheritance of desired genetic constructs. 
 
2.2.2 Drosophila Genetic Manipulation 
The majority of transgenic Drosophila stocks (RNAi lines) used in this research were 
generated by insertional mutagenesis by various Drosophila stock centres (VDRC, NIG 
and Bloomington).  To manipulate the Drosophila genome P-elements (a class of 
transposon) carrying specific constructs are micro- injected into the Drosophila 
embryo. Once P-elements have integrated into the genome transformant flies are 
identified by markers (typically eye colour) present in the P-element vector. 
Drosophila have 1 pair of sex chromosomes and 3 pairs of autosomes. The X, 2nd and 
3rd chromosomes can all be genetically modified, whilst the 4th chromosome is rarely 
used due to its smaller size and heterochromatic regions. Across these 4 
chromosomes there are approximately 14,000 genes which have been fully mapped 
and annotated (Bernards & Hariharan, 2001; Dahman, 2008; Potter et al., 2000). 
 
Most experiments in this research required genetic manipulation using mosaic 
techniques which enabled the generation of subsets of mutant cells (clones) within a 
wild-type environment. This process comprises 3 sophisticated genetic techniques: 
 
2.2.2.1 Upstream activating sequence (UAS)/Gal4 system 
The Gal4/UAS system enables the expression of transgenes in a specific cell type at a 
particular time point in the animals’ development. The Gal4 gene encodes a yeast 
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transcription activator protein that recognises and binds to upstream activation 
sequences (UAS) located alongside a gene of interest, such as a GFP reporter or RNAi 
hairpin. In the presence of the Gal4 protein, the UAS-transgene is subsequently 
expressed. Gal4 can be engineered under the control of different promoters (Table 
2.3) (Brand, Manoukian, & Perrimon, 1994). 
 
2.2.2.2 Flp/FRT system 
The genetic background of the fly can be easily manipulated using flippase (Flp)/ 
flippase recognition target (FRT) which is a site-directed recombination system. 
Induced by the recombination enzyme flippase, post-mitotic recombination can occur 
between identical FRT sites located on homologous chromosomes during G2 phase of 
the cell cycle. In this system the exchange of chromosome arms generates daughter 
cells which are either homozygous mutant or homozygous wild-type. Here flippase is 
under the control of the Ultrabithorax (Ubx) promoter, which restricts expression to 
the notum (Xu & Rubin, 1993). 
 
2.2.2.3 Mosaic Analysis with a Repressible Marker (MARCM) 
To enhance the degree of UAS responder regulation, the mosaic analysis with a 
repressible marker (MARCM) technique combines these systems with the addition of 
a Gal4 repressor, Gal80 (Fig. 2.1). When present, Gal80 represses gene activation 
initiated by Gal4 in heterozygous animals. However, following flp induced 
recombination; daughter cells that are homozygous mutant will have lost the Gal80 
repressor, thus allowing expression of UAS-transgenes specifically in the homozygous 
mutant tissue (T. Lee & Luo, 2001). For example, if the transgene is a GFP-reporter 
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then mutant cells will be GFP positive whilst wild-type cells will be GFP negative. 
Multiple UAS-constructs can be inserted into the genome, allowing homozygous 
mutant cells to not only be specifically labelled, but also to simultaneously express an 
additional transgene. 
 
 
Figure 2.1 MARCM system  
One chromosome arm of the parental cell contains the mutant lgl[4] allele, flp and 
FRT site whilst the other contains an identical FRT site and GAL80 under the tubulin 
promoter (A). Following DNA replication, flp drives recombination between the two 
FRT sites (B). Daughter cells are either homozygous mutant (C) in which tubGAL80 is 
lost, allowing Gal4 to drive transgene expression, or homozygous wild-type (D) where 
tubGAL80 represses Gal4 activity. 
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2.2.2.4 Labelling Individual Cells 
As well as generating GFP positive homozygous mutant clones individual well-spaced 
mutant cells can also be labelled on the back of the fly for a more detailed analysis of 
cell morphology. This is achieved by using a GAL4 driver under the control of the 
neuralised promoter, which restricts transgene expression to the sensory organ 
precursor cells and their progeny, which at the time of analysis are not yet fully 
committed to a precursor cell fate and so are representative of all cells within the 
epithelium (Cohen et al., 2010). 
 
2.2.2.5 RNA interference (RNAi) 
For loss of function studies P-elements can be inserted into the Drosophila genome 
which have a DNA inverted repeat, which, when transcribed forms an RNA hairpin. . 
Expression of a transgenic RNAi hairpin results in reduced expression of the target 
gene. dsRNA hairpins are cleaved by dicer into small interfering RNA (siRNA) of 20-
22nt, which are transported to the RNA induced silencing complex (RISC). RISC 
unwinds the siRNA to produce small single stranded RNA, of which the anti-sense 
strand then binds with high specificity to target messenger RNA (mRNA) resulting in 
its degradation or loss of function. Appendix B-C lists all the RNAi lines used in this 
research (Dietzl et al., 2007).  
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Figure 2.2 Expression of a UAS-RNAi transgene  
UAS-RNAi transgenes can be expressed in a tissue specific manner using the Gal4/UAS system. 
Cleavage of dsRNA hairpins by dicer generates siRNA complementary to target endogenous mRNA. 
Binding of the complimentary strands results in the degradation of mRNA and subsequent gene 
silencing.  
 
2.2.3 Fly genotypes for genetic experiments 
2.2.3.1 Using MARCM to generate wild-type GFP labelled clones 
Genotype imaged was:  Ubx-flp; FRT40A, FRTG13/Tub-GAL80, FRT40A; Pnr-
GAL4,UAS-Moe:GFP/MKRS 
 
2.2.3.2 Using MARCM to generate homozygous mutant clones for 
scribble complex polarity genes 
Genotypes imaged for lgl-/- mutant:  Ubx-flp; lgl4, FRT40A/Tub-GAL80, FRT40A; Pnr-
GAL4, UAS-Moe-GFP/MKRS. dlg -/- mutant: Ubx-flp, dlg, FRT19A/Tub-GAL80, 
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FRT19A;;Pnr-GAL4, UAS-Moe-GFP/MKRS. And scrib-/- mutant: Ubx-flp; Act-GAL4, 
UAS-Moe-GFP/IF; FRT82b, scrib/FRT82b, Tub-GAL80. 
 
2.2.3.3 Using MARCM to specifically express UAS-transgene on the 3rd 
chromosome in otherwise WT clones. 
Note UAS-transgene includes RNAi, Apoliner and P35. Genotype imaged: Ubx-flp/+; 
Tub-GAL80, FRT40A/FRT40A, FRTG13; Pnr-GAL4, UAS-Moe-GFP/UAS-transgene. Ubx-
flp;lgl[4], FRT40a/Tub-GAL80, FRT40A; Pnr-GAL4, UAS-Moe-GFP/UAS-transgene. 
 
2.2.3.4 Using MARCM to specifically express UAS-transgene on the 3rd 
chromosome in lgl homozygous mutant clones 
Genotype imaged: Ubx-flp;lgl[4], FRT40a/Tub-GAL80, FRT40A; Pnr-GAL4, UAS-Moe-
GFP/UAS-transgene. 
 
2.2.3.5 Using MARCM to specifically express UAS-RNAi on the X in lgl 
homozygous mutant clones 
Genotype imaged: UAS-RNAi/Ubx-flp; Tub-GAL80, FRT40A/ lgl[4], FRT40a; Pnr-GAL4, 
UAS-Moe-GFP/+. Only female flies were used. 
 
2.2.3.6 Labelling individual well-spaced cells in the notum 
Genotype imaged: Neu-GAL4, UAS-moe:GFP/+ 
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2.2.3.7 Generating negatively marked Dscam mutant clones 
Genotype imaged: Ubx-flp/+ ; FRT42, Dscam21/23 /FRT42, Ubi-nls-GFP  
 
2.2.3.8 Generating positively marked Dscam mutant clones 
Genotype imaged: Ubx-flp/+ ; FRT42, Dscam21/23 /FRT42, Tub-GAL80 ;Pnr-GAL4,UAS-
moe:GFP/+ 
 
2.2.3.9 Generating positively marked Dscam mutant clones with lgl 
RNAi 
Genotype imaged: Ubx-flp/+ ; FRT42, Dscam21/23 /FRT42, Tub-GAL80; Pnr-GAL4,UAS-
moe:GFP/lgl-RNAi 
 
2.2.3.10 Expressing live Cadherin in Dscam mutant animals 
Genotype imaged: Ubx-flp; FRT42, dscam21/FRT42, Ubi-mRFP-nls; Neu-GAL4, UAS-
Moe-GFP/Ubi-cad-GFP. 
 
2.2.3.11 Blocking apoptosis in lgl mutant clones 
Genotype imaged: Ubx-flp/UAS-p35; lgl[4], FRT40a/Tub-GAL80, FRT40A; Pnr-GAL4, 
UAS-Moe-GFP/+. Only females imaged. 
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2.2.4 Mounting for live imaging 
For live imaging, white pre-pupae (0 hours after puparium formation (APF)) were 
collected and incubated at 29oC. Once aged accordingly, pupae were immobilised 
ventral side down onto a microscopic slide and the notum was exposed by removing 
a region of the pupal case with tungsten forceps. Glass coverslips (0.13x0.17mm) 
were fixed to the anterior and posterior ends of the microscope slide generating a 
stage on which a long coverslip (24x50mm) coated with 10S Voltalef injection oil was 
placed creating an interface between the coverslip and exposed notum.  
 
2.2.5 Dissecting Drosophila nota 
Pupae were pinned dorsal side down in a silicon dish in cold PBS and the pupal casing 
was removed. The head and ventral regions were then excised using dissecting 
scissors and the animal flushed with PBS. The lateral regions of the remaining tissue 
were then removed leaving the central region of the notum where Pnr-GAL4 drives 
transgene expression (Simpson, 2007).  
 
2.2.6 Molecular Biology Techniques 
2.2.6.1 Immunostaining 
Dissected nota (Section 2.2.5) were fixed in 4% para-formaldehyde (PFA) for 25mins 
at room temperature (RT) and washed in PBS-T.  Tissue samples were incubated in a 
humidified chamber overnight at 4oC with primary antibody (Table 2.8), then washed 
again in PBS-T and incubated for another hr in secondary antibody. Samples were left 
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overnight in PBS(50%):Glycerol(50%)  at 4oC and mounted in mounting media (20% 
PBS, 80% Glycerol, 2% N-Propyl galate, 25mg/ml DAPI) the following day for imaging.  
 
2.2.6.2 Mutagenesis and Cloning 
pCFD3 plasmid (see plasmid map in Appendix A) was digested for 3 hrs at 37oC (1µg 
pCFD3, 5µl 2.1 RE buffer, 1µl BbsI made up to a final volume of 50µl with ddH20) and 
dephosphorylated by adding 0.5µl CIP for an additional 30mins. Digested pCFD3 was 
then run on a 1% agarose gel for 1hr at 120V. The band was visualised using a 
transilluminater and excised with a scalpel. The DNA was then purified using Qiagen 
gel extraction kit (Qiagen, 28704) following manufacturers protocol.  
 
Oligos required for mutagenesis and cloning were designed using Primer3 software 
(Table 2.4). Sense and anti-sense oligos were annealed and phosphorylated by 
setting up the following reaction: 1µl each oligo, 1µl 10x T4 ligation buffer, 0.5µl T4 
PNK, and 6.5µl ddH20. The following thermocycler program was then used: 37
oC 
30min, 95oC 5min, ramped down to 20oC at a rate of 0.1oC per second. Once 
annealed and phosphorylated the oligos were then diluted 1:200 with ddH20.  
 
For ligation, 50ng of previously digested pCFD3, 1µl annealed oligos (diluted 1:200), 
1.5µl 10x T4 buffer, 1µl T4 ligase made up to a final volume of 15µl, was incubated at 
RT for 2hrs. The reaction was then heat inactivated at 65oC for 15 mins. 4µl of the 
ligation mix was then added to 50µl of chemically competent E-coli DH5α cells and 
kept on ice for 30mins. The cells were then heat-shocked for 45 seconds at 42oC and 
immediately placed back on ice for a further 2 mins. 250µl of SOC media (0.5% Yeast 
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Extract, 2% Tryptone, 10mM NaCl, 2.5mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM 
Glucose) was added to the mix and placed for 1 hr in a 37oC shaking incubator. 100µl 
of transformed cells were spread on LB agar plates containing 100µg/µl ampicillin 
and incubated overnight at 37oC.  
 
Single colonies were used to inoculate 3ml of LB broth (1% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 1% (w/v) NaCl) containing 100µg/µl ampicillin and grown overnight at 
37oC in an orbital shaker at 225rpm.  
 
1.5ml of bacterial culture was centrifuged to generate a pellet and plasmid DNA was 
purified using Qiagen miniprep kit (Qiagen, 27104) following manufacturer’s 
protocol. 100ng/µl of purified plasmid was finally sent for Sanger sequencing (DNA 
sequencing facility, University of Nottingham) using the T3 primer.  
 
Qiagen PCR purification kit (Qiagen, 28104) was then used according to 
manufacturer’s protocol to further purify samples before sending to the Cambridge 
fly facility, UK, for microinjection of DNA into flies where Cas9 on the X chromosome 
is under the nanos promoter for germline specific expression (Bloomington 54591).  
 
2.2.6.3 PCR to check CRISPR mutagenesis 
Surviving micro-injected flies received from the Cambridge fly facility were screened 
for vermilion (present in the pCFD3 backbone) and individually crossed to a balancer 
line containing CyO-GFP. Heterozygous CRISPR*/CyO-GFP flies were crossed back to 
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the balancer line and used to make a stock. Parent CRISPR*/CyO-GFP were 
simultaneously used to verify desired mutations. Genomic DNA was extracted from 
the flies by crushing individual whole flies in 50µl squishing buffer (10mM Tris-HCl 
pH8, 1mM EDTA, 25mM NaCl) containing 200µg/ml Proteinase K (added fresh). The 
following thermocycler conditions were then used: 
37oC/ 30min, 95oC/ 2min and hold at 4oC. 
 
To amplify the target DNA, 5µl of DNA, 25µl OneTag 2x MasterMix, 1µl of each 10µM 
primer made up to a final volume of 50µl with dH20 was prepared and run in the PCR 
machine with the following program: 
94oC/30secs, then 35 cycles of 94oC/30secs, 65oC/1min, 68oC/50secs, finally 
68oC/5mins and hols at 4oC. 
 
Samples were run on a 2% agarose gel for 1hr at 120V to check for a single band at 
the appropriate PCR product size. Samples were then purified using the Qiagen PCR 
purification kit (Qiagen, 28104) following manufacturers protocol and eluted in 
ddH2O before being sent for sequencing at the DNA sequencing facility, University of 
Nottingham, using the forward CG1 primer (Table 2.6). 
 
2.2.6.4 RNA extraction 
To extract RNA from cell lines, cells were pelleted (Section 2.3.3) and lysed by 
pipetting in 0.75mL Trizol reagent. Samples were then incubated for 5mins at RT then 
shaken vigorously for 15 seconds following addition of 0.2mL chloroform. To separate 
the RNA from the phenol-chloroform phase, samples were centrifuged for 15mins at 
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12,000 rpm, 4oC. The aqueous layer containing RNA was then isolated. 0.5mL 100% 
Isopropanol was then added to the aqueous layer and incubated for 10mins at RT 
before centrifuging a further 10mins at 12,000 rpm, 4oC. The supernatant was 
removed leaving the RNA pellet which was washed with 1mL 75% ethanol and 
centrifuged for 5mins at 7,500rpm, 4oC. Excess wash was removed and allowed to air-
dry for 10mins. The pellet was re-suspended in 50µl RNase-free water and incubated 
for 15mins at 55oC. RNA concentration was measured using a Nanodrop2000.   
 
2.2.6.5 cDNA synthesis 
cDNA synthesis of RNA extracted from cell lines (section 2.2.6.4) was carried out in 
order to perform RT-PCR . For DNase treatment 1µg RNA, 1µl 10x buffer and 1µl 
DNase1 made to a final volume of 10µl was incubated at 37oC for 30min. The reaction 
was then stopped by adding 1µl EDTA and incubated at 65oC for 10mins. For cDNA 
synthesis 1µl OligoDT, 1.5µl dH20, 4µl 5x reaction buffer, 0.5µl RNase inhibitor, 2µl 
10mM dNTP and 1µl RevertAid were added to the mix and incubated at 42oC for 
60mins then 70oC for a further 10mins.  
 
2.2.6.6 RT-PCR 
Real-time RT-PCR was used in order to determine the relative mRNA levels of target 
genes in each cell line following transfection using SYBER-green detection. For each 
sample 1µl cDNA, 12.5µl IQ SYBR master mix, 2.5µl each of each primer, was made 
up to a final volume of 25µl in a 96-well plate. A C1000 thermal cycler CFX96 RT 
system was used with the following conditions:  
95oC/10min then 40cycles of 95oC/15secs, 60oC/1min, 72oC/30secs then 72oC/10min. 
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2.3 Cell Culture 
2.3.1 Cell maintenance 
U87 and MDA-MB-231 cells were cultured in DMEM supplemented with 10% (v/v) 
foetal bovine serum (FBS), and 1% penicillin/streptomycin (P/S). Cells were grown in 
T75 culture flasks at 37oC in a 5% CO2 atmosphere. Cells were routinely passaged 
when 80% confluent. Growth medium was removed and cells washed in Hanks 
Balanced Salt Solution (HBSS). Cells were incubated for 5mins at 37oC with 0.05% 
Trypsin in HBSS to detach cells. Pre-warmed growth medium was then added to 
deactivate the trypsin. Desired numbers of cells were seeded into new T75 flasks 
containing appropriate amount of media. 
 
2.3.2 Cell counting 
To count cells, 10µl of cell suspension was applied to a haemocytometer BS 748 
(Hawksley, UK). Cells were counted in all 4 squares in the corners of the 
haemocytometer. As the number of cells in each square equates to the number of 
cells x 104/ml the following equation was used to count and seed appropriate 
number of cells. 
𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑙 =  (
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑓𝑟𝑜𝑚 4 𝑐𝑜𝑟𝑛𝑒𝑟 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
4
)  𝑥 104 
 
2.3.3 Cell storage and recovery 
Growth medium was removed from a confluent T75 flask of cells and washed in 
HBSS. Cells were trypsinised (Section 2.3.1) and re-suspended in growth medium.  
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Cells were then pelleted by centrifuging for 5mins at 800rpm and re-suspended in 
freezing medium consisting of 90% fetal calf serum (FCS) and 10% dimethylsulfoxide 
(DMSO). Cells were counted as previously described (section 2.3.2) and diluted to 
1x106 cells/ml in freezing medium. 1ml of cell suspension was transferred to cryovials 
and stored at -80oC in a Mr Frosty freezing container for at least 24hr. For long term 
storage tubes were transferred to liquid nitrogen.  
 
2.3.4 Transfections 
5x104 cells were seeded in single wells of a 6-well plate in antibiotic-free medium and 
incubated at 37oC with 5% CO2 for 24hrs until 60-80% confluent. 5µM siRNA stock 
solution was diluted 1:20 with serum-free medium and added to DharmaFECT diluted 
1:100 with serum-free medium and incubated 20mins at RT. Transfection medium 
was then diluted with antibiotic-free medium to a final siRNA concentration of 25nM 
and total transfection volume of 2ml per well. Transfection medium was added drop-
wise to each well after removing the culture medium and incubated at 37oC with 5% 
CO2 for 48hrs. Culture medium was removed from wells and cells were washed with 
HBSS. Cells were trypsinised and re-suspended in growth medium as previously 
described (Section 2.3.1) and centrifuged for 5mins at 800rcf to harvest a cell pellet 
for downstream application (RT-PCR – Section2.2.6.4, invasion assay- Section 2.3.5)  
 
Percentage knockdown was calculated using the Δ ΔCq method:  
ΔCq1 = Cq(Target) – Cq (Ref),  ΔCq2 = Cq(Scram) – Cq (Ref) 
ΔCq expression = 2−ΔCq 
Δ ΔCq = ΔCq1exp/ ΔCq2exp 
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%KD = (1- Δ ΔCq)*100 
(Target represents the gene being knocked down, Ref represents the reference gene 
(GAPDH) and Scram is the non-targeting control) 
 
2.3.5 Invasion Assay 
Invasion assays were carried out in invasion chambers containing inserts with an 8µm 
pore size polycarbonate membrane coated in an ECL cell attachment matrix (Merk 
Millipore) in single wells of a 24-well plate. Prior to performing the assay the matrix 
was diluted to 20µg/mL with serum-free medium and added to the inserts to a final 
concentration of 4µg and incubated for an hr at 37oC.  48 hours post-transfection 
cells were washed with HBSS and incubated for 10mins at 37oC with HBSS with 0.05% 
trypsin and 25mM HEPES. Serum-free medium containing 5% BSA (quenching 
medium) was then added to each well and cells were centrifuged at 1500rpm for 
10mins to produce a pellet which was re-suspended in 1ml quenching medium. Cells 
were counted (section 2.3.2) and bought to a final volume of 0.5x106 cells/mL. 250µl 
of cell suspension was added to each insert and 500µl of culture medium with 10% 
FBS was added to the lower chamber. Plates were incubated for a further 48hrs at 
37oC with 5% CO2. Following incubation the cell suspension was removed from the 
upper chamber and the insert was placed into a new well containing detachment 
solution (ECM554, Merk Millipore). Cells that had invaded through the matrix were 
allowed to detach from the membrane for 30mins at 37oC. CyQuant dye was diluted 
1:75 with lysis buffer (ECM554, Merk Millipore) and added to wells containing the 
detached invading cells and incubated for 15mins at RT. Samples were transferred to 
a 96-well plate and read on a fluorescent plate reader using 480/520 nm filters and 
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optimal gain. To image invading cells, instead of placing inserts in detachment 
solution, the inserts were washed with ddH20 and the upper-side of the membrane 
was blotted with cotton buds to remove non-invasive cells. The membrane was then 
stained with 0.1% crystal violet solution for 2 mins and washed again with ddH20 
prior to imaging.  
 
2.4 Microscopy and Image Analysis 
For screening, imaging was performed using an inverted Leica SP2 confocal laser 
scanning microscope with 40x oil immersion objective and Ar/HeNE (488nm) laser. 
Clones were imaged by generating z-stacks of 1μm planes from the cuticle to basal 
lamina at a resolution of 1024x1024. For other experiments requiring multi-channel 
acquisitions a Zeiss LSM880 or LSM exciter confocal laser scanning microscope was 
used with 40x oil immersion objective, optimal resolution and lasers 405nm, 488nm, 
543nm and 633nm. Fiji (ImageJ) software was used to analyse images and Prism 
(GraphPad) was used to generate graphs and carry out statistical analysis. Where 
student t-tests were performed, significance was shown as: p<0.05*, p<0.01**, 
p<0.001***, p<0.0001****. Additionally ApoE software was used to analyse 
chromatograms, and R Studio for hierarchical clustering.  
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Chapter 3 Pilot Screen 
3.1 Introduction 
As discussed in Section 1.3 functional alterations to epithelial polarity protein 
networks are crucial to the pathology of cancer. The polarity proteins Scribble (Scrib), 
Discs-Large (Dlg) and Lethal giant larvae (Lgl) which form the basolateral Scribble 
complex, genetically interact to cooperatively regulate cell polarity, junction integrity 
and cell proliferation.  The Scribble polarity module maintains epithelial apicobasal 
polarity, defining distinct cellular domains and positioning of adherens junctions (AJ) 
and septate junctions (tight junctions in mammalian cells) (Bilder & Perrimon, 2000). 
 
First identified in Drosophila, members of the Scribble complex contain highly 
conserved protein-protein interaction domains, including SH3 and PDZ domains, 
which enable them to recruit various protein networks to cooperatively regulate 
polarity (Bilder, 2003; Schneiderman & Gateff, 1967). Additionally, the correct 
localisation of these proteins is vital for their function in maintaining apicobasal 
polarity (Section 1.4). In mutants for Scrib/Dlg/Lgl AJs become disorganised through 
the mislocalisation of apical determinants, resulting in the loss of communication 
between cells and integrity of the epithelium (Bilder, 2003; Tanentzapf & Tepass, 
2003). 
 
Members of the Scribble complex have long been classified as neoplastic tumour 
suppressors and are linked to the progression of mammalian tumours (Bilder & 
Perrimon, 2000). There are various human orthologues of these polarity genes which 
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play a role in the formation of epithelial malignancies where expression is either 
downregulated or lost. Gene expression studies have shown that human Dlg1 binds 
to known tumour suppressor genes APC and pTEN, and is implicated in HPV-induced 
malignancies (S. S. Lee, Weiss, & Javier, 1997; Matsumine et al., 1996; Valiente et al., 
2005). Similarly, the mammalian orthologue of Scribble is associated with the APC/β-
catenin pathway. While human Lgl1 has been linked to a variety of cancers, including 
breast and colon adenocarcinomas, glioblastomas, and melanomas (Grifoni et al., 
2004; Kuphal et al., 2006; Schimanski et al., 2005). The cancer phenotypes of 
lgl/dlg/scrib mutants can be rescued by their mammalian homologues, suggestive of 
their tumour suppressive function in human cells, and implicating them as potential 
targets of anti-cancer therapies. In both transgenic mouse models and human 
cancers these genes commonly show a reduced expression, mislocalisation or 
depletion of protein products. Significantly, the human homologue of Lgl is 
downregulated or lost in a variety of cancers including breast cancer (76%), colon 
carcinomas (75%) and lung cancer (63%). 
 
Scrib/Dlg/Lgl are widely used in loss-of-functions (LOF) studies when investigating the 
transformation of epithelial cells into their malignant derivatives. Studies in 
Drosophila larvae have demonstrated that mutations causing LOF phenotypes in any 
one of the polarity proteins forming the Scribble complex results in polarity defects, 
aberrant cell architecture, cellular hyper-proliferation and invasion, all of which are 
characteristics of mammalian carcinomas (Bilder & Perrimon, 2000). 
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Loss of lgl in the Drosophila eye results in mislocalisation of the hippo kinase, an 
integral component of the highly conserved Salvador/Warts/Hippo (Hpo) pathway 
which prevents phosphorylation of the transcriptional activator Yorkie (Yki). This 
leads to upregulation of the pathway which is a known regulator of cell proliferation 
and survival. Targets of the Hpo pathway, including Cyclin E are upregulated in lgl 
mutant tissue, directly linking defects in cell polarity, hyperproliferation and evasion 
of cell death in the neoplastic tissue (Fig. 3.1) (Grzeschik, Amin, Secombe, Brumby, & 
Richardson, 2007; Grzeschik, Parsons, Allott, Harvey, & Richardson, 2010). 
Additionally, when neoplastic lgl mutant brain tumours from Drosophila, labelled 
with lacZ encoded β-galactosidase, were grafted onto the abdomen of a wild-type fly, 
lacZ positive cells were later detected in the ovaries. As Drosophila ovaries are 
enclosed within a non-porous epithelial sheet with two basement membranes, these 
results conclude that lgl mutant cells are also capable of invading and metastasising 
(Beaucher et al., 2007).  
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Figure 3.1 Lgl and the Hippo pathway 
Lgl facilitates the interaction in which Hippo kinase phosphorylates the 
transcriptional activator Yorkie (Yki) preventing transcription of genes involved in cell 
growth. Loss of Lgl therefore prevents inactivation of Yki allowing it to translocate to 
the nucleus and transcriptionally activate target genes such as cyclin E.  
 
The formation of epithelial tumours is largely dependent on the cooperation 
between mutations in tumour suppressor genes and oncogenes. In 2003, a model of 
tumour progression in the larval eye antennal imaginal disc was generated in the Xu 
and Richardson labs to study the development of metastatic tumours (Pagliarini & 
Xu, 2003). They showed that over-expression of activated Ras (RasV12) in the eye 
imaginal disc generates large non-invasive tumours which, when combined with a 
homozygous scrib mutation (scrib-/-) resulted in the metastasis of GFP positive 
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RasV12; scrib-/- cells to the ventral nerve cord and other tissues. Moreover, this 
metastatic behaviour could be inhibited by over-expressing Scrib. As scrib-/- flies 
alone produce non-invasive tumours, Pagliarini and Xu demonstrated that both 
mutations in scrib and over-expression of Ras were required for invasion. Similarly, 
during a clonal analysis of the eye disc (using MARCM), scrib-/- clones were also 
shown to require cooperative interactions with oncogenic Ras or Notch in order to 
exhibit clonal overgrowth (Brumby & Richardson, 2003). Additionally, in the absence 
of oncogenic signalling, scrib- clones generated during the 3rd instar larval stage of 
development had significantly diminished in size following pupation. Interestingly, 
scrib-/- clone size was significantly increased when Jun-N-terminal Kinase (JNK) was 
blocked, suggesting that the surrounding WT tissue was able to outcompete the 
mutant clones by initiating JNK-mediated apoptosis, resulting in a proliferative 
advantage over the scrib-/- tissue (Brumby & Richardson, 2003). Similarly, Chen et al 
2012 showed that when clones of cells mutant for scrib were generated, they were 
capable of forming large neoplastic tumours in animals where all cells within the 
imaginal discs were mutant. However when scrib- cells were surrounded by wild-type 
cells, the mutant cells were eliminated by apoptosis through a JNK-dependent 
mechanism (C. L. Chen et al., 2012). In these examples, overgrowth is seen when the 
whole tissue is mutant, but cell competition prevents these when clones of mutant 
tissue are generated in an otherwise WT tissue. This is mainly seen in the imaginal 
discs which is a highly proliferative epithelium.  As originally characterised in 
Drosophila, cell competition describes the apoptotic elimination of cells surrounded 
by a population of more rapidly proliferating cells. Local cell-cell interactions between 
two populations of cells that differ in the expression of a particular protein lead to 
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the elimination of ‘loser’ cells through apoptosis, whilst surviving ‘winner’ cells 
proliferate to replace the outcompeted cells (C. L. Chen et al., 2012; Morata & Ripoll, 
1975; Simpson & Morata, 1981). Therefore cell competition between mutant and 
wild-type cells acts as a tumour suppressing mechanism. 
 
In previous Drosophila studies, the wing and eye imaginal discs have served as the 
prime model for studying cancer epithelial cells; however using this system it is 
difficult to image the behaviour of individual cells, thus precluding a more detailed 
analysis of tumour development. To overcome these limitations Baum and Georgiou 
(Georgiou et al., 2008) (Georgiou & Baum, 2010) developed an in vivo system which 
could be used to generate and visualise both clones of mutant tissue and individual 
well-spaced epithelial cells within the dorsal thorax (notum) of the fly, thus allowing 
mutant cells to be followed in the hours/days following tumour induction. This 
system has already enhanced our understanding of junction integrity and the 
cooperation of apical polarity proteins with Rho-GTPases in controlling epithelial cell 
morphology and dynamic protrusion formation. We now aim to use this system to 
help improve our understanding of the early events in tumourigenesis and tumour 
progression. 
 
As mentioned previously (Section 1.5) the aim of my PhD was to carry out a large-
scale genetic screen using the Drosophila notum as a model for tumour progression, 
and from this to identify and characterise genes that significantly perturb tumour 
progression. To do this RNAi would be used to knock-down genes specifically within 
neoplastic tumours (mutant clones) on the back of the fly to see how the gene of 
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interest affects tumour progression. The aim of this chapter was to initially determine 
the genetic background with which to carry out the enhancer/suppressor screen. As 
members of the Scribble complex have been shown to act as neoplastic tumour 
suppressors, these would be investigated as potential genetic backgrounds for the 
screen. The second aim of this chapter was to carry out cooperative experiments 
with Notch in the genetic background to validate our novel in vivo assay. Finally, to 
carry out a pilot screen on a selection of well-characterised cancer associated genes 
with the following main objectives: 
 Optimise conditions for the full RNAi-screen  
 Verify that RNAi-mediated knockdown was working as expected 
 Verify that two independent RNAi lines for the same gene give the same 
phenotype 
 Verify that phenotypes seen in the pilot screen correspond with expected 
phenotypes for well characterised cancer-associated genes. 
 To generate a database to qualitatively analyse a range of tumour phenotypes 
for each gene studied relative to the mutant background alone.  
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3.2 Results 
3.2.1 Scribble complex mutants generate tumours of varying 
phenotypes. 
Using the MARCM system clones of GFP-marked cells homozygous mutant for scrib, 
dlg and lgl were generated in the notum of the fly.  The behaviour of transformed 
cells was then observed in high temporal and spatial resolution in living pupae (20-
24APF).  The GFP fusion protein Moe-GFP (consisting of the actin binding domain of 
Moesin fused to GFP) was utilised to target GFP to the actin cytoskeleton, allowing 
for a detailed analysis of epithelial cell morphology.   
 
Wild-type columnar epithelial cells form an organised monolayer on the back of the 
fly (Fig. 3.2 A) and cells are characteristically polygonal in shape at the apex. In 
comparison, lgl, dlg and scrib mutant clones showed significant alterations to clone 
size and cell morphology (Fig. 3.2 B-D). Compared to WT, lgl homozygous mutant 
clones were slightly larger (ns), however clones mutant for dlg or scrib were 
significantly small or non-existent (p<0.0001) (Fig. 3.2 E). 80% of animals expressing a 
mutant allele for dlg presented no clones in the notum at 20hrs APF.  Although dlg 
and scrib mutant clones were consistently small in size it is important to note that 
when pupae were screened at 0APF large clones could be seen using a Leica GFP 
microscope. Visually, all three mutant phenotypes lost their typical polygonal shape 
(indicating effects on apicobasal polarity) resulting in epithelial multi-layering and 
hyper-proliferation (Fig. 5.2 B’-D’). This morphological alteration was notably more 
severe in dlg and scrib mutants. A variety of other cancer-associated phenotypes 
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were observed and subsequently quantified. Cells undergoing division could be 
identified through their characteristic cortical cell rounding, and quantified as 
another indicator of hyper-proliferation. For evidence of these cells dividing into two 
daughter cells see Fig. 3.3 in which UAS-His-RFP was used to label chromosomes. In 
this transgene, RFP is linked to the coding region of histone 2A, labelling 
chromosomes with RFP, so they can be visualised during time-lapse movies of cells 
undergoing cell division. As seen, dlg and scrib had significantly fewer (p<0.0001) 
visible cells undergoing cell division compared to lgl-/- and WT (Fig. 3.2 F). lgl-/- 
tumours also presented an invasive phenotype, whereby individual GFP-positive cells 
could be seen beneath the epithelium (Fig. 3.2 G). Another phenotype associated 
with loss of apicobasal polarity is the length of the cell, from the cell apex to the basal 
protrusions. WT cells are typically 10-13µm long, whereas dlg-/- and lgl-/- showed an 
increase in cell length, most significantly was lgl-/- (p=0.0002), whereby cells were on 
average 16µm long (Fig. 3.2 H).  
 
Pnr-Gal4 drives expression in a central stripe of the dorsal thorax epithelium, and was 
used together with MARCM to positively label WT, lgl-/- and dlg-/- mutant clones 
with GFP. However due to scribble and Pnr being on the same chromosome, an Actin-
Gal4 driver was used to label scrib mutant clones. Interestingly, in scrib mutant cells, 
Moe-GFP appeared to be mis-localised and was observed throughout the cell, 
including the nucleus (Fig. 3.2 C’). 
 
From this data, it could be inferred that lgl-/- was the ideal genetic background for a 
enhancer/suppressor screen as large mutant clones could be generated and mutant 
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tissue was slightly multi-layered and invasive. Therefore both positive and negative 
effects on this phenotype could be easily detected.   
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Figure 3.2 Homozygous Scribble complex mutants 
Confocal images of the Drosophila notum (A-D) GFP positive clones of wild-type 
tissue in the notum (A,A’), and clones homozygous mutant for the tumour 
suppressor gene lgl (B,B’), scrib (C,C’) and dlg (D,D’). Scale bars = 50µm (A-D), or 
10µm (A’-D’). (E-H) Graphs represent the mean percentage of notum covered in GFP-
labelled clonal tissue (E), the percentage of cells undergoing cell division (F), the 
percentage of invading cells detected beneath the epithelium (G) and epithelial cell 
length, in µm (H). Graphs indicate the mean with error bars representing standard 
error (SEM). Each genotype was compared to WT using a students’ t-test and 
considered significant when p<0.05. WT (n=10 animals), lgl (n=32), dlg (n=14), scrib 
(n=13).  
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Figure 3.3 Time-lapse of mitotic wild-type cell 
Clones of GFP-marked cells expressing Ubi-His-RFP (magenta) in wild-type 
background. Tissue expresses the transgene His-RFP in which RFP is linked to the 
coding region of histone 2A. Snap shots taken from an 8min time lapse. Scale bar = 
50µm. 
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3.2.2 Oncogenic Notch cooperates with mutant lgl in the Drosophila 
notum 
As mentioned (Section 3.1), it has been shown in other Drosophila systems that the 
scribble polarity tumour suppressor gene cooperates with oncogenes to enhance the 
malignant phenotype (Brumby & Richardson, 2003; Pagliarini & Xu, 2003). 
 
To test that lgl has the same cooperative effects in this system, an activated allele of 
the Notch oncogene (N[intra]) was overexpressed specifically within the lgl 
homozygous mutant tissue. Through diverse effects on differentiation, survival and 
proliferation, Notch signalling is a key player in normal development. Truncated 
forms of Notch can act as potent oncogenes and are seen in a large number of 
cervical and colon carcinomas. 
 
Overexpressing Notch in an otherwise WT animal generated clones relatively similar 
to WT, with the epithelium remaining highly structured and organised (Fig. 3.4 A). As 
seen previously (Fig. 3.2 B’) lgl homozygous mutant tissue was multi-layered and 
invasive, however these phenotypes were dramatically enhanced when oncogenic 
Notch was simultaneously expressed specifically within the lgl mutant tissue (Fig. 3.4 
B-F). The cooperation between the lgl tumour suppressor mutation and oncogenic 
Notch resulted in significantly more invasive tumours when compared with lgl-/- 
(p=0.0233), WT (0.0009) and N[intra] (p=0.0354) genotypes. Additionally, cells were 
seen growing on-top of one another in multi-layers (Fig. 3.4 B). Also, significantly 
more cells could be seen undergoing cell division when compared to lgl-/- 
(p=0.0461), WT (p=0.0045) and N[intra] (p=0.0009) (Fig. 3.4 E).  
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These results illustrate that lgl-/- cooperates with the Notch oncogene to enhance 
the neoplastic cancer phenotype in the Drosophila notum.   
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Figure 3.4 Cooperation between oncogenic Notch and mutant lgl in the 
notum 
(A-D) Confocal images of mutant clones in the notum. GFP-marked clones expressing 
oncogenic Notch (N[intra]) (A) or simultaneously expressing N[intra] in homozygous 
lgl mutant clones (B-D). Scale bars = 50µm (A, C, D) or 10µm (B). Red arrows indicate 
cells undergoing cell division (C) and invading cells beneath the epithelium (D). (E-F) 
The mean and standard error for each genotype was plotted whereby the number of 
dividing/invading cells is illustrated as a percentage of the total number of mutant 
cells within the notum for each animal. WT (n=10 animals), lgl-/- (n=32), N[intra] 
(n=7), lgl-/-; N[intra] (n=11).  
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3.2.3 Pilot screen 
During an initial pilot screen a wealth of candidate genes previously implicated in 
cancer were studied to ensure the system was working efficiently. These candidates 
included various oncogenes, tumour suppressor genes, MMPs, and regulators of cell 
morphogenesis, with a range of biological functions (Fig. 3.5 A). In addition, genes 
which are not normally expressed in the notum were knocked down; acting as 
negative controls.  UAS-RNAi constructs were used to knockdown candidate genes 
specifically within the lgl homozygous mutant tissue. Where possible two different 
RNAi constructs were used for each gene. In total, the pilot consisted of 67 RNAi lines 
targeting 46 well-known genes (Appendix B).   
 
During the pilot screen a database of cancer-associated phenotypes was set up 
whereby each RNAi was qualitatively analysed. For each animal, a range of 
phenotypes was given a score relative to the lgl mutant phenotype alone. The 
phenotypes scored included: clonal tissue coverage, invading cells, dividing cells, 
apex size, multi-layering, basal protrusions, and cell length. Qualitative analysis for 
each RNAi was carried out blind by at least two scientists in the Georgiou lab due to 
the subjective nature of the analysis. Thresholds were then applied to each 
phenotype to identify ‘hits’ which appeared to dramatically enhance or suppress the 
tumour phenotype. Fig. 3.5 B-G outlines the biological processes of the genes which 
were identified as ‘hits’ for various categories. Genes identified for notably affecting 
the size of clonal tissue were shown to have a known role in regulating proliferation 
and growth, similar to those genes with strong multi-layering phenotypes. Highly 
invasive genes picked up in the screen were mostly involved in polarity, cell migration 
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and adhesion, whereas hits for apex defects and elongated/defected basal 
protrusions often came from knocking down known actin regulators.   
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Figure 3.5 Biological functions and phenotypes of pilot screen genes 
Break down of the main biological functions of all the genes studied in the pilot 
screen (A). Breakdown of the biological functions of the genes identified as ‘hits’ for 
various phenotypes, including percentage of mutant tissue within the notum (B). Hits 
for invasion (C), multilayering (D), apex size/defects (E), protrusion length/defects (F) 
and loss of polarised cell shape (G). n=46 (a few genes listed under more than 1 main 
biological function, see Appendix B for full list of pilot genes and their biological 
functions). 
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Throughout the pilot screen a range of phenotypes were observed, including hyper-
proliferation, multi-layering, invasion, apoptosis and effects on subcellular structures 
(junctions, microvilli, basal protrusions) (Fig. 3.6). For example, knocking down APC in 
the lgl mutant background produced highly invasive multi-layered clones with basal 
bundles and long thick protrusions (Fig. 3.6 A-A’’), whilst knocking down TSC1 
resulted in phenotypes indicative of hyper-proliferation such as clonal tissue 
overgrowth and increased cell division (Fig. 3.6 B-B’).  Misshapen, blebbing dividing 
cells were also observed with Moesin RNAi (Fig. 3.6 C). Knocking down p53 in the lgl 
mutant background drastically affected apex integrity, and clones were multi-layered 
and highly invasive (Fig. 3.6 D-D’’). Whilst loss of E-cadherin drastically reduced the 
size of clonal tissue in the notum and altered cell morphology. As well as affecting the 
length of basal protrusions, often these actin rich membrane extensions had other 
morphological changes such as branching (Fig. 3.6 E-E’’). Negative controls failed to 
give drastic phenotypes (see Appendix G (CD) for scoring system of all genes). 
 
A range of the observed phenotypes where then quantified for a variety of different 
genotypes (Fig. 3.7). When compared to the lgl mutant phenotype alone, it could be 
seen that loss of APC (p=0.0004), E-cadherin (p=0.0124) and pTEN (p=0.0475) in the 
mutant background significantly enhanced the invasive phenotype of the tumour 
(Fig. 3.7 A). TSC1 RNAi however had a negative effect on the invasive properties of 
the tumour (p=0.0450). Knocking down E-cad, APC and P53 all produced clones of 
mutant tissue significantly smaller than that seen in lgl mutants alone (p=0.0161, 
0.0242, 0.0343 respectively) (Fig. 3.7 B). Cell length was also significantly increased 
with APC, TSC1, and pTEN RNAi (p=0.0006, 0.0068, 0.0022 respectively) (Fig. 3.7 D).   
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It is also important to note that the quantitative analysis of various phenotypes 
reflected the qualitative analysis previously carried out. For example, when scoring 
for invasion animals where given a score of whole numbers from -2 to 2, where an 
invasive phenotype comparable to lgl alone was given a score of 0; increased 
invasion was given a positive score and decreased invasion a negative score. Across 
all the animals where APC was knocked down the average score for invasion was 0.65 
which exceeded the >0.5 threshold set to identify hits for invasion. Similarly 
quantification of invasion in these animals showed a significant difference compared 
to lgl alone. Therefore it could be confidently assumed that qualitative analysis of 
genes would be sufficient to pick up ‘hits’ from the screen which could be further 
quantified and characterised.  
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Figure 3.6 Cancer-associated phenotypes observed in the pilot screen 
lgl homozygous mutant tissue expressing UAS-RNAi hairpin constructs for APC (A-A’’), 
TSC1 (B-B’), Moesin (C), P53 (D-D’’), and E-cadherin (E-E’’). Scale bars = 50µm in all 
panels except (C) where the scale bar is 10µm. Various cancer-associated phenotypes 
were observed: basal bundles (A), polarised invading cells (A’,D’’,E), long thick 
filipodia (A’’), clonal tissue overgrowth (B), large numbers of cells undergoing cell 
division (B’), blebbing of mitotic cells (C), apex defects (D), multi-layering (D’), and 
long branched basal protrusions (E’-E’’).   
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Figure 3.7 Quantification of phenotypes when expressing UAS-RNAi 
targeting various cancer associated genes.  
Quantification of some cancer phenotypes for a small population of genes studied in 
the pilot screen compared to lgl homozygous mutant background. Looking at the 
percentage of mutant cells that had invaded and detected beneath the epithelium 
(A), the percentage of the notum that was mutant (B), the number of mutant cells 
undergoing cell division (C) and the length of mutant cells, in µm (D). Bars represent 
the mean (n=10 animals) and error bars represent SEM.  
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Where possible two independent RNAi lines, ideally from different sources, were 
used to target each gene to ensure observed phenotypes were in fact a direct result 
of RNAi knockdown rather than through off target effects. In Fig. 3.8 A-C’ two 
independent RNAi lines (35731-GD and 5671R-1) were used to target pTEN mRNA for 
degradation. When either of these RNAi constructs was expressed in the lgl mutant 
background similar phenotypes were observed, from multi-layering (Fig. 3.8 A-A’), 
long basal protrusions (Fig. 3.8 B-B’) and invading cells detected beneath the 
epithelium (Fig. 3.8 C-C’).  Similarly, when comparing RNAi lines for other genes such 
as APC, TSC1 and P53 there was no significant difference between the phenotypes 
observed (Fig. 3.8 D-G). In only two instances was there a low significance (p<0.05) 
between RNAi lines: the percentage of invading cells between RNAi lines targeting 
APC, and dividing cells between RNAi lines for TSC1. 
 
On the whole, this showed that RNAi lines for the same gene generated similar 
phenotypes, and so it could be inferred with confidence that in this system the 
phenotypes observed were due to the knockdown of particular genes and not off-
target effects.  
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Figure 3.8 Comparing independent RNAi lines targeting the same gene 
lgl homozygous mutant tissue simultaneously expressing two independent RNAi lines 
targeting pTEN (35731-GD, 5671R-1). For both, tissue was multi-layered (A,A’), with 
long basal protrusions (B,B’) and invasive (C,C’). Scale bars = 50µm. When 
independent RNAi lines for the same gene were compared to each other for various 
phenotypes (D-G), in most cases there was no significant different between the RNAi 
lines (n=10 animals for each RNAi line).  
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During the pilot screen 10 animals were imaged per RNAi line, analysis of these 
animals indicated that in most cases animals with the same genotype gave similar 
phenotypes. To help visualise this we collaborated with several mathematicians who 
generated a statistical code and carried out some preliminary analysis. Here I show 
the results using hierarchical clustering, which uses a statistical code to cluster genes 
with similar phenotypes. To do this, Gowers statistical analysis was applied which 
analyses the distance between mean values for each gene. Using R studio, a 
statistical code was designed, whereby a hierarchical clustering algorithm groups 
animals according to Gowers analysis. Figure 3.9 shows the dendrograms produced 
using this analysis. All animals analysed during the pilot screen are illustrated in Fig. 
3.9 A, and by zooming into separate branches on the hierarchy tree (Fig. 3.9 B) 
clustering of these animals can be analysed. In this example, animals with KD for P53, 
Rbf1, Mnt, TSC1, Ex-IR, PAK3, Scrib, pTEN and cytochrome c can be seen clustering 
together. Analysis of these dendograms gives confidence that in most cases animals 
give similar phenotypes.  
 
As mentioned, qualitative analysis of each animal was carried out blind by at least 
two scientists in the Georgiou lab due to the subjective nature of the analysis. Scoring 
by individual scientists was often checked against one another to ensure there were 
no major discrepancies. Additionally, mathematical analysis could be applied to 
determine if there were any particular phenotypes where scientists scored 
particularly differently. To do this, paired t-tests were used to compare the means of 
each phenotype then false discovery rate (FDR) analysis was used to calculate 
correction of the p-value. This analysis therefore looks at all the errors in the 
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hypothesis across multiple comparisons. From this various phenotypes scored were 
identified which appeared to result in regular scoring differences between scientists. 
These included clonal tissue, dividing cells, basal protrusions and clonal shape. 
Although this test indicates there is error between scientists scoring for these 
categories, it is important to note that in most instances the scores given still reflect 
positive or negative regulation of the phenotype. Some discrepancies are obviously 
expected due to the subjective nature of this analysis. 
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Figure 3.9 Hierarchial dendograms of pilot genes screened 
(A) Dendrogram of all pilot genes screened using Gowers analysis. (B) Magnification 
of branches. Each end branch represents a single animal imaged during the screen.  
Animals expressing the same RNAi can be seen grouping together. 
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3.3 Discussion 
Cancer is defined by an uncontrolled proliferation of abnormal cells that are able to 
invade other tissues, most commonly deriving from an epithelium. In order for these 
cancer cells to form secondary tumours at distant sites, they must lose cell-cell 
contacts within the epithelial sheet and breach the basement membrane for local 
invasion. Using the MARCM system, neoplastic tumours were generated in the 
notum of the fly, which were homozygous mutant for lgl, dlg or the scrib tumour 
suppressor genes. Clones of mutant tissue surrounded by wild-type tissue were 
generated to prevent lethality and to more accurately mimic tumour development in 
humans, thus allowing the role of the microenvironment to also be investigated.  
 
Alterations to cell morphology and clonal size were observed in mutant tissue for all 
three tumour suppressor genes when compared to clones of labelled wild-type 
tissue. Unlike the lgl-/- mutant clones generated in the notum, both dlg-/- and scrib-
/- mutant clones were comparatively smaller in size, which was likely to be a result of 
cell competition between the wild-type and homozygous mutant tissue. Why cell 
competition was seen in dlg and scrib mutant clones and not in lgl-/- clones in this 
system is still not fully understood. However, unlike Dlg and Scrib, Lgl has been 
shown to regulate the Salvador/Warts/Hippo pathway associated with cell survival 
and proliferation.  This pathway comprises a kinase cascade leading to the 
phosphorylation of the transcriptional co-activator Yorkie (Yki), subsequently 
excluding it from the nucleus. Dephosphorylated Yki can translocate to the nucleus 
where binding to the scalloped (sd) transcription factor results in the transcription of 
genes associated with cell survival and proliferation (Grzeschik et al., 2010).  
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This may explain why lgl mutant cells were not outcompeted by the surrounding 
wild-type cell population in this system. Additionally, unlike previous work which 
looks at the imaginal discs, the notum is not a highly proliferative epithelium which 
could explain why larger clones are seen with lgl-/-.  Therefore, in contrast to 
previous work, the notum can provide a ‘one hit’ system, inducing many of the 
hallmarks of cancer through a single mutation to a tumour suppressor, and so can be 
used as a model system to characterise the critical events underlying tumour cell 
invasion.  
 
lgl-/- mutant clones exhibited cancer phenotypes including invasion, multi-layering 
and loss of polarised cell shape. As these phenotypes were not severe, and the 
mutant tissue wasn’t being eliminated through cell competition, lgl-/- provided the 
ideal genetic background with which to carry out an enhancer suppressor screen as 
both increases and decreases in the cancer phenotype could be identified.  
 
Although all mutant cells were labelled with Moe-GFP which targets GFP to the actin 
cytoskeleton, unexpected nuclear staining was seen in scrib-/- clones.  Unlike dlg and 
lgl mutant clones (which used Pnr-Gal4), we saw a mislocalisation of Moe-GFP 
throughout the cell in scrib-/- clones (which used Actin-Gal4). Actin-Gal4 drives the 
expression of UAS-transgenes throughout the animal and in our experiment could 
result in Moe-GFP being driven too strongly, which could explain the mislocalisation 
of Moe-GFP in scrib-/- clones. This mislocalisation would make it difficult to study the 
actin cytoskeleton during the screening process. Additionally, global expression of 
Moe-GFP would mean that other cell types might be labelled in the notum (other 
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than epithelial cells) so it would be difficult to accurately identify invading cells that 
had come from the mutant tissue. In order to overcome this problem, other 
members of the Georgiou lab recombined mutant scrib with the Pnr-Gal4 driver 
which are both located on the 3rd chromosome. As expected, driving Moe-GFP with 
Pnr-Gal4 in scrib -/- clones resulted in the correct localisation of GFP to the actin 
cytoskeleton. scrib-/- mutant clones were still invariably small and so this was still not 
an ideal genetic background to use in an enhancer/ suppressor screen, however this 
recombined stock could be useful in any pertinent secondary screens. 
 
It has been shown in other systems that the Scrib tumour suppressor gene requires 
cooperation with activated alleles of oncogenic Ras or Notch in order to produce 
dramatic overgrowth and become invasive (Brumby & Richardson, 2003; Pagliarini & 
Xu, 2003). Additionally lgl mutant clones were shown to require cooperation with 
oncogenic cMyc in the imaginal wing disc (Froldi et al., 2010). Similarly, in our system 
this cooperative effect was mimicked when the phenotype of lgl-/- tumours was 
enhanced when combined with an oncogenic form of Notch. However, unlike these 
previous Drosophila studies in which scrib-/-, dlg-/- and lgl-/- mutant clones remained 
hyperplastic without oncogenic cooperation, lgl-/- was sufficient to generate invasive 
tumours without over-expressing Notch in our system. 
 
During the pilot screen of over 40 well characterised cancer-related genes, a range of 
phenotypes was observed, including, hyper-proliferation, multi-layering, invasion, 
apoptosis and effects on subcellular structures. By observing these phenotypes a 
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database comprising various categories was set up in order to qualitatively score 
tumour behaviour relative to lgl alone during the main candidate screen.  
 
One of the aims of the pilot was to determine whether expected phenotypes for well 
characterised genes were replicated in this system. This was true in most cases, for 
example, a highly invasive phenotype was seen when expressing UAS-RNAi targeting 
E-cadherin, APC or TSC1. All three of these genes have been linked to progressive, 
invasive tumours through the loss of cell polarity, cooperation with potent oncogenes 
and regulation of the mTOR pathway respectively (Canel, Serrels, Frame, & Brunton, 
2013; Y. Chen, Wei, Liu, & Guan, 2014). E-cadherin is an integral member of AJs and 
thus is pivitol for the maintenance of cell polarity; the loss of which effects epithelial 
integrity and promotes invasion (Canel et al., 2013). APC is most commonly known 
for its role in suppressing Wnt signalling which plays a key role in controlling cell 
proliferation and differentiation. APC inactivation studies have also linked APC to the 
maintenance of cell adhesion (Bienz & Hamada, 2004) and knockout mouse models 
result in defects in cell migration as well as proliferation and differentiation (Sansom 
et al., 2004). TSC1 knockout experiments in mice have resulted in significantly 
increased rates of proliferation compared to the control, along with invasive and 
migratory activity (Y. Chen et al., 2014). This was replicated in the pilot screen where 
large tissue over-growth, and invasive tumours were generated. Similarly, other 
phenotypes observed in Moesin, pTEN and p53 were also validated based on 
previous literature. For example, blebbing mitotic cells were seen when knocking 
down Moesin which is known for its role in the regulation of cell rounding during 
mitosis, where loss of Moesin results in disorganisation of the actin cortex resulting in 
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a phenotype comparable to apoptotic blebbing (Kunda, Pelling, Liu, & Baum, 2008). 
Misshapen dividing cells were also observed during the pilot screen when knocking 
down the kinase Slik which facilitates the phosphorylation of Moesin during the 
regulation of cell shape during mitosis (Carreno et al., 2008). An invasive phenotype 
was observed in pTEN KD animals which is also seen clinically, whereby pTEN 
mutations are highly prevelent in metastatic human tumours (Gonzalez-Angulo et al., 
2011). In previous Drosophila studies, clones of pTEN mutant cells have an increased 
proliferation rate caused by antagonistic effects on Dp110 (Drosophila homologue of 
PI3-K), linking pTENs growth regulatory activity to the TOR pathway (H. Huang et al., 
1999). pTEN has also been shown to modulate cell polarity and cytoskeletal 
arrangements in both Drosophila  and mouse models (Tamura et al., 1998); 
additionally overexpression studies  in vitro result in suppression of tumour cell 
invasion and metastasis (Tamura, Gu, Takino, & Yamada, 1999). It is unsurprising that 
severe phenotypes were seen for p53 since p53 activity is affected in more than 50% 
of all human cancers, and plays a critical role in signalling pathways that affect 
proliferation, EMT and apoptosis (Muller & Vousden, 2014).  
 
As well as generating expected phenotypes based on previous literature when 
knocking down well known cancer-related genes, two independent RNAi lines for the 
same gene typically produced similar phenotypes. This confidently validated that 
RNAi was working efficiently in this system. Occasionally there was some variation 
between RNAi lines for the same gene, whereby phenotypes were more severe in 
one RNAi line compared to the other. Because, the two independent RNAi lines 
target different regions of the mRNA for the target gene, it is possible that one RNAi 
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transgene is having more of an effect than the other. One RNAi construct could be 
knocking down expression better than the other, or possibly one RNAi transgene may 
not work at all. For the full candidate screen, two RNAi lines for the same gene would 
still be used where possible to ensure phenotypes were not being missed. However it 
should be stressed that the vast majority of RNAi transgenes targeting the same gene 
gave the same phenotypes (Fig. 3.8). Additionally, our original plan was to image 10 
animals per RNAi line for the entire candidate screen. However, since results from 
the pilot screen showed a low level of phenotypic variation in transformed cells 
between animals, we decided to reduce the number of animals to be imaged per 
RNAi line to 5, thereby maximising speed and efficiency. 
 
In conclusion, from this chapter it was inferred that lgl-/- was the best genetic 
background with which to carry out an enhancer/suppressor screen, and that RNAi 
was working efficiently in this system. It was also shown that the co-operative nature 
between tumour suppressor genes and oncogenes could be replicated and studied. A 
range of phenotypes were seen, which lead to the generation of a database for the 
qualitative analysis of candidate genes relative to lgl alone.  Additionally, I have 
shown that hits for specific phenotypes identified from this qualitative analysis were 
shown to be statistically significant when quantified. All of these results suggested 
that the large-scale candidate screen would likely pick up genes that are important in 
tumour progression.  
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Chapter 4 Large-scale RNAi screen 
 
4.1 Introduction 
Following on from the pilot screen (Chapter 3) a large-scale candidate screen was 
carried out. This screen is now almost complete, with all animals (a total of 478 
genes/696 RNAi lines) now imaged. Since the qualitative analysis of these genes is 
still in progress, I will be presenting a preliminary analysis of 418 genes (610 RNAi 
lines). Therefore, the data presented here represent a preliminary analysis of those 
genes that have been qualitatively analysed to date.  
 
Drosophila has become the favourable model organism with which to carry out large-
scale genetic screens, as they are cheap and easy to look after. Additionally, they 
have a relatively short life-cycle and are genetically easy to manipulate. In this way 
Drosophila screens are commonly used to identify novel genes which play an 
important role in a specific biological process. As mentioned in Chapter 1, notably the 
most famous genetic screen in Drosophila was carried out by Eric Wieschaus and 
Christiane Nusslein-Volhard in 1980. In this paper they did a mutagenesis screen in 
the embryo to identify essential patterning genes. Since this pioneering research, 
many different genetic screens have been carried out in Drosophila. In recent years 
RNAi mediated screens have identified new genes and regulatory networks involved 
in a variety of processes (Nusslein-Volhard & Wieschaus, 1980). For example in 2015 
Zeng et al  carried out a genome-wide screen which identified more than 400 genes 
involved in stem cell renewal in the adult Drosophila intestine (Zeng et al., 2015).  
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To select genes for the screen various online databases including the catalogue of 
somatic mutations in cancer (COSMIC) and publications from the Getz lab (Lawrence 
et al., 2014) were used to generate a compilation of genes commonly mutated or 
down-regulated in human cancers. As our model system is the Drosophila notum, 
only genes mis-regulated in epithelial cancers were selected. Genes were then listed 
in order of mutation rate, and cross-referenced to check for Drosophila orthologues 
and available transgenic RNAi lines. RNAi lines had to be on the X or 3rd chromosome 
as the lgl[4] mutation is on the 2nd. A range of genes were then selected from those 
well-characterised to those completely uncharacterised. For our screen, genes were 
ordered in batches to keep fly maintenance to a minimum, with a total of 7 batches 
being ordered from the Vienna Drosophila stock centre (VDRC), the National Institute 
of Genetics, Japan (NIG) and Bloomington, Indiana stock centres, over 3 years.  This 
screen would not have been possible without the development of these near 
genome-wide RNAi stock centres. Overall, our screening process is relatively cheap 
and timely (we developed the methodology to generate labelled tumours on the back 
of the fly in the living animal and to image these tumours in high temporal and spatial 
resolution). The screening process required several members of the Georgiou Lab, all 
of whom were involved in every aspect of the process. For each transgenic RNAi line 
a minimum of 5 animals were imaged, with approximately 60 animals being imaged 
each week during high-throughput screening periods enabling us to analyse hundreds 
of genes relatively quickly.  
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Recently, the relative ease with which human cancer samples can be sequenced and 
deep-sequenced has resulted in a plethora of publications and online databases that 
demonstrate genetic and/or epigenetic aberrations in different human cancers. 
However, for many of these implicated genes, little is known about their function 
other than the fact that they have been shown to be commonly mutated/down-
regulated in a variety of human cancers. This screen will hopefully address this 
current lack of knowledge.  
 
4.1.1 Aims  
The main aim of the candidate screen was to identify novel genes that promote or 
inhibit the tumour progression in the Drosophila notum. Once identified, potential 
hits would be characterised in more detail to improve our understanding of their role 
in tumour progression, and may provide potential targets for future therapeutic 
intervention.  See Chapters 5 and 6 for examples of genes that gave interesting 
phenotypes that were deemed suitable for further characterisation. 
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4.2 Results 
 
4.2.1 Qualitative scoring of phenotypes 
During the pilot screen, a database was generated with which to record and 
qualitatively score different phenotypes for every animal imaged. This was developed 
further following analysis of the pilot screen. Using the database, for a single animal 
all observed phenotypes would be given a numerical score. For each phenotype this 
score represents the extent of similarity/difference between the animal being 
analysed compared to lgl-/- animals. Table 4.1 outlines the main phenotypes 
analysed and the scoring system used. The phenotypes which best represented that 
seen in lgl-/- animals were given a score of 0, with positive and negative effects being 
scored accordingly. Confocal images demonstrating this scoring system are shown in 
Figure 4.1.  As scoring was a qualitative measure, done by eye, a minimum of two 
researchers from the Georgiou Lab scored and analysed every animal imaged.  
 
Table 4.1 Scoring system for various phenotypes 
Phenotype Description Scoring system  
Clonal Tissue <5% (Fig. 4.2.1 A) -2  
5-15% (Fig. 4.2.1 A’) -1 
15-35% (Fig. 4.2.1 A’’) 0 
35-50% (Fig. 4.2.1 A’’’) 1 
>50% (Fig. 4.2.1 A’’’’) 2 
Invasion No invading cells (Fig. 4.2.1 B) -2 
Few invading cells (Fig. 4.2.1 B’) -1 
Moderate level of invasion (Fig. 4.2.1 
B’’) 
0 
Increased invasion (Fig. 4.2.1 B’’’) 1 
Highly invasive (Fig. 4.2.1 B’’’’) 2 
Basal protrusions Absent filopodia (Fig. 4.2.1 C) -3 
Short filopodia (Fig. 4.2.1 C’) -2 
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Normal filopodia (Fig. 4.2.1 C’’) -1 
Long filopodia (Fig. 4.2.1 C’’’) 0 
Very long filopodia (Fig. 4.2.1 C’’’’) 1 
Apex size Very small (Fig. 4.2.1 D) -2 
Small (Fig. 4.2.1 D’) -1 
Normal (Fig. 4.2.1 D’’) 0 
Large (Fig. 4.2.1 D’’’) 1 
Multi-layering 
Multi-layering was scored 
based on the amount of 
clonal tissue that had 
become multi-layered 
0% -1 
0-15% 0 
15-50% 1 
>50%  2 
Cell length <7µm -2 
8-12µm -1 
13-19 µm 0 
>20µm 1 
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Figure 4.1 Scoring system applied for various phenotypes 
Confocal images of phenotypes observed during the screen and their relative scores 
compared to the lgl-/- phenotype. (A-A’’’) Clonal tissue and (B-B’’’) invasion (invading 
cells highlighted by red arrows) scale bars 100 µm. (C-C’’’) Basal protrusions (red 
arrows) and (D-D’’’) apex size. Scale bars 20 µm. 
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4.2.2 Correlation between qualitative scores and quantitative analysis  
Quantitative analysis was performed on a selection of genes chosen at random in 
order to compare the quantitative measurements to the qualitative scores given. The 
aim of this analysis was to ensure that the scoring system employed to analyse genes 
was truly representative and could be relied upon when selecting genes for 
characterisation.  
 
Figure 4.2 compares the scores given for various phenotypes to the quantitative 
measurements made for the same animals. When mutant GFP positive tissue was 
measured as a percentage of the whole notum (Fig. 4.2 A) there was a positive 
correlation between increases in the score given and percent of clonal tissue. 
Similarly this positive correlation was observed when quantification was carried out 
for other measurable phenotypes including invasion (Fig. 4.2 B), length of basal 
protrusions (Fig. 4.2 C), apical area (Fig. 4.2 D) and cell length (Fig. 4.2 E). While 
overall there appeared to be a good correlation between the scores and actual 
measurements taken, as expected from such subjective analysis there was some 
variation between the quantitative results taken for animals with a given score. 
Despite this, the positive trend provides confidence that strong phenotypes will be 
easily identified during the screen. 
 
From these results the scoring system appeared to be a good method for the 
relatively quick analysis of genes from the screen. By using the database generated in 
Chapter 3 queries could then be designed to filter genes based on the scores given 
for an individual phenotype or groups of phenotypes with the aim of identifying 
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potential hits which could be characterised further (see Appendix G (CD)  for all 
genes and scores given for a range of phenotypes). 
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Figure 4.2 Correlation between qualitative scores and quantitative 
results. 
Graphs comparing the scores given to individual animals against the quantitative 
measure for a range of phenotypes including: (A) clonal tissue, (B) invasion, (C) basal 
protrusions, (D) apical area and (E) cell length. Different shapes represent different 
animals. n=10.  
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4.2.3 Gene ontology of genes analysed during the screen 
So far 696 transgenic RNAi lines have been imaged, targeting 478 genes within the 
Drosophila genome. The human orthologues of these genes have all been shown to 
be mis-regulated in human cancers. As the qualitative analysis hasn’t been finished 
for all animals to date, here I will be presenting analysis on 418 genes (610 RNAi lines) 
(see Appendix C for full list of genes). Of these, 45 genes had no known function, and 
remain uncharacterised in Drosophila. The remaining 373 genes have a known role in 
a variety of processes, based on the gene ontology (GO) terms assigned to them 
within the Gene Ontology Consortium database (Ashburner et al., 2000). Figure 4.3 
shows the range of GO terms associated with the genes that have so far been studied 
in this screen. These vary from epigenetic processes to cell adhesion, tissue/organ 
morphogenesis, immune response and neuron/axon development.  
 
In total, we qualitatively analysed more than 20 different phenotypes and using our 
database it is very easy to identify genes which dramatically affect a particular 
phenotype. Figure 4.4 shows the key GO terms for strong hits for 8 major categories. 
Of all the genes with no known function, 7 were identified as strong hits for invasion, 
4 with apex defects, 4 highly multi-layered, 18 had elongated cells and 2 with very 
long basal protrusions.  
 
From the screen, 80 genes were identified as hits for invasion (average score >0.5). 
Approximately half of these genes were shown to have known roles in cell adhesion, 
intracellular signalling pathways, actin/cytoskeletal regulation, cell cycle and 
cell/tissue/organ developmental processes; as you would expect from invasive 
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tumours (Fig. 4.4 A). Top hits for invasion included regulators of metabolic processes 
(Trax, PP2C1), neurogenesis (Su(var)2-HP2, CG11180), cell migration and axon 
guidance (Unc5), spermatogenesis (CG7379), adhesion (Dscam3), circadian cycle (iH), 
epithelium morphogenesis (Ser) and intracellular signalling (RhoGap19D, Sdr). 
CG4393 was also identified as a top hit for invasion which has no known function. 
 
Half of the genes identified as hits for invasion were also identified as hits for multi-
layering. Multi-layering was the most common phenotype observed, with 
approximately 200 genes being scored an average of 1 or greater. Genes with the 
most severe multi-layered phenotypes (>1.8) included regulators of adhesion (ft, 
18w, shot, mys), polarity (jbug), neurogenesis (cap), epigenetic processes (CTCF) and 
cell death (iz). Additionally, the uncharacterised gene CG10600 was identified within 
the top 20 hits for multi-layering.  
 
Along with multi-layering, genes that scored highly for invasion also showed apical 
constriction. Additionally, apical constriction and multi-layering were often seen 
together without increased invasion. A large proportion of hits for both multi-layering 
(Fig. 4. 4 B) and apex defects (Fig. 4. 4 C) also had known roles in cell adhesion as well 
as epigenetic processes. Just over 40 genes were given an average score of <-1 for 
apex size, indicating that target gene KD is causing apical constriction. These genes 
included regulators of neurogenesis (Su(var)2-HP2), axon guidance and adhesion 
(Cont, troll, sema1b, Nrg, lea), polarity (Jbug) and cell cycle/cell death (bel). Genes 
identified with unknown function were CG15395 and CG42672.  
129 
 
Other phenotypes analysed included clonal tissue (Fig. 4.4 D), basal protrusions (Fig. 
4.4 E) and cell length (Fig. 4.4 F). Both decreases and increases in clonal tissue were 
seen during the screen. More commonly gene KD caused a reduction in clonal tissue 
with more than 170 genes resulting in an average score of -1. On the other hand only 
10 genes resulted in increased clonal tissue (>0.5). Top hits for reduced clonal tissue 
(<-1.5) included regulators of cell cycle (mrtf, Smr), development/adhesion (how, 
Cont) and morphogenesis/polarity (Cora). While increased clonal tissue included 
regulators of synaptic growth and neurogenesis (NGI2, MKK) and epigenetic 
processes (fd102c, nub). While no genes with unknown function were shown to 
increase clonal tissue within the notum, CG5645 was identified as a hit for reducing 
clonal tissue. 
 
Only 27 genes from the screen resulted in a phenotype exhibiting long basal 
protrusions. Of these, unsurprisingly many were involved in regulating the actin 
cytoskeleton and cell-adhesion (kug, Pvr, Rac2, p120ctn). Additionally, top hits 
included those with known roles in axon guidance and migration (side, unc5); 
epigenetic processes (lilli) and cell cycle (myb, Trf4-2), as well as CG11593 and 
CG10669 with unknown function. 
 
More than 120 genes were identified (score >0.5) which caused cells to elongate 
along the apicobasal axis. 4 genes with no known function (CG16868, CG10600, 
CG33288, and CG5550) were identified within the top 10 hits for increased cell 
length, while other genes within the top 10 included regulators of cell cycle (myb), 
cell death (fkh) and renal protein absorption (cubn).   
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Figure 4.3 GO terms for all genes analysed during the screen 
Breakdown of the main biological functions of the 418 genes studied during the 
screen, including the percentage of genes involved in each process. 
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 GO term Invasion Multi-
layering 
Apex 
Defect 
Clonal 
Tissue 
Basal 
Filopodia 
Cell 
Length 
 Actin Regulation 7.2 3.1 2.6 2.0 15.8 3.1 
 Epigenetic Processes 5.4 10.3 11.5 14.9 10.5 6.7 
 Cell Adhesion 9.01 11.3 14.1 9.9 10.5 11.0 
 Metabolic Processes 3.6 3.1 5.1 7.9 13.2 5.5 
 Intracellular Signalling 9.01 8.2 10.3 9.9  9.2 
 Transport Processes 7.2 8.2 7.7 7.9 5.3 4.9 
 Axon Guidance 5.4 5.2 1.3 1.0 5.3 6.1 
 Polarity 1.8 2.1 3.8 1.0 2.6 3.7 
 Cell Cycle 8.1 6.2 7.7 7.9 7.9 2.5 
 Other 2.7 4.1 2.6 2.9 2.6 6.1 
 Neuron/Axon/Dendrite 
Development 
2.7 5.2 6.4 4.9 5.3 3.1 
 Migration 2.7 2.1 1.3  5.3 1.9 
 Synaptic Regulation 1.8 2.1 2.6 1.0  0.6 
 Cell Death 0.9 6.2 2.6 2.9  2.5 
 Response to Stress  2.1  2.0 2.6 3.1 
 Sensory Perception 7.2 2.1 2.6  2.6 1.2 
 Tissue/Organ 
Morphogenesis 
1.8 3.1 1.3 2.9 5.3 2.5 
 PTMs 3.6     0.6 
 Notch Signalling 2.7 1.0  2.0  2.5 
 Phagocytosis 1.8   1.0  0.6 
 Cell Morphogenesis   2.6    
 Microtubule movement 0.9 1.0 1.3   3.1 
 Immune Response 0.9 2.1  2.9  3.1 
 Development 7.2 6.2 7.7 7.9  4.9 
 Proliferation  1.0  1.0  0.6 
 Unknown 6.3 4.1 5.1 1.0 5.3 11.0 
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Figure 4.4 GO terms for genes which were identified as hits for a variety 
of phenotypes 
Breakdown of the biological functions of the genes identified as ‘hits’ for various 
cancer-associated phenotypes, (A) hits for invasion, (B) multilayering, (C) apex 
size/defects, (D) clonal tissue, (E) protrusion length/defects and (F) cell length. (See 
Appendix G (CD) for the full list of genes and scores given). Numbers represent the 
percentage of genes within each category identified as a hit.  
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4.2.5 Identification of protein complexes involved in tumour 
progression 
To further visualise and analyse hits identified during the screen the online tool 
COMPLEAT was used to carry out a complex enrichment analysis on all the genes 
screened. From this, a variety of protein complexes were identified which have a 
potential role in tumour progression (Fig. 4.5). The graphs in Figure 4.5 A-A’’ 
compare the average scores given to each gene for various phenotypes. In each 
graph the black nodes represent genes which were hits for both phenotypes plotted. 
By zooming in to each node COMPLEAT identifies protein complexes using both 
literature and various protein-protein interaction prediction tools. Figure 4.5 B-B’’’’ 
illustrates a few of these protein complexes which were identified during the screen. 
Protein complexes identified included: Smcb-Scmcf-PW29; ITGB11-RAP1A-PKD1; 
ITGB1-NRP1; and G protein complexes.  
 
KD of genes which are members of the SMEA4A-PlexinD1 (Sema-1a, Sema-2a and 
plexB), ITGB11-RAP1A-PKD1 (mys, pdk2 and R) and ITGB1-NRP (mys, Ddr, Hml and 
CG34380) protein complexes resulted in multi-layered, invasive tumours with apical 
constriction. Apex defects and multi-layering were seen together when members of 
the Smcb-Scmcf-PW29 (SMC1 and Cap) and G protein complexes (GBeta13F) were 
knocked-down in the Drosophila notum.  
 
Other protein complexes identified from the enrichment analysis included the ITGA5-
ITGB1-FN1-TGM2 complex (mys, Dscam, Tg, Ptp4E) and NRP2-VEGFR3 complex (Ddr, 
134 
 
CG34380, Hml, Pvr) which were enriched in all datasets for invasion, multi-layering 
and apex size.  
 
Comparing invasion against cell length (Fig. 4.6) produced a linear graph, whereby 
increases in cell length were accompanied with increased invasion. Protein 
complexes enriched in a positive direction along the X and Y axis included ITGB11-
RAP1A-PKD1 and ITGB1-NRP1which were identified previously (Fig. 4.5). Conversely, 
decreased cell length resulted in a rescue of the invasion phenotype seen in lgl-/- 
animals. Protein complexes that had reduced cell length and decreased invasion 
included P300-CBP-p270-SWI/SNF complex (Osa, brm and Snr) and ETS2-SMARCA4-
INI1 complex (brm and Snr). 
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Figure 4.5 Protein enrichment analysis of identified genes 
COMPLEAT online database results comparing all genes from the screen. (A-A’’) 
Graphs compare different phenotypes, with black nodes representing genes/gene 
clusters which were enriched in both phenotypes along the X and Y axis; blue nodes 
represent genes with positive scores only for the phenotype on the Y axis, cyan for 
those on the X, pink for those enriched in both X and Y but in opposite directions and 
grey representing the genes which were not enriched in either phenotype. (B-B’’’’) 
Protein complexes identified from the enrichment analysis. Grey nodes represent 
members of the protein complex which were not included in the screen, while the 
other nodes represent the genes which were studied and identified as hits. A gene 
given maximum score is coloured red and colour is seen as a gradient from red to 
blue where genes were given a minimum score for that phenotype.   
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Figure 4.6 Protein enrichment analysis comparing invasive phenotypes 
and cell length 
COMPLEAT online database result comparing all genes from the screen. (A) Graph 
comparing invasion against cell length, with black nodes representing genes/gene 
clusters which were enriched in both phenotypes along the X and Y axis; blue nodes 
represent genes with positive scores only for the phenotype on the Y axis, cyan for 
those on the X, and grey representing the genes which were not enriched in either 
phenotype. (B) Protein complexes identified from the enrichment analysis. Grey 
nodes represent members of the protein complex which were not included in the 
screen, while the blue nodes represent genes which gave negative scores for both 
cell length and invasion. 
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4.2.6 Hierarchical clustering of genes 
Another way in which genes from the screen could be analysed was through the use 
of hierarchical clustering, which tries to cluster genes which have a similar 
phenotype.  To do this, Gowers statistical analysis was applied (described in Chapter 
3). A hierarchical clustering algorithm then groups genes according to this Gowers 
analysis. Figure 4.7 shows the dendrograms produced using this analysis. All genes 
analysed during the screen are illustrated in Fig. 4.7 A, and by zooming into separate 
branches on the hierarchy tree (Fig. 4.2.7 B, C) clustering of these genes can be 
analysed. 3 separate branches of the dendrogram are shown in Figure 4.7 C-C’’. In 
Fig. 4.7 C the genes Rab40, CG11180 and wrapper have all been shown to regulate 
processes involved in neuron/axon/dendrite development, while CG7708 has no 
known function. Similarly in Fig. 4.7 C’ trol and Gbeta13F have known roles in 
polarity, while CG10623 is unknown. Finally in Fig. 4.7 C’’, all the genes except 
CG10669 (function unknown) regulate the actin cytoskeleton and adhesion. It is 
hoped that by using analyses such as this, that the function of unknown genes can be 
hypothesised based on the function of genes they cluster with.  
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Figure 4.7 Hierarchial dendograms of genes screened 
(A) Dendrogram of all genes screened using Gowers analysis. (B-C) magnification of 
branches produced, with a group of genes shown to cluster together in C. red 
asterisks indicates genes with no known function.  
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4.3 Discussion 
Drosophila has become an increasingly popular model organism to study tumour 
progression and due to its easy genetic manipulation and short life-cycle is often used 
in large-scale screens.  Baum and Georgiou developed an in vivo system using the 
Drosophila notum in which both clones of mutant tissue and individual epithelial cells 
could be studied in real time (Georgiou et al., 2008) (Georgiou & Baum, 2010). This 
system provides a ‘one hit’ system in which most of the hallmarks of cancer can be 
induced by mutating a single tumour suppressor gene. By generating clones on the 
back of the fly which were homozygous mutant for lgl, a screen was established such 
that transgenic RNAi was used to knockdown additional genes in the mutant 
background.  
 
Our screen has been ongoing for a number of years, with many people contributing 
to its progress. Additionally, we collaborated with several mathematicians for the 
statistical clustering analysis. The initial aim of our genetic screen was to screen 
through 500 genes and from this identify novel genes which affect tumour 
progression in this system. Although I have only presented a preliminary analysis on 
418 genes (610 RNAi lines) in this chapter, an additional 60 genes had been imaged 
but still need to be qualitatively analysed or re-imaged. Therefore we have almost 
(but not quite) completed the screen and as such are only just beginning to explore 
the mathematical tools available to analyse this data. Additionally, with the vast 
collection of highly complex confocal images obtained during the screen, it will be a 
challenge to extract as much information as possible from these images.  From my 
preliminary analysis more than 200 genes were identified which were shown to 
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drastically promote tumour progression in this system. It is unsurprising that so many 
genes were identified as hits for multi-layering, as the human orthologues of these 
genes have already been implicated in cancer. Of these, 80 genes were able to 
promote invasion. While this system in the notum has already improved our 
understanding on how polarity proteins and Rho-GTPases regulate junction integrity 
and dynamic protrusions, we have now used it to identify genes which seem to play a 
role in tumour progression and invasion.   
 
Using COMPLEAT protein enrichment analysis various protein complexes were 
identified which promoted tumour progression during the screen. Some of these 
complexes have already been implicated in cancer, including the NRP2-VEGFR3 
complex. This complex has recently been linked to progression of breast cancer and 
metastasis (Luo et al., 2016) and during our screen was identified from genes which 
promoted invasion, multi-layering and apical constriction. Additionally, the complex 
SME4A-plexinD, a hit for invasion, multi-layering and apical constriction during the 
screen and known to regulate axon guidance during neuronal development, has been 
implicated in metastatic breast cancers (Luchino et al., 2013). This strengthens 
confidence in the results from the screen and the scoring method used.  
 
During the screen a relationship was observed between invasion and cell length 
phenotypes whereby gene KD, which caused cell elongation along the apicobasal 
axis, also promoted invasion. Elongation along the apicobasal axis is a common 
feature in developing tissues and organs, such as Drosophila ventral furrow 
formation. This cell elongation is generated by changes in actomyosin contractility 
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regulated by Rho-GTPases (Kolsch, Seher, Fernandez-Ballester, Serrano, & Leptin, 
2007). Additionally, these changes in actomyosin contractility are seen during EMT as 
cells adopt a mesenchymal-like morphology and front-rear polarity for cell migration 
(Etienne-Manneville & Hall, 2002). Therefore it is unsurprising that changes in cell 
shape were observed when gene KD promoted invasion. Invasive phenotypes were 
also regularly observed alongside apical constriction and multi-layering. Apical 
constriction is an essential process during certain developmental processes such as 
gastrulation. This process is also largely regulated by Rho family members, along with 
the developmental transcription factors twist and snail (Kolsch et al., 2007). 
Moreover in this process snail has been shown to induce myosin contraction by 
down-regulating transcription of E-cadherin (Oda, Tsukita, & Takeichi, 1998). In 
cancer, EMT is associated with the upregulation of both snail and twist. In this way, 
apical constriction and cell elongation, allow cells to be extruded from the epithelial 
sheet and invade/metastasise.    
 
Using hierarchical clustering and Gowers statistical analysis genes could be grouped 
based on the distance between them (calculated using mean phenotypic scores). 
From this predictions can be made for genes with unknown function. For example, 
CG7708 was found to be clustered with genes involved in neuron/axon/dendrite 
development, based on the phenotypes observed during the screen. Therefore it 
could be hypothesised that this gene could be involved in similar processes. In this 
way COMPLEAT and statistical analysis can be used to make simple predictions.  
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The database and scoring system implemented provided a relatively simple approach 
to analysing such a large data-set, and by setting up different queries, data could be 
easily extracted to find genes which promote or inhibit specific phenotypes. 
Moreover, it is hoped that when publishing the screen data, this database will be 
made available online for the public and science community. It is hoped that by the 
end of the year we will reach our initial aim of 500 genes.  Additionally it is hoped to 
use other statistical methods to better present the data. For example, to look at the 
amount of variance in the data principal component analysis (PCA) could be used, 
which allows high dimensional data to be viewed in 2D. Additionally, linear 
discriminant analysis could also be used for classification of the data such that further 
predictions could be made based on phenotypes observed in unknown genes. Similar 
to PCA, this analysis is used to reduce the dimension of the data by seeking axes 
which would give the best separation of classes. For classification the data can then 
be separated into two groups, where one group acts as a training set and the other as 
a predicting set. In this way we will be able to see how accurate predictions of gene 
function will be based on our data set. Clustering could also be used to identify novel 
genes in a known signalling pathway, or could implicate a novel pathway that had not 
previously been implicated in cancer before. 
 
From our screen a wealth of candidate genes were identified which dramatically 
affect a variety of phenotypes and from these, genes would be selected to 
characterise. Selection of genes depends on several factors, including the scientific 
interests of the researcher, the availability of tools for characterisation and current 
knowledge from literature. Moreover, genes could be selected which were identified 
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as hits for a single phenotype or present with multiple phenotypes. Using Drosophila 
there are many ways in which these genes can be characterised. For example, genes 
could be knocked-down in the notum without the lgl[4] mutation. If available, 
mutants for these genes could be analysed. Immunohistochemistry techniques could 
be used to stain for a variety of junction, adhesion, cytoskeletal and polarity proteins. 
Individual mutant epithelial cells could be labelled and followed in real time for a 
more detailed analysis of cell morphology. Additionally, the human orthologues of 
these genes could be studied in vitro and assayed for a number of processes such as 
invasion, metastasis, proliferation and adhesion. I have carried out a number of these 
experiments, which are detailed in the following results chapters.   
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Chapter 5 Characterisation of two novel 
Drosophila genes: CG7379 and CG10600 
 
5.1 Introduction 
From the RNAi-mediated screen (Chapter 4), I identified two novel Drosophila genes: 
CG7379 and CG10600 as giving strong and interesting phenotypes. This introduction 
will give an overview of what is currently known about these two genes and their 
human orthologues.  
 
5.1.1 CG7379 
CG7379 is a Drosophila gene spanning 1787nt on the right arm of chromosome 3 and 
encodes a single polypeptide consisting of 433 amino acids (Attrill et al., 2016). Very 
little is known about CG7379 as it remains uncharacterised in Drosophila, however it 
has been proposed to play a role in chromatin modification and zinc binding due to 
its highly conserved zinc finger and PHD-type domains (He, Helbing, Wagner, Sensen, 
& Riabowol, 2005). The human orthologue of CG7379 is ING1 and other ING family 
members (Inhibitor of growth proteins N-terminal histone-binding). Although there is 
only 28% identity and 41% similarity between these protein orthologues, it is 
important to note that there is a very strong identity of 78% within the conserved 
PHD smart domains (Fig. 5.1) (Flockhart et al., 2012).  
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Figure 5.1 Conserved domains between CG7379 and ING 
Conserved N-terminal and PHD/zinc finger protein domains between Drosophila 
CG7379 (A) and its human orthologue ING1 (B). 
 
In mammals there are five isoforms of the ING family proteins, all of which contain C-
terminal PHD-type zinc finger domains enabling these proteins to specifically bind 
post-translational modifications (PTMs) (typically lysine-4-trimethylated H3) on 
histone residues. Covalent PTMs to histones results in the alteration of chromatin 
structure and therefore can have a dynamic impact on gene expression (Garkavtsev, 
Demetrick, & Riabowol, 1997; Loewith, Meijer, Lees-Miller, Riabowol, & Young, 2000; 
Soliman & Riabowol, 2007). There are many ways that histone residues can be 
modified, from acetylation, methylation, ubiquitylation to phosphorylation; for 
example when lysine residues 4 and 36 on H3 undergo methylation the euchromatin 
structure opens up allowing transcriptional activation. However when lysines 9 and 
27 on H3 are methylated a ‘closed’ heterochromatin structure is formed which is 
associated with gene silencing. Often, these PTMs result in the recruitment of 
‘reader’ and ‘effector’ proteins which subsequently effect downstream biological 
functions (Litt, Simpson, Recillas-Targa, Prioleau, & Felsenfeld, 2001; Santos-Rosa et 
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al., 2002). Therefore histone PTMs and the reader and effector proteins acting 
downstream play an important role in gene expression and regulation.  
 
Allelic loss and reduced expression of ING family members has been reported in a 
variety of mammalian cancers including glioma (Garkavtsev et al., 2004) and breast 
cancer (S. Kim, Chin, Gray, & Bishop, 2004). As well as their obvious role in modifying 
gene expression, ING proteins have been linked to the regulation of cell proliferation 
through p53 dependent and independent pathways. DNA damage and stress signals 
trigger a cascade of PTMs which regulate p53 activity for DNA repair, apoptosis or cell 
cycle arrest/senescence (Garkavtsev et al., 1998; Tsang et al., 2003). ING has been 
shown to enhance p300 acetylase activity resulting in the acetylation of p53 and 
subsequent transcription of regulators of cell cycle arrest and apoptosis, including 
p21 and bax. Additionally, ING expression has been shown to increase prior to cell 
death (Shiseki et al., 2003). Moreover, p53 mutants compromise apoptosis induced 
via ING activity, while c-myc has been shown to cooperate with ING to regulate cell 
death. Therefore, in cancer it has been proposed that loss/misregulation of ING 
provides cancer cells protection from apoptosis (Helbing, Veillette, Riabowol, 
Johnston, & Garkavtsev, 1997).  
 
Recently, several studies with ING3 and ING4 have shown that overexpression of 
these proteins can inhibit migration of hepatoma cells in culture, whilst 
downregulation promotes cell motility. With their known role in regulating apoptosis 
it is no surprise that downregulation of these proteins enables cancer cells to survive, 
however these recent studies have also highlighted INGs potential role in regulating 
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cell matrix proteins for increased motility (M. Lu et al., 2012). For example, ING1 was 
shown to interact with liprin-alpha-1 which directs LAR to localise to and regulate cell 
focal adhesions. Additionally, overexpression of ING4 was shown to decrease activity 
of various Matrix-metalloproteinases (MMPs) which have a known role in cell 
migration as well as apoptosis (Shen et al., 2007). In September 2015, further 
evidence came to light linking ING5 to cell migration and EMT in vitro. In MDA-MB-
231 and MCF-7 breast cancer cell lines, overexpression of ING5 was shown to 
increase epithelial markers and decrease mesenchymal markers both at an mRNA 
and protein level (Zhao, Ju, Wang, Ma, & Zhao, 2015). Although our understanding of 
how ING family proteins affects these regulators of EMT still remains unclear, these 
recent studies make ING a very interesting gene to study with regards to tumour 
progression.     
 
5.1.2. CG10600  
CG10600 is an uncharacterised Drosophila gene located on the 2nd chromosome and 
encodes a 1377 amino acid protein with unknown function. Its human orthologue is 
round spermatid basic protein 1-like (RSBN1L) which is so called due to its expression 
in the nucleus of haploid round spermatids (Takahashi et al., 2004). Protein alignment 
of RSBN1L and CG10600 show 31% identity with 47% similarity (Hu et al., 2011). Both 
CG10600 and RSBN1L have no known or predicted protein domains. It has been 
suggested that RSBN1L may regulate transcription of haploid germ cells, however, 
like CG10600, the function and biological processes of RSBN1L remain largely 
unknown (Takahashi et al., 2004). Interestingly, RSBN1L is seen to be downregulated 
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in a variety of cancers including gliomas, breast and colorectal cancer (Attrill et al., 
2016; Flockhart et al., 2012).   
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5.2 Results 
 
5.2.1 Knocking-down CG7379 in lgl-/- mutant background promotes 
invasion 
During the candidate screen (Chapter 4) CG7379 was identified as a strong hit for 
invasion and multi-layering. Two independent RNAi lines both from VDRC (27988, 
27989) were used to knock-down CG7379 in lgl homozygous mutant tissue (lgl -/-) in 
the notum, with both RNAis producing very similar phenotypes. The most striking 
phenotype observed when knocking down CG7379 (CG7379 KD) was the excessive 
number of epithelial cells seen beneath the epithelium (Fig. 5.2 A, B). When 
quantified as a percentage of the total number of mutant cells in the notum, there 
was a significant (p=0.0066) increase in the amount of invasion when knocking down 
CG7379 during the screen compared to lgl-/- alone. The mutant tissue was also 
consistently multi-layered, at a greater extent to that seen in lgl-/- mutants alone, 
with cells losing their typical polarised cell shape and growing on top of one another 
in a disorderly fashion. Table 5.1 outlines the average scores for CG7379 for each of 
the main phenotypes analysed during the screen. From this it can be seen that 
CG7379 was a hit only for invasion and multi-layering. See Section 4.1 for a summary 
of the scoring system used when qualitatively analysing each cancer-associated 
phenotype. 
Table 5.1 Qualitative scores for various phenotypes in lgl-/-; CG7379KD 
animals 
Phenotype: Clonal 
Tissue 
Invasion Multi-
layering 
Basal 
Protrusions 
Division Cell 
Length 
Apex size 
Score: -0.18 1.36 0.73 -1.5 0 0 0 
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To see whether the phenotype observed was a direct result from knocking down 
CG7379 or whether it was a cooperative effect seen with the lgl  mutation, UAS-RNAi 
targeting CG7379 was also expressed in a completely WT background. From this, the 
tumours produced appeared relatively normal, forming an organised mono-layered 
epithelium with no multi-layering. Some invading cells were detected beneath the 
epithelium, which was significant (p=0.0004) compared to WT (Fig. 5.2 D). CG7379 KD 
was therefore sufficient to promote invasion, with the phenotype being exacerbated 
when combined with the lgl mutation. 
 
In conclusion, this data shows that CG7379 cooperates with Lgl in a tumour 
suppressive manner, and when downregulated in cancer cells promotes tumour 
progression and invasion. 
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Figure 5.2 Cooperation between lgl mutant and CG7379 knockdown 
promotes invasion 
(A-C) UAS-RNAi was used to knockdown CG7379 specifically within lgl homozygous 
mutant tissue in the Drosophila notum during a large scale genetic screen. (A,B) 
Mutant clones were multi-layered and highly invasive. (C) RNAi targeting CG7379 
expressed in a WT background without the lgl mutation. Red arrows indicate invading 
cells. Note the lack of multilayering in C. Scale bars represent 50µm. (D) 
Quantification of the percentage of invading cells in the mutant tissue with mean and 
SEM. (lgl-/- n=32, CG7379 n=5, lgl-/-;CG7379 n=10 from two different RNAis: 
27988,27989 VDRC).  
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5.2.2 Blocking apoptosis in lgl -/- tissue does not mimic the phenotype 
seen when knocking down CG7379 
The human orthologue of CG7379, ING, has been implicated in metastatic cancers 
and shown to act as a tumour suppressor, protecting tissues from cancerous cells by 
regulating the apoptotic cascade (Helbing et al., 1997). Therefore there are two 
potential hypotheses for the increased invasion seen when knocking down CG7379 in 
the Drosophila notum: 1) lgl mutant cells regularly invade but die through apoptosis. 
If KD of CG7379 inhibits apoptosis this could therefore lead to more surviving 
invading cells. 2) KD of CG7379 actually promotes invasion of epithelial cells.  
 
To see whether the invasive phenotype seen previously (Fig. 5.3) was a result of 
cancer cells evading apoptosis, P35 was overexpressed specifically within the lgl-/- 
mutant tissue using the MARCM system. Overexpression of P35 has been shown to 
block apoptosis and is widely used in Drosophila cell death studies (Hay et al, 1994). 
However, when P35 was expressed specifically in the lgl-/- mutant tissue, the invasive 
phenotype observed with CG7379 KD was not replicated. Compared to lgl-/- alone, 
expressing P35 had no significant effect on invasion, however when compared to lgl-
/- with CG7379 KD (compare panel A in Fig. 5.2 to panel A Fig. 5.3) there was a 
significant decrease in invasion (p=0.0036) (Fig. 5.3 B).  
  
As blocking apoptosis in the lgl -/- mutant background wasn’t sufficient to promote 
invasion, it could be inferred that knocking down CG7379 in the mutant background 
promotes invasion through other independent mechanisms.    
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Figure 5.3 Over-expressing P35 in lgl -/- mutant background has no 
effect on invasion 
(A) The Drosophila baculovirus P35 was expressed under UAS control specifically in 
lgl -/- homozygous mutant tissue on the back of the fly. Scale bar represents 50µm. 
(B) Quantification of the percentage of invading cells in mutant tissue in lgl-/-, lgl-/-; 
CG7379 KD and lgl-/-; UAS-P35 animals. Mean and SEM plotted. (lgl -/- n=32, CG7379 
RNAi, lgl-/- n=10, UAS-P35, lgl-/- n=5).  
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5.2.3 CG7379 plays an important role in junctional integrity and cell 
adhesion 
As shown, CG7379 KD appeared to promote invasion independently of its possible 
role in regulating apoptosis (Section 5.2.2). CG7379 must therefore be able to 
regulate other factors linked to invasion and EMT, such as adhesion and polarity. To 
study the function of CG7379 in epithelial adhesion, Drosophila nota were fixed and 
stained with E-cadherin antibodies to give a detailed analysis of adherens junction 
(AJ) architecture and junction integrity.  For this experiment, clones were generated 
in the Drosophila notum, which were either homozygous mutant for lgl (lgl-/-), 
expressing RNAi targeting CG7379 (CG7379 KD) or simultaneously homozygous 
mutant for lgl and expressing an RNAi construct targeting CG7379 (lgl-/-; CG7379 
KD).  
 
As a control, lgl -/- clones were fixed and stained for E-cadherin; which compared to 
the surrounding WT tissue was mostly unaffected (Fig. 5.4 A). Strikingly, CG7379 KD 
clones showed a severely altered distribution of E-cadherin levels (Fig. 5.4 B). Ectopic 
accumulation or a significant reduction of E-cadherin was frequently observed along 
disjointed AJs within the mutant clone. Similarly, in lgl-/-; CG7379 KD clones (Fig. 5.4 
C) E-cadherin appeared fragmented along cell junctions and poorly distributed. 
Quantification of E-cadherin intensity levels at epithelial junctions (Fig. 5.4 D) 
confirmed that knocking down CG7379, with or without an accompanying lgl 
mutation, significantly (p<0.0001) reduced overall E-cadherin levels of at the 
junction.  
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Along with reduced E-cadherin levels, several junction abnormalities were also 
observed (Fig. 5.4 E). These included junctional breaks and atypical ectopic junction 
extensions, which were never observed in WT tissue or lgl-/- mutant clones. Ectopic 
junction extensions were seen a significant number of times in both CG7379 KD 
clones (p=0.0371) and lgl-/-; CG7379 KD clones (p=0.0484) (Fig. 5.4 F). 
 
Additionally, in CG7379 KD clones (where E-cadherin levels were sufficient to 
visualise junctions) there was a significant expansion of apex area in the XY plane 
(p<0.00001) (Fig. 5.4 G, H).   
 
Overall knocking down CG7379, with or without an accompanying lgl mutation, had 
significant effects on E-cadherin levels and junctional architecture, suggesting that 
CG7379 has a role in regulating cell adhesion and junction integrity.  
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Figure 5.4 E-cadherin localisation and junction integrity is affected in 
Drosophila mutants 
Positively marked clones from Drosophila nota were fixed and stained for E-cadherin. 
(A) E-cadherin staining in WT (left side of dotted line) and lgl homozygous mutant 
tissue (right side of dotted line). (B) Disruption to junction integrity in a CG7379 KD 
clone (highlighted by red dashed line). (C) An lgl-/-; CG7379 KD clone (highlighted by 
red dashed line) showing disruption to AJ integrity and mislocalisation of E-Cadherin. 
(D) Quantification of E-cadherin fluorescence intensity at cell junctions (n ≥40 from 
≥4 animals for each genotype). (E) E-cadherin staining showed disruption to adherens 
junction architecture with junctional breaks (red triangle arrowhead) and ectopic 
junctional extensions (red square arrowheads) in lgl-/-; CG7379 KD cells. (F) 
Quantification of ectopic E-cadherin extensions (average number per animal) (n= 4 
animals for each genotype). (G) Larger apical area was observed in CG7379 KD cells 
(mutant cells are in top and bottom sections). This effect is quantified in (H) (n≥40 
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from ≥4animals for each genotype). Graphs represent mean with error bars showing 
SEM. Scale bars in panels A, B, C and F = 50µm; scale bar in E = 5µm.  
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As shown, CG7379 KD clones severely altered E-cadherin localisation, with significant 
alterations to AJ architecture. To further study the effect of CG7379 on junction 
integrity, Drosophila nota were fixed and stained for Armadillo (β-catenin) - another 
core component of the AJs.  
 
Similar to E-cadherin, Armadillo localisation was unaffected in lgl-/- mutant tissue 
when compared to WT (Fig. 5.5 A). However in CG7379 KD clones (Fig. 5.5 B) 
Armadillo levels were significantly reduced (p<0.0001) (Fig. 5.5 E) and although 
junction architecture remained intact, a significant number (p<0.0001) of ectopic 
puncta were observed within the mutant tissue (Fig. 5.5 F). Similarly, in lgl-/-; CG7379 
KD clones (Fig. 5.5 C) Armadillo levels were also significantly reduced (p<0.0001) with 
a significant number of puncta (p<0.0001) observed (Fig. 5.5 E-F). Additionally, 
Armadillo was often seen abnormally distributed (Fig. 5.5 D), no longer localising to 
the junctions.  
 
These results show that CG7379 appears to maintain junction integrity and cell 
adhesion by regulating the junctional proteins E-cadherin and Armadillo (β-catenin).  
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Figure 5.5 Armadillo localisation is affected in Drosophila mutants  
Drosophila nota were fixed and stained for Armadillo (β-catenin). (A) Armadillo levels 
are similar in WT (left side of dotted line) and lgl-/- mutant tissue (right side of dotted 
line). (B-C) Armadillo levels are reduced and puncta are observed in CG7379 KD (B; 
left side of dotted line) and lgl-/-; CG7379 KD clones (C; right side of dotted line). 
Scale bars = 50µm. (D) Abnormal distribution of Armadillo below the junction in an 
lgl-/-; CG7379 KD clone; scale bar = 10µm. (E-F) Quantification of Armadillo 
fluorescence intensity at the AJ (E) and the number of ectopic puncta observed (F) 
(n>20 from ≥4 animals for each genotype) Bars represent mean with error bars 
plotting SEM.  
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5.2.4 CG7379 is important for septate junction integrity but does not 
affect apicobasal polarity 
As shown, CG7379 is important in maintaining epithelial junction integrity and cell 
adhesion through its effects on E-cadherin and Armadillo, which localise to the AJs. 
To see whether CG7379 also has an integral role in apicobasal polarity, tissue was 
fixed and stained for various polarity proteins essential to regulating and maintaining 
epithelial polarity. FasIII localises to the septate junctions in Drosophila (the 
Drosophila equivalent of tight junctions in mammals) which is basally located to the 
AJs in flies (see Fig. 1.5 and Fig. 1.8). FasIII is a homophillic adhesion molecule 
required for cell-cell signalling and polarity (Wells et al., 2013). 
 
In CG7379 KD clones a significant (p=0.0294) reduction in FasIII localisation at the 
septate junctions was observed when compared to WT tissue (Fig. 5.6 A, C). 
Moreover, this phenotype was significantly (p<0.0001) enhanced in lgl-/-; CG7379 KD 
clones (Fig. 5.6 B, C).  
 
This data shows that knocking down CG7379 is sufficient to affect FasIII levels at the 
septate junction, and that FasIII localisation is further disrupted when loss of CG7379 
is combined with lgl loss.   
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Figure 5.6 FasIII localisation is affected in CG7379 KD clones 
Drosophila nota were fixed and stained with an antibody against FasIII. (A) FasIII 
localisation is disrupted in CG7379 mutant clones (mutant tissue highlighted by red 
dotted line) and (B) severely disrupted in lgl-/-; CG7379 KD clones (mutant tissue 
below red dotted line). Scale bars represent 10µm. (C) Quantification of the 
fluorescence intensity of FasIII at septate junctions. Mean and SEM plotted (n≥4 with 
≥50 junctions measured for each genotype).   
  
164 
 
5.2.5 CG7379 KD has no effect on the localisation of aPKC or Baz 
aPKC and Bazooka (Par-3) are members of the apical Par complex and, through a 
process of mutual exclusion with other polarity complexes, their localisation is 
restricted apically to maintain apicobasal polarity (see section 1.4). To further 
investigate whether CG7379 is important for the regulation of apicobasal polarity in 
epithelial cells, nota were fixed and stained for either aPKC or Baz.  
 
In lgl -/- mutant tissue both aPKC and Baz localisation was unaffected when 
compared to WT tissue (Fig. 5.7 A). Similarly, CG7379 KD clones also had no effect on 
aPKC or Baz. Moreover, aPKC and Baz localisation was still unaffected in lgl-/-; 
CG7379 KD clones (Fig. 5.7 C, D). These results suggest that CG7379 does not affect 
apicobasal polarity through effects on aPKC or Baz. 
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Figure 5.7 aPKC and Baz levels are unaffected in CG7379 KD animals 
Quantification of the mean fluorescence intensity of (A) aPKC and (B) Baz in WT, lgl-/, 
CG7379 KD and lgl-/-; CG7379 KD animals. Mean and SEM plotted (n=4 with >40 
junctions measured for each genotype). 
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5.2.6 Knocking-down ING1 in human cell lines promotes invasion 
As previously shown, knocking down CG7379 in the Drosophila epithelium promotes 
tumour cell invasion. To see whether knocking down the mammalian orthologue 
ING1 in human cells has the same effect, and whether this cancer-promoting role is 
limited to epithelial cells, an in vitro invasion assay was performed.  
 
RT-PCR was performed on cells harvested from breast adenocarcinoma (MDA-MB-
231) and adult glioblastoma (U87) using ING1 and GAPDH specific primers to check 
the relative expression levels of ING1 in these cells (Appendix D). As moderate levels 
(see Appendix D for CT values compared to control) of ING1 were expressed in both 
cell lines, MDA-MB-231 and U87 cells were then transfected with siRNA targeting 
human ING1. Percentage knockdown was calculated using the ΔΔCT method (see 
section 2.3.4) normalising to scrambled (non-silencing) and GAPDH controls. Using 
this formula the level of ING1 knockdown was 91% and 86% in U87 and MDA-MB-231 
cells respectively (Fig. 5.8). Transfected cells were seeded in invasion chambers 
containing an ECM-like membrane and after 48hours cells that had invaded through 
the ECM- matrix were detached, lysed and dyed with a fluorescent label. 
Fluorescence intensity correlates directly to the extent of invasion. As seen in Fig. 5.9 
C, knocking down ING1 in both U87 and MDA-MB-231 cell lines significantly 
(p=0.0228 and p=0.0042 respectively) increased the amount of invasive cells that had 
breached the membrane relative to untransfected cells.  Relative to U87 and MDA-
MB-231 untransfected controls, ING1 KD increased invasion by 88% and 325% 
respectively.  
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These results confirm that the down-regulation of ING1 (the human orthologue of 
CG7379) alone is sufficient to significantly promote invasion in mammalian epithelial 
cancers as seen in the Drosophila model. Additionally, knocking down ING1 was 
sufficient to promote invasion in glioblastomas.   
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Figure 5.8 RT-PCR data for ING1 expression 
(A) U87 and (B) MDA-MB-231 cells were transfected with siRNA targeting ING1 or 
scrambled (non-silencing) siRNA. After 48hrs, cells were harvested for RNA 
purification, and RT-PCR was carried out using ING1 specific primers (shown) and 
GAPDH (house-keeping) primers (for KD calculations). 3 replicates were carried out 
for each.  
  
169 
 
 
Figure 5.9 Knocking-down ING promotes invasion in mammalian cell 
lines   
Invasion assay performed on the glioblastoma cell line U87 and the breast 
adenocarcinoma cell line MDA-MB-231. These cell lines were transfected with siRNA 
targeting the human ING1 gene, and data compared relative to un-transfected 
control cells. Invasion assays were performed with and without the chemoattractant 
FBS. (A-D) Both qualitative (A-D) and quantitative invasion assays (E) were conducted 
separately. In the qualitative assay, invasion was determined via an in situ stain. In 
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the quantitative assay invasion was determined by lysing cells and labelling with a 
dye to establish relative fluorescence. (n=3) Mean and SEM plotted. Significance was 
calculated when comparing treated cells to untreated cells from the same cell line 
(+FBS).  
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5.2.7 Loss of CG10600 cooperates with the lgl[4] mutation to promote 
tumour progression in the Drosophila notum. 
Following the candidate screen (Chapter 4) a second novel gene, CG10600, was 
identified as a hit for a range of different cancer-associated phenotypes. Two distinct 
RNAi lines from two independent stock centres 10600R2 (NIG) and 31276 (VDRC) 
were used to knock-down CG10600 specifically within lgl -/- mutant clones. Both 
RNAi lines presented with similar phenotypes and in total 10 animals were imaged. 
Correct development of the Drosophila notum was often impaired, where the lateral 
dorsal epithelium failed to close properly during embryogenesis (Fig. 5.10 A). Clones 
of mutant tissue were typically multi-layered (Fig. 5.10 B) and presented a 
significantly (p=0.0473) invasive phenotype (Fig. 5.10 C, G). Additionally basal 
filopodia were significantly longer (p<0.0001) in lgl-/- ; CG10600 KD animals 
compared to lgl -/- alone (Fig. 5.10 D, H) and cells were significantly (p=0.0071) 
elongated along the apicobasal axis (Fig. 5.10 I). Refer to Figure 4.1 for examples of 
phenotypes and their relative scores, or Appendix G (CD) to see the average 
phenotypic scores given for every gene. 
 
To see whether the observed phenotypes were due to a cooperative effect between 
CG10600 and Lgl, CG10600 was knocked down in a WT background. In animals of this 
genotype (Fig. 5.10 E) clones retained their typical mono-layered structure with no 
changes in cell length or invasion. Interestingly CG10600 KD was sufficient to produce 
basal filopodia which were significantly longer (P<0.0001) than WT (Fig. 5.10 F, H).  
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These results show that knocking down CG10600 cooperates with the lgl mutation to 
promote the tumour phenotype, but is unable to elicit such an effect on its own.  
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Figure 5.10 Cooperation between lgl mutant and CG10600 knockdown 
promotes tumour progression 
Live confocal imaging of animals expressing an RNAi-hairpin targeting CG10600 
specifically within lgl homozygous mutant clones in the Drosophila notum. Animals 
presented a variety of strong phenotypes including (A) dorsal closure defects, 
(B)multi-layering, (C) invasion and (D) long basal filopodia. (E) CG10600 KD without 
the lgl mutation had no multi-layering and appeared relatively WT, however (F) long 
basal filopodia were seen. Scale bars = 50µm. Quantification of (G) invasion, (H) 
epithelial cell length and (I) length of basal protrusions. For invasion and cell length 
n=10 animals. For basal protrusions >50 cells were measured from ≥4 animals. Error 
bars represent SEM. 
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5.2.8 CG10600 cooperates with Lgl to regulate E-cadherin expression 
As CG10600 was shown to cooperate with Lgl to suppress tumour progression, nota 
were fixed and stained for E-cadherin to study the effects of CG10600 on AJ stability 
and cell adhesion. 
 
As expected (Fig. 5.10), knocking down CG10600 in a WT background had no effect 
on E-cadherin expression levels or localisation (Fig. 5.11 A, D). However when 
CG10600 was knocked down specifically within lgl-/- mutant clones, the cooperative 
effect resulted in a significant (p=0.0008) decrease in mean E-cadherin intensity at 
the AJs compared to the surrounding WT tissue (Fig. 5.11 B, E). E-cadherin appeared 
very fragmented along the junctions with junctional breaks, and even missing 
junctions (Fig. 5.11 C).  
 
These results confirm that CG10600 requires cooperation with Lgl to act as a tumour 
suppressor in this system. Moreover, the cooperation between CG10600 and Lgl 
maintains E-cadherin localisation, junction integrity and cell adhesion. 
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Figure 5.11 Cooperation between CG10600 and Lgl regulates E-cadherin 
localisation and adherens junction integrity 
Drosophila nota were fixed and stained for E-cadherin. (A-C) Positively marked clones 
expressing an RNAi construct targeting CG10600 in an otherwise WT animal (A; 
below red dashed line) and specifically within lgl homozygous mutant clones (B; 
below red dashed line). Junction breaks indicated by red arrows in C. Scale bars = 
10µm. (D-E) Quantification of mean fluorescence intensity of E-cadherin at cell 
junctions (n>20 cells from ≥4 animals for each genotype) Bars represent mean with 
error bars plotting SEM.  
  
176 
 
5.2.9 Knocking-down RSBN1L in a mammalian breast adenocarcinoma 
cell line promotes invasion 
As previously shown, knocking down CG10600 in the Drosophila epithelium, in 
combination with an underlying lgl mutation, promotes tumour cell invasion. To see 
whether knocking down human RSBN1L (the human orthologue of CG10600) has the 
same effect, the same in vitro invasion assay from Section 5.2.7 was performed.  
 
RT-PCR was performed on cells harvested from breast adenocarcinoma (MDA-MB-
231) and adult glioblastoma (U87) using RSBN1L and GAPDH specific primers to check 
the relative expression levels of RSBN1L in these cells (Appendix D). As moderate 
levels (see Appendix D for CT values compared to control) of RSBN1L were expressed 
in both cell lines, MDA-MB-231 and U87 cells were transfected with siRNA targeting 
human RSBN1L. Percentage knockdown was calculated using the ΔΔCT method (see 
section 2.3.4) normalising to scrambled (non-silencing) and GAPDH controls. Using 
this formula the level of RSBN1L knockdown was 67% and 86% in U87 and MDA-MB-
231 cells respectively (Fig. 5.12). Fig. 5.13 shows that knocking down RSBN1L in adult 
glioblastoma derived U87 cells had no effect on the invasive properties of the cells. 
However, in the breast adenocarcinoma derived MDA-MB-231 cell line, knocking 
down RSBN1L was sufficient to significantly (p=0.0003) promote invasion. 
 
These results confirm that the down-regulation of RSBN1L (CG10600), promotes 
invasion in mammalian epithelial cancers as seen in the Drosophila model. However, 
RSBN1L KD was not sufficient to promote invasion in the glioblastoma cell line. 
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However, it can’t be excluded that RSBN1L has a role in glioblastoma migration which 
precedes invasion.    
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Figure 5.12 RT-PCR data for RSBN1L expression 
U87 (A) and MDA-MB-231 (B) cells were transfected with siRNA targeting RSBN1L or 
scrambled (non-silencing) siRNA. After 48hrs, cells were harvested for RNA 
purification, and RT-PCR was carried out using RSBN1L specific primers (shown) and 
GAPDH (house-keeping) primers (for KD calculations). 3 replicates were carried out 
for each.  
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Figure 5.13 RSBN1L KD promotes invasion in MDA-MB-231 cells 
These cell lines were transfected with siRNA targeting the human RSBN1L gene, and 
data compared relative to un-transfected control cells. Invasion assays were 
performed with and without the chemoattractant FBS.  Both qualitative (A-D) and 
quantitative invasion assays (E) were conducted separately. In the qualitative assay, 
invasion was determined via an in situ stain. In the quantitative assay invasion was 
determined by lysing cells and labelling with a dye to establish relative fluorescence. 
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(n=3) Mean and SEM plotted. Significance was calculated when comparing treated 
cells to untreated cells from the same cell line (+FBS).  
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5.2.10 Using CRISPR/Cas technology to generate CG10600 mutants. 
As CG10600 has not been characterised in Drosophila, experiments were limited by 
the lack of tools available. Therefore CRISPR/Cas technology was employed in order 
to generate a mutant for this gene to further study its role in cancer progression. 
CRISPR/Cas technology is a relatively novel approach to genome engineering and 
requires two main components: a guide RNA (gRNA) and an RNA-guided 
endonuclease (cas9). The gRNA is composed of CRISPR RNA (crRNA), a 20nt sequence 
complementary to the target DNA, and transactivating RNA (tracrRNA). The gRNA 
directs cas9 to the genomic target region creating double stranded DNA breaks. The 
error prone non-homologous end joining repair system then generates mutations in 
the DNA when repairing the cleaved site (Port, Chen, Lee, & Bullock, 2014).  
 
Figure 5.14 illustrates the CRISPR/Cas methodology employed in order to generate a 
CG10600 mutant allele. CRISPR/Cas requires a guide RNA (gRNA) core which includes 
a 20 nucleotide target sequence. Additionally the complementary strand 
(protospacer) must be directly followed by a short protospacer adjacent motif (PAM) 
which is specifically recognised by the cas9 nuclease. Fig. 5.14 A illustrates the target 
region found in the N- terminal coding sequence of CG10600 (see Appendix E for the 
full sequence of CG10600 and location of target sequence). Annealed oligos were 
then cloned into the pCFD3 vector backbone (Fig. 5.14 B). The vector contains a 
gRNA scaffold sequence- which along with PAM sequence is essential for cas9 
recognition, and the vermillion gene which produces a red eye phenotype when the 
plasmid has been successfully inserted in the Drosophila genome. DNA containing the 
plasmid and ligated oligos were then sent for micro-injection (Department of 
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Genetics, Cambridge), where it was injected into 200 embryos with the genotype: y1 
P(nos-cas9, w+)M(3xP3-RFPattP)ZH-2A w* (Fig. 5.14 C). In this fly stock cas9 is 
downstream of the nanos (nos) promoter and is therefore expressed specifically in 
the germline (and the attp landing is marked with RFP under the 3xP3 artificial 
promoter). Of the surviving larvae, 41 flies emerged which possessed the vermilion 
red eye phenotype and of these sequencing revealed 2 which contained single 
nucleotide mutations (see Section 5.2.11).    
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Figure 5.14 CRISPR/Cas methodology 
(A) The 20nt target sequence in CG10600 genomic DNA on Drosophila chromosome 
2, and PAM sequence. Oligos are designed with GTCG and CAAA sequence overhangs 
which recognise and bind to sticky ends created when pCFD3 is digested with BbsI. 
(B) Oligos were annealed together and cloned into BbsI digested pCFD3. (C) Purified 
plasmids containing the insert were then injected into the embryos of cas9 
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expressing flies and Drosophila stocks containing potential induced CRISPR mutations 
over the CyO-GFP balancer chromosome were generated.  
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5.2.11 Identification of CG10600 mutant 
CRISPR-induced mutations produce a double peak in the chromatogram following 
direct sequencing. These double peaks are observed when the DNA contains 
heterozygous alleles, indicating a single nucleotide change. Following sequencing, 
two stocks were observed which contained heterozygous double peaks. (Fig. 5.15 B, 
D). The first mutant generated (CG10600*1) contained a large number of base 
changes throughout the genomic DNA resulting in numerous amino acid changes in 
the translated polypeptide (Appendix F). After a few generations the CRISPR* stock 
was checked to see if the CyO balancer was maintained within the stock. As the stock 
contained flies with both straight and curly wings, this showed that the mutations are 
not homozygous lethal. The second mutant (CG10600*2) contained only one single 
base pair change, which when translated produces the same amino acid (Aspartate) 
as found in the WT amino acid sequence, therefore it is a silent mutation.  
 
Further sequencing of CG10600*1 is still required to determine the amino acid 
sequence for the full protein, which will be carried out by current lab members. Once 
fully sequenced, programmes such as discovery studio will be used to predict how 
protein structure is altered compared to WT and how this might affect function.  
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Figure 5.15 Identification of CG10600 mutants using Sanger sequencing 
technology. 
(A, C) Chromatograms of WT, (B) CG10600*1 and (D) CG10600*2. Arrows indicate 
double peaks in the mutant chromatograms.  
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5.3 Discussion 
Following the genetic screen two genes were identified as hits due to their dramatic 
effect on tumour progression. Both genes, CG7379 and CG10600, had never been 
characterised in Drosophila.  
 
5.3.1 CG7379 promotes invasion through its effects on junction 
integrity and cell polarity 
CG7379 was identified as a hit from the genetic screen due to its dramatic effect on 
the organisation and invasiveness of epithelial cells in the Drosophila notum. 
Knocking down CG7379 in both WT and lgl homozygous mutant clones in the living 
epithelium resulted in a significant percentage of the clonal tissue becoming invasive, 
with the epithelium becoming multi-layered and disorganised. The phenotype was 
enhanced when RNAi targeting CG7379 was combined with the lgl[4] mutation. This 
data showed that CG7379 acts a tumour suppressor, which, when down-regulated 
can promote tumour cell invasion and cooperates with Lgl in this system. 
 
The human orthologue of CG7379 is ING1 which is a relatively well characterised 
member of ING family proteins and has been widely linked to cancer. ING has been 
linked to cancer through its links to P53 and its consequent role in the regulation of 
the cell cycle and apoptosis. Cell attrition in populations of rapidly proliferating cells 
acts as a natural defence against cancer.  Therefore, one of the hallmarks of cancer, 
as first described in 2000 by Hanahan and Weinberg, is that cancer cells must be able 
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to evade this programmed cell death.  Therefore, one possible reason for observing 
high numbers of invading cells in lgl-/-; CG7379 KD animals could be due to an 
inhibition of apoptosis in the absence of CG7379 function, i.e. there are normally 
many invading cells in lgl-/- mutant clones, however they usually apoptose; when 
combined with a loss of CG7379 function these cells do not undergo apoptosis and 
therefore we see many surviving invading cells. To test whether the invasive 
phenotype seen when knocking down CG7379 was due to reduced levels of 
apoptosis, I overexpressed P35 specifically in lgl homozygous mutant clones, to block 
apoptosis. However, preventing cell death in the lgl mutant background was not able 
to mimic the phenotype seen when knocking down CG7379 under the same 
conditions. In fact my data showed that blocking apoptosis in the lgl mutant 
background reduced the level of invasion; one possible explanation for this could be 
that as cells apoptose they delaminate, and some of the cells seen beneath the 
epithelial sheet in lgl mutant animals are actually dying cells. Therefore blocking 
apoptosis reduces the number of cells detected beneath the epithelium. From these 
results it is likely that evasion of cell death is not the cause of the increased number 
of cells observed beneath the epithelial sheet in lgl-/-; CG7379 KD animals. Hence, I 
believe CG7379 suppresses tumour cell invasion in the epithelium through other 
mechanisms outside of promoting apoptosis. In order for tumour cells to invade the 
basement membrane and surrounding local tissue many poorly understood 
physiological changes must occur. The Cadherin-Catenin complex which makes up 
the AJ forms adhesive connections between adjacent cells in the epithelium and is 
important for junction integrity and planar cell polarity. E-cadherin, which couples 
adjacent cells and is a core component of AJs, has long been identified as a 
189 
 
suppressor of invasion and is downregulated in many cancers. Meanwhile, Armadillo 
(β-catenin) links the cytoplasmic tail of E-cadherin to α-catenin, creating a network 
which directly interacts with the actin cytoskeleton (Gumbiner, 1996). 
 
Knocking down the novel Drosophila gene CG7379, either with or without an 
accompanying lgl mutation, significantly altered E-cadherin levels and localisation. AJ 
breaks and increased levels of E-cadherin in ectopic junctional tubules have been 
observed previously in mutants that affect the turnover of junctional material 
(Georgiou et al., 2008). In order to maintain stable AJs, E-cadherin and other 
junctional proteins are actively recycled through clathrin-mediated endocytosis. This 
turnover of cadherin is essential to the dynamic nature of the AJs, allowing the 
junction to be regularly assembled and disassembled during cell division, death, 
development and invasion. Genes that affect cadherin junctional recycling have been 
shown to include regulators of the actin cytoskeleton, p120 and cdc42 (Davis, Ireton, 
& Reynolds, 2003; Georgiou et al., 2008). Therefore this data suggests that CG7379 
may be involved in regulating this recycling process. CG7379 has been proposed to 
play a role in chromatin remodelling; therefore CG7379 KD could result in a 
decreased expression of genes that regulate this recycling process. Additionally, the 
human orthologue of CG7379, ING1, has recently been shown to regulate senescence 
and the Rb pathway by inducing expression of Intersectin-2, which is involved in 
endocytosis (Rajarajacholan, Thalappilly, & Riabowol, 2013). This supports the 
hypothesis that CG7379 might be affecting junction integrity and E-cadherin 
localisation by regulating endocytosis.  
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Further experiments would therefore be used to test whether the ectopic E-cadherin 
structures in CG7379 KD animals are due to a reduction in the endocytosis-mediated 
recycling of junctional material. For this, fluorescently labelled dextran could be used 
in an assay for endocytosis, as it is preferentially internalised by early endosomes. By 
staining WT, lgl-/-, CG7379KD and lgl-/-; CG7379 KD nota with E-cadherin and 
fluorescently-labelled dextran, we would be able to see whether E-cadherin and 
dextran co-localise in ectopic structures and if endocytosis is down-regulated in 
CG7379 mutants.  
 
Knocking down CG7379 significantly reduced Arm, and similar to E-cadherin, ectopic 
puncta were highly abundant. Future experiments could test whether E-cadherin and 
Armadillo ectopic puncta and tubules remain at the cell surface due to reduced 
junctional turnover. To do this, nota could be fixed and stained for antibodies against 
extracellular E-cad/Arm in PBS before permeabilisation with PBT. Then, following 
permeabilisation, tissue would be stained for intracellular proteins and imaged. 
Additionally, CG7379 KD significantly reduced levels of the cell adhesion glycoprotein 
FasIII. FasIII is an important component of the septate junction (SJ) - which mediates 
transport between adjacent cells, and maintains junction integrity. As both Arm and 
FasIII were seen to be mislocalised, loss of CG7379 is likely to affect cell adhesion as a 
whole, and is not limited to E-cadherin or the AJ. To strengthen this claim, mutant 
nota could be stained for other proteins known to localise to the SJ including dlg, 
coracle and neurexin.  Moreover, phalloidin could be used to stain actin filaments to 
see how CG7379 KD affects the actin cytoskeleton. 
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Apicobasal polarity is fundamental to normal cell physiology and defines distinct 
apical, lateral and basal domains for the asymmetric organisation of cell components 
(Fristrom, 1988; Januschke & Gonzalez, 2008). Various polarity proteins are 
important in the formation and maintenance of this epithelial polarity and are 
commonly mis-regulated in cancer (see Section 1.3). The data showed that both aPKC 
and Baz expression/localisation was not visibly affected when knocking down 
CG7379. These results indicate that CG7379 appears to be involved in the regulation 
of junction integrity at both the AJ and SJ, but does not seem to be directly involved 
in regulating apicobasal polarity. To look further at the dynamics of the AJ and SJ in 
CG7379 KD animals’ fluorescence recovery after photobleaching (FRAP) experiments 
could be used to study the recovery of junctional components at sites which have 
been photobleached. FRAP has become a popular tool in Drosophila for studying 
junction dynamics for example, De Beco et al (2009) used this approach to show how 
endocytosis regulates levels of E-cadherin at the AJs, while others have used FRAP to 
study the dynamics of core SJ components (de Beco, Gueudry, Amblard, & Coscoy, 
2009; Oshima & Fehon, 2011). To verify that apicobasal is unaffected, mutant nota 
could be stained for other polarity proteins such as crumbs.   
 
The human orthologue ING1 was also shown to promote invasion when knocked 
down in mammalian cancer cell lines in vitro. As well as promoting invasion in the 
epithelial breast adenocarcinoma cell line MDA-MB-231, knocking-down ING1 also 
promoted invasion in an adult glioblastoma (U87). These data suggest that ING1 anti-
invasive functions in different types of cancer, and indicates that the research carried 
out in the Drosophila model can be translated to human cancers in this instance. To 
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see whether ING1 KD promotes invasion by impairing junction integrity in vitro as 
seen in vivo, transfected cells could similarly be fixed and stained for E-cadherin (AJ), 
ZO-1 (TJ) and other junctional proteins. For this, both transformed and 
untransformed cell lines (MDCK) would be used. MDCK cells forms polarised cysts in 
vitro and are commonly used to study epithelial cell polarity and junction integrity (A. 
Z. Wang, Ojakian, & Nelson, 1990).  Additionally, experiments could be repeated with 
other ING family members: ING2-5, which have also been implicated in tumour 
progression.  
 
All together these results show that CG7379 has a strong tumour suppressive 
function by regulating junction stability and the adhesive properties of epithelial 
cells. Moreover, downregulation of CG7379 in cancer is sufficient to significantly 
promote invasion through its effects on junctional integrity and cell-cell adhesion. 
Future experiments will involve investigating the role of CG7379 in maintaining 
junction integrity as a defence against invasion and whether these junction defects 
are mimicked with ING1 KD in mammalian cells. Additionally, apoliner, TUNEL assay 
and anti-caspase-3 staining could be used to verify that the invasion seen in CG7379 
KD is not a result of decreased apoptosis.  
 
5.3.2 CG10600 cooperates with Lgl to enhance the tumour phenotype 
During the genetic screen CG10600 was a strong hit for a range of cancer-associated 
phenotypes. These included multi-layering, invasion, reduced apical area, dorsal 
closure defects and long basal filopodia. These phenotypes however were not 
prominent when CG10600 was knocked down alone without the lgl4 mutation. This 
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suggests that CG10600 cooperates with Lgl in the Drosophila notum to prevent 
tumour progression.  
 
This cooperative affect was also shown to alter E-cadherin localisation, and resulted 
in breaks in the AJs. This shows that CG10600 and Lgl cooperate in a tumour 
suppressive mechanism by regulating E-cadherin and AJ stability.  To further study 
the effects of CG10600 KD on AJ stability, other AJ markers could be stained for, 
including Arm and α-catenin. Additionally, it would be interesting to see whether 
unlike CG7379, CG10600 directly affects apicobasal polarity by staining for antibodies 
against aPKC and Baz. As CG10600 KD affected E-cadherin expression, both a live-
cadherin marker (ubi promoter drives expression of E-cadherin tagged GFP) and FRAP 
experiments could also be used to look at junction dynamics in real time. The effects 
seen with CG10600 were less severe than those seen with CG7379; therefore it is 
likely that loss of junction integrity is not the main cause of the invasive phenotype.  
 
The human orthologue RSBN1L, which remains uncharacterised in mammalian 
systems, was shown to promote invasion when knocked-down in a breast 
adenocarcinoma cell line, but had no effect on invasion in adult glioblastomas. This 
suggests that the tumour suppressing function of RSBN1L (CG10600) may be 
restricted to epithelial cancers. With breast adenocarcinomas arising from epithelial 
cells and glioblastomas found in the brain deriving from astrocytes, these differing 
cell types might suggest why RSBN1L appeared to promote invasion in a tissue 
specific manner. The switch between hyper-proliferative and invasive phenotypes in 
glioblastomas has been shown to arise mostly from signals from the tumour 
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microenvironment. Additionally, increased anaerobic glycolysis, hypoxic conditions 
and increases in angiogenic factors are largely associated with increases in 
glioblastoma invasiveness (Xie, Mittal, & Berens, 2014). Recently, evidence has 
bought to light similarities between pathways associated with EMT in epithelial 
derived cancers and those associated with glioblastoma invasion (Zarkoob, Taube, 
Singh, Mani, & Kohandel, 2013). These include c-myc, EGF, TGFβ, NFκB and WNT 
signalling (Bruna et al., 2007; Dhruv et al., 2013; P. Lu et al., 2016; Q. Meng et al., 
2014; Zheng, Yang, Aldape, He, & Lu, 2013). As previously discussed ING1 is capable 
of promoting tumour invasion in both U87 and MDA-MB-231 cells and so it could be 
hypothesised that this gene acts through signalling pathways and processes involved 
in both tumour types. RSBN1L KD on the other hand was only sufficient to promote 
invasion in MDA-MB-231 cells which could suggest that this gene acts via different 
molecular mechanisms and signalling pathways associated with the adaptive EMT 
process and not glioblastoma invasion.    
 
As CG10600 has never been characterised in Drosophila, experiments were limited by 
the lack of tools available. Therefore to try and improve our understanding on how 
this gene works CRISPR/Cas technology was used to generate a mutant, which could 
then be studied further. Further sequencing will be required to determine the full 
amino acid sequence of the mutant generated and predict protein structure using 
tools such as discovery studio and I-Tasser. From this, the mutant could be 
recombined with an FRT site to allow a clonal analysis of mutant tissue in a WT 
background using MARCM. The mutant allele could then be put in trans with a 
deficiency to see if the phenotype is enhanced and test if the mutant is a null.  
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In conclusion, two novel genes: CG7379 and CG10600, previously uncharacterised in 
Drosophila were found to promote tumour progression in the Drosophila notum. 
Early characterisation experiments show that a loss CG7379 function promotes 
invasion, not by a loss of apoptosis, but through a loss of AJ and SJ integrity.  
CG10600 KD was also shown to affect AJ integrity to a limited extent and new mutant 
fly stocks were generated to further our understanding of CG10600 function. Both 
genes were also shown to promote invasion when knocked down in human cancers 
in vitro, strongly implicating these genes as possible candidates to study further as 
potential future therapeutic targets.  
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CHAPTER 6 
Characterisation of Dscam 
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Chapter 6 Characterisation of Dscam 
 
6.1 Introduction 
Drosophila Dscam (Down syndrome cell adhesion molecule) is a member of the 
immunoglobulin superfamily, which is integral to various neurological processes in 
the central nervous system including synaptic adhesion, self-avoidance and axon 
guidance. Dscam is a transmembrane protein consisting of 10 immunoglobulin (Ig) 
domains, 6 fibronectin III extracellular domains, and a divergent cytoplasmic tail (Fig. 
6.1). There are 4 Dscam homologues in Drosophila (Dscam1-4); however it has been 
shown that more than 38,000 isoforms can be generated through alternative splicing 
of Dscam1 alternative exons. Dscam1 genomic DNA spans approximately 60,000bps 
containing 115 exons, of these 21 are constituently expressed while the remaining 95 
exons are divided into 4 cassettes, which are alternatively spliced. Exon clusters 4, 6, 
9 and 17 contain 12, 48, 33 and 2 exons respectively which can be alternatively 
spliced into the mRNA exclusively (Fig. 6.1).  
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Figure 6.1 Alternative splicing in Drosophila Dscam1 and sequence 
homology with human Dscam 
Drosophila Dscam1 contains 4 exon cassettes which are alternatively spliced into 
mRNA resulting in >38,000 different possible isoforms (A).  The translated protein 
contains the same immunoglobulin and fibronectin domains however Ig2, Ig3, Ig7 
and the transmembrane domain have differing amino acid sequences due to 
alternative splicing (B). Human Dscam shows high sequence identity in the 
extracellular domain, however little sequence identity in the intracellular domain (C).  
 
Isoform diversity is thought to be vital to the function and specificity of Dscam1 in the 
nervous system (Schmucker et al., 2000). Neurites belonging to the same neuron 
express a subset of the same Dscam1 alternatively spliced isoforms. During self-
avoidance identical isoforms selectively recognise each other and exhibit homophillic 
interactions causing them to repel one another. Meanwhile neighbouring cells can 
contact one another as they express differing Dscam1 isoforms (B. E. Chen et al., 
2006; Hattori et al., 2007; Hughes et al., 2007; Matthews et al., 2007; Soba et al., 
2007). Similarly, Dscam2 mediates tiling whereby neurites belonging to the same cell 
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type promotes homophillic repulsion (Millard, Flanagan, Pappu, Wu, & Zipursky, 
2007).  
 
There are two closely related mammalian orthologues of Drosophila Dscam: DSCAM 
and DSCAM1L. These genes function in a similar manner; however unlike their 
Drosophila orthologues do not undergo alternative splicing. It has been suggested 
that unlike the highly conserved diversity generated in Drosophila via alternative 
splicing, the human genome has developed other mechanisms to generate such 
diversity. For example, combinations of genes and large protein families in mammals 
give rise to a diverse number of neuronal cell surface proteins which are similar to 
Dscam, capable of recognising each other and functioning in a similar way 
(Wojtowicz, Flanagan, Millard, Zipursky, & Clemens, 2004).  
 
Compared to Drosophila, human DSCAM shows 29% identity with 46% similarity, and 
high homology within the extracellular domain. The intracellular domains however 
show no sequence similarities (Fig. 6.1) (Schmucker et al., 2000). Both Drosophila and 
mammalian Dscam regulate the actin cytoskeleton through Pak/JNK signalling. In 
humans, Dscam directly interacts with Pak1 whilst Drosophila Dscam activates Pak1 
through the SH3/SH2 adaptor protein Dock. Pak1 is a Ser/Thr kinase linking small 
GTP-binding proteins (cdc42 and Rac) to JNK signalling. Rac1 has been shown to 
enhance the interactions between DSCAM and Pak1.  Once activated, Pak1 
phosphorylates MAP2K1 which in turn activates downstream MAPKs and JNK, 
mediating a variety of physiological processes including cytoskeletal reorganisation 
and migration (Fig. 6.2) (Qu et al., 2013; Schmucker et al., 2000).  
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Figure 6.2 Dscam activates PAK1 and JNK signalling 
The cytoplasmic tail of transmembrane DSCAM interacts with PAK1 (enhanced by 
cdc42/Rac1) which leads to phosphorylation and activation of MAPK and JNK 
signalling pathways.  
 
Additionally, in the nervous system Dscam has been shown to act as a Netrin-1 
receptor to regulate neuronal guidance (Ly et al., 2008). Netrin-1 is a 
chemoattractant which is secreted by plate floor cells in the nervous system which 
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guides the neuronal growth cone for axon extension (Kennedy et al, 1994). 
Inactivation of Netrin-1 signalling and loss of similar receptors including DCC (deleted 
in colorectal cancer) have been implicated in the progression of malignant tumours 
(Ly et al., 2008).  
 
Clinically, DSCAM is implicated in many human diseases including Downs syndrome 
and congenital heart disease. Expression of DSCAM is regularly increased in various 
neurological disorders; however it is has also been shown to be deregulated in 
mammalian cancer including breast cancer (Miano et al., 2016). While Dscam has 
been studied extensively in the nervous system; no-one has really looked at how it 
may function with regards to tumour progression or its biological role outside of the 
nervous system. 
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6.2 Results 
 
6.2.1 Knocking-down Dscam1 in lgl-/- mutant background promotes 
tumour progression 
During the candidate screen (Chapter 4) Dscam was identified as a strong hit due to 
its drastic effect on tumour progression. Dscam remains extremely novel with 
regards to its role within the epithelium and cancer development, however due to it 
being well characterised in the nervous system there are many genetic tools 
available, making it an ideal candidate to study further.  
 
A variety of strong cancer-related phenotypes were observed when RNAi targeting 
Dscam1 was expressed alongside the lgl[4] mutation on the back of the fly. Many 
animals presented with developmental problems whereby the lateral dorsal 
epithelium failed to close properly during embryogenesis (Fig. 6.3 A), whilst the size 
of clonal tissue and percentage coverage within the notum was significantly reduced 
(p=0.0135) compared to lgl-/- mutant animals. Moreover, the apex of mutant cells 
were significantly smaller (p<0.0001) and malformed compared to cells in lgl-/- 
mutant clones alone (Fig. 6.3 B, H). As expected from neoplastic tumours, clones 
were highly disorganised with cells growing on-top of one another in a multi-layered 
fashion (Fig. 6.3 C) to a greater extent than that seen in lgl-/- animals. See Appendix 
G (CD) for all genes and scores given for each phenotype. Compared to WT there was 
also a significant (p=0.0022) increase in invasion in lgl-/-; Dscam1 KD animals 
however, there was no significant difference when compared to lgl-/- (Fig. 6.3 D, J). 
Additionally, basal filopodia were significantly longer (p<0.0001) than those seen in 
203 
 
lgl-/- mutants (Fig. 6.3 E, I). See Section 4.2.1 for examples of phenotypes and their 
scores compared to lgl-/-.  
 
Additionally, using confocal microscopy, movies could be made to see how tumours 
behaved over time. Figure 6.4 shows an invasive cell which was detected beneath the 
epithelium. Due to being labelled with UAS-Moe-GFP the cell would have originated 
from the lgl-/-; Dscam1 KD mutant clone. As shown, the invasive mutant cell had long 
intermediate lamellipodia and basal filopodia, which, when followed over time were 
very dynamic. Additionally, the invading cell moves laterally in the XY plane. The 
images in Fig. 6.4 taken every minute show these actin rich protrusions extending 
and retracting over time. While invading cells with protrusions were only seen a few 
times in lgl-/-; Dscam1 KD animals, they were never seen in lgl-/- alone. For 
comparison, Fig. 6.5 shows a delaminated lgl-/- mutant cell which moves laterally in 
the XY plane but does not have any lamellipodia or filopodia.  
 
Dscam1 was then knocked down in a WT background to see whether the phenotypes 
observed were due to Dscam1 alone or cooperation between Dscam1 and Lgl. 
Knocking down Dscam1 alone, without the lgl[4] mutation however was not 
sufficient to produce neoplastic tumours on the back of the fly (Fig. 6.3 F), with cells 
appearing characteristically WT. This data suggests that in this system, Dscam1 
cooperates with Lgl to promote tumour progression. 
 
All together these results show that Dscam1 and Lgl cooperate in the Drosophila 
notum in a tumour suppressive manner, and when both are down-regulated produce 
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highly disorganised tumours with constricted apices and long dynamic basal 
filopodia.  
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Figure 6.3 Cooperation between lgl mutant and Dscam1 knockdown 
promotes tumour progression 
(A-E) Live confocal images of clones within the notum expressing RNAi targeting 
Dscam1 specifically within lgl-/- mutant tissue. A range of cancer-associated 
phenotypes were observed including, (A) dorsal closure defects, (B) reduced apex 
size, (C) multi-layering, (D) invasion (red arrows) and (E) long basal filopodia  (red 
arrows). (F) Confocal image of animal expressing RNAi targeting Dscam1 without the 
lgl[4] mutation. (G-J) Quantification of (G) the percentage of clonal tissue within the 
notum, (H) apex area, (I) length of basal filopodia and (J) invasion. Mean and SEM 
plotted. Number of animals quantified for clonal tissue: WT: n=10, lgl-/-: n=32, lgl-/-
;Dscam1-RNAi: n=7, Dscam1-RNAi: n=5. For apex size and basal filopodia, n≥5 animals 
with >40 cell apices/protrusions measured for each genotype. Scale bars = 50µm. 
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Figure 6.4 Delaminated lgl-/-; Dscam1-RNAi mutant cell has dynamic 
protrusions 
Confocal snap-shots from a real-time movie following a mutant cell that had 
delaminated from the epithelium. Cell is homozygous mutant for lgl with Dscam1 
simultaneously knocked down. Snapshots taken every minute (t); scale bar = 20µm. 
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Figure 6.5 Delaminated lgl-/- mutant cell 
Confocal snap-shots from a real-time movie following a mutant cell that had 
delaminated from the epithelium. Cell is lgl homozygous mutant. Snapshots taken 
every minute (t); scale bar = 20µm. 
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6.2.2 Drosophila Dscam homologues produce similar phenotypes 
In Drosophila there are 4 different Dscam homologues (Dscam1-4). To see whether 
different homologues function in a similar manner to Dscam1 in this system, Dscam2 
and 4 were separately knocked down in lgl homozygous mutant tissue within the 
notum.   
 
Like Dscam1, both Dscam2 and Dscam4 enhanced the tumour phenotype when 
knocked-down in the lgl-/- mutant background, generating clones with similar 
phenotypes. For example, knocking down these Dscam homologues resulted in multi-
layering of the mutant epithelium (Fig. 6.6 A) and reduced clonal tissue coverage 
within the notum (when compared to lgl-/- alone, p=0.0396) (Fig. 6.6 B, H). 
Compared to Dscam1 KD, expressing RNAi targeting Dscam2 and Dscam4 had 
significantly larger apices (Dscam2>Dscam1 p=0.0025, Dscam4>Dscam1 p=0.0027), 
however both still caused significant (p<0.0001) apical constriction compared to lgl-/- 
alone. (Fig. 6.6 C, G). Both Dscam2 and Dscam4, like Dscam1, seem to play a role in 
regulating cellular membrane extensions, as knockdown of either homologue 
generated significantly long basal filopodia compared to lgl-/- (lgl-/-; Dscam2 KD>lgl-
/- p<0.0001, lgl-/-;Dscam4 KD>lgl-/- p=0.0002) (Fig. 6.6 D, H). However, these basal 
protrusions were significantly shorter than those generated when knocking down 
Dscam1 (lgl-/-; Dscam2 KD>lgl-/-; Dscam1 KD p=0.0039, lgl-/-; Dscam4 KD>lgl-/-; 
Dscam1 KD p=0.0097). Additionally, one animal with the genotype lgl-/-; Dscam2 had 
filopodia with sheet like protrusions extending from it (Fig. 6.6 E).    
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These data indicate that all Drosophila homologues of Dscam cooperate with lgl in 
this system and when knocked down promote tumour progression, notably causing 
apical constriction, multi-layering and elongated basal protrusions compared to lgl-/- 
alone. However, compared to Dscam1 KD, the effects seen knocking down Dscam2 
and Dscam4 were not as severe. Additionally, like Dscam1, Dscam2 and Dscam4 KD 
without the lgl mutation was not sufficient to promote tumour progression.   
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Figure 6.6 Dscam homologues produce similar phenotypes 
Live confocal imaging of lgl homozygous mutant clones labelled with GFP in the 
notum, simultaneously expressing RNAi targeting either (A-D) Dscam4 or (E) Dscam2. 
A range of phenotypes were observed including, (A) multi-layering, (B) reduced clone 
size, (C) small apices, (D) bundles of basal protrusions and (E) abnormal protrusions. 
Scale bars = 50µm. (F-H) Quantification of (F) clonal tissue coverage, (G) size of 
epithelial apex, and (H) length of basal protrusions (n≥5 animals, with >40 cell 
apices/protrusions measured for each genotype). 
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6.2.3 Subcellular localisation of Dscam  
Dscam has previously only been implicated and studied in the nervous system, where 
it has been shown to localise to the cell membrane, soma, and dendrites (Soba et al., 
2007). To determine the subcellular localisation of Dscam1 in epithelial cells WT 
tissue was fixed and stained with an antibody labelling Dscam (N-terminal). To do this 
Neuralised-Gal4, which drives expression of UAS-constructs (including GFP) in 
sensory organ precursor cells and their progeny, was used to specifically label WT 
individual well-spaced cells on the back of the fly and the whole notum was fixed and 
stained for both E-cadherin and Dscam.  
 
In WT tissue Dscam appeared to localise cytoplasmically at the level of the AJs, 
however did not colocalise with E-cadherin at the junctions (Fig. 6.7 A-A’’). Moving 
basally through the cell, Dscam localises to the cortex (Fig. 6.7 B-B’’) and then finally 
to the basal filopodia (Fig. 6.7 C-C’’). This differential localisation of Dscam 
throughout the columnar epithelial cell may explain why a variety of different 
phenotypes were seen when knocking-down Dscam in the notum- from apical 
defects to elongated basal filopodia.  
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Figure 6.7 Subcellular localisation of Dscam in epithelial cells 
WT Drosophila nota (Neu-Gal4, UAS-Moe-GFP) were fixed and stained for GFP, E-
cadherin and N-terminal Dscam. (A-A’’) Confocal snapshots were taken at the level of 
the AJs, (B-B’’) at an intermediate level and (C-C’’) at the level of the basal 
protrusions. Arrows indicate basal filopodia where Dscam is highly expressed. Scale 
bars represent 5µm. 
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6.2.4 Dscam is highly expressed in bristle precursor cells in the notum 
As there are limitations using RNAi, for further analysis of the Dscam phenotype, two 
Dscam mutants- Dscam21 and Dscam23- were analysed, both of which have previously 
been described as strong loss-of-function mutant alleles when studied in olfactory 
receptor neurons (Hummel et al., 2003; Schmucker et al., 2000). Initially negatively 
marked clones expressing Dscam21 and Dscam23 mutant alleles were generated in the 
notum and stained for E-cadherin and Dscam.  
 
Surprisingly, Dscam staining within the mutant clone appeared largely unaltered (Fig. 
6.8 A-A’’’). However this could be due to the antibody recognising the mutant protein 
- if the protein is truncated. While the mutant alleles have been described as loss-of-
function, exactly what these mutants are is not described in the published literature. 
It has been shown that the antibody binds to the constant region of Dscam (binding 
to variable exons 4, 6 and 9 were ruled out using western blotting). Additionally, 
previous published work with these mutants and the same antibody showed no 
staining or detection on a western blot (Hummel et al., 2003; Schmucker et al., 2000). 
Unexpectedly, in WT tissue Dscam expression was notably upregulated in the 
machrochaetes (Fig. 6.8 B-B’’), whilst in Dscam mutant machrochaetes this 
expression was drastically reduced (Fig. 6.8 C-C’’). 
 
Sensory organ precursor (SOP) cells are evenly spaced within the Drosophila dorsal 
thorax and from 12APF they divide and give rise to the microchaetes (small bristles) 
on the back of the fly. This process requires various signalling pathways including 
EGFR and Notch signalling, which when disrupted often lead to irregular bristle 
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growth and spacing. However when both Dscam mutants were analysed they 
appeared to have no effect on bristle development.  
 
As it is still unclear why Dscam was seen to be upregulated in the bristle precursor 
cells and then lost in the Dscam mutants, a much more detailed analysis would be 
required, including immunostaining using a different Dscam antibody to ensure 
results were not due to non-specific labelling.  
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Figure 6.8 Dscam localisation appears normal in Dscam23 mutant 
epithelial cells, while expression is reduced in mutant macrochaetes 
(A-A’’’) Negatively marked clones were generated in the notum homozygous mutant 
for Dscam23, with surrounding WT tissue labelled with nuclear GFP (nls-GFP). Scale 
bar = 50µm. (B-C) Nota were fixed and stained at 15h APF for GFP, E-cadherin and 
Dscam. Close up of WT (B-B’’) and Dscam23 mutant (C-C’’) macrochaetes. Scale bars = 
10µm.   
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6.2.5 Knocking-down Lgl in Dscam21 mutant background promotes 
tumour progression.  
In Section 6.2.1 Dscam was shown to cooperate with Lgl in this system when studying 
the genotype lgl-/-;Dscam1-RNAi. For comparison, Dscam21 homozygous mutant 
clones were generated with or without the simultaneous knockdown of Lgl using 
RNAi. 
 
In Dscam21 mutant clones, the phenotype produced was similar to that seen when 
Dscam1 was knocked down using RNAi, with clonal tissue forming an organised 
monolayer (Fig. 6.9 A). Additionally, Dscam21 had no significant effect on the 
percentage of clonal tissue within the notum, however when combined with Lgl-
RNAi, clonal tissue was significantly reduced (p=0.0215) (Fig. 6.9 G). However, this 
was not to the same extent as that seen with lgl-/-;Dscam1 KD, whereby clonal tissue 
was significantly (p<0.0001) smaller.  
 
As seen previously, knocking down Dscam1 in lgl-/- mutant tissue resulted in apical 
constriction. This phenotype was not mimicked when Dscam1 was knocked down in 
WT tissue alone (Fig. 6.3). Strangely, Dscam21 mutant apices were significantly larger 
than WT (p<0.0001) (Fig. 6.9 B, H). When combined with Lgl KD, Dscam21 mutant 
apices were significantly reduced in size (p<0.0001), however the apex size in 
Dscam21; Lgl KD was still not significantly different from WT (Fig. 6.9 E, H).  
 
Also, Dscam21 mutant cells had long actin rich basal filopodia (Fig. 6.9 C, I) which 
were significantly (p=0.0018) longer than WT cells. Moreover, when combined with 
219 
 
Lgl KD the length of basal protrusions was significantly increased (p=0.0009) (Fig. 6.9 
F, I). However, once again this phenotype was not as severe as that seen with lgl-/-; 
Dscam1 KD, which presented with significantly (p<0.0001) longer basal protrusions 
(Fig. 6.9 I). Additionally, closure defects were often seen in Dscam21; Lgl KD animals 
(Fig. 6.9 D).  
 
In conclusion, knocking down Lgl in the Dscam21 mutant background enhances the 
tumour phenotype compared to Dscam21 alone, however is rarely significant 
compared to WT. Moreover, the phenotype for lgl-/-; Dscam1 KD is more severe than 
that seen with Dscam21; Lgl KD.   
  
220 
 
 
221 
 
Figure 6.9 Cooperative effect seen between Dscam21 and Lgl-RNAi 
Dscam21 homozygous mutant clones were generated without (A-C) or with (D-F) the 
simultaneous knockdown of lgl using RNAi. Scale bars = 50µm. Quantification of (G) 
clonal tissue coverage, (H) apex size, and (I) length of basal protrusions. Error bars 
represent SEM. (n=5 animals and ≥40 apices and filopodia measured for each 
genotype). 
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6.2.6 Dscam affects cell adhesion and junction integrity 
The main phenotypes observed when combining lgl and dscam mutants were multi-
layering, apical constriction and elongated filopodia. These phenotypes are all 
associated with localised changes in cell shape. Therefore the AJ protein E-cadherin 
was studied to see whether Dscam plays a role in regulating and maintaining cell 
adhesion and junction integrity, which are typically disrupted during tumour 
progression and lead to a loss of polarised cell shape. For this experiment, Dscam21; 
WT and Dscam21; Lgl KD clones were generated in the notum and fixed and stained 
for E-cadherin. Additionally a live-cadherin reporter (ubi promoter drives expression 
of E-cadherin tagged GFP) was used to study E-cadherin in real time in Dscam21 
mutants.  
 
Cells within Dscam21 mutant clones showed a significant (p<0.0001) reduction in E-
cadherin expression at the AJs. Moreover, E-cadherin at junctions at the edge of a 
clone (i.e. a junction shared between mutant and wild-type cells) was also 
significantly reduced (P<0.0001) compared to WT (Fig. 6.10 A-B). Bright ectopic 
puncta were observed in Dscam21 mutant tissue, however, strangely these were also 
seen in WT tissue with no significant difference in the average number of puncta per 
cell (Fig. 6.10 B’). Similarly, ectopic E-cadherin junction extensions and junctional 
breaks were observed, however, again this was not significant compared to WT (Fig. 
6.10 B’’-B’’’). When using live-cadherin to label AJs, Dscam21 mutant junctions 
showed a significant (p=0.0002) decrease in E-cadherin levels compared to WT. 
However, unlike that seen with the E-cadherin antibody, border junctions had normal 
E-cadherin levels (Fig. 6.10 C-D). Additionally, atypical ectopic E-cadherin rich 
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junction extensions were seen in mutant tissue which was significant compared to 
WT (p=0.0167) (Fig. 6.10 D’). Using the live-cadherin, no junctional breaks or ectopic 
puncta were seen.   
 
When Dscam21 was combined with Lgl KD these phenotypes were significantly 
enhanced. Compared to the surrounding WT tissue Dscam21; Lgl KD mutant junctions 
had a significant reduction (p<0.0001) in E-cadherin levels (Fig. 6.10 E, F). E-cadherin 
in junctions bordering WT and mutant tissue was also significantly reduced 
(P<0.0001). Indicating that loss of E-cadherin from mutant side of the clone boundary 
was sufficient to decrease E-cadherin on the WT side. Additionally, a significant 
number of junctional breaks (p=0.0452) and ectopic E-cadherin junction extensions 
(p=0.0139) were seen in mutant tissue compared to WT  (Fig. 6.10 E’-E’’, F-F’’). 
 
The data shows that a loss of Dscam function leads to a mild disruption to E-cadherin 
localisation and junction integrity in epithelial cells. Dscam21 alone was sufficient to 
reduce E-cadherin in the mutant tissue, however this affect was enhanced when 
combined with Lgl KD, again emphasising the cooperative effect between Lgl and 
Dscam in Drosophila epithelial cells.  
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Figure 6.10 E-cadherin localisation is mildly disrupted in Dscam mutants 
Visualising E-cadherin in Dscam mutant clones in the Drosophila nota. Tissue was 
either fixed and stained with antibodies against E-cadherin (A, E-E’) or live animals 
were imaged expressing a live-cadherin construct in the notum (B). (A-C) Dscam21 
mutant clones (A, below red dashed line; B, to the left of the red dashed line) show 
mildly reduced E-Cadherin levels in the mutant cells. Arrow indicates ectopic E-
cadherin tubules. (E) Dscam21; Lgl KD clone (mutant cells are to the right of the red 
dashed line).  (E’-E’’) Higher magnification image of a Dscam21; lgl KD clone. Arrow 
indicates a junctional break (E’) and ectopic E-cadherin extensions (E’’). Scale bars = 
10µm in panels A, C, E’; 20µm in panel E and 5 µm in panel E’’. (B,D,F) Quantification 
of fluorescence intensity of E-cadherin in WT, border and mutant AJs. (B’) 
Quantification of the average number of ectopic puncta per cell. (B’’,D’,F’) 
Quantification of the average number of ectopic E-cadherin tubules. (B’’’,D’, F’’). 
Quantification of average number of junction breaks. (n=4 for live-cadherin; n=3 for 
fixed staining; with ≥50 junctions measured for fluorescence intensity and ≥50 cells 
analysed for junction breaks, puncta and ectopic tubules). 
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6.2.7 Cooperation between Dscam and Lgl affect apicobasal polarity  
The polarity proteins Bazooka (Baz) and aPKC localise to and regulate assembly of AJs 
in Drosophila epithelial cells and are vital in regulating and maintaining apicobasal 
polarity. To further analyse whether Dscam is important for apicobasal polarity, RNAi 
was used to knock down Lgl in Dscam21 mutant clones, and nota were fixed and 
stained with antibodies against Baz and aPKC. 
 
In Dscam21; lgl KD mutant animals Baz staining was significantly (p<0.0001) reduced 
at AJs compared to WT (Fig. 6.11 A’, C). Additionally, within the mutant tissue 
junctional breaks and atypical ectopic Baz rich tubules were often seen. Moreover, 
when looking at E-cadherin staining from the same animal, these junction breaks 
were often seen in the same place (Fig. 6.11 A-A’’).  
 
Similarly, aPKC staining was also significantly (p<0.0001) reduced in Dscam21; Lgl KD 
mutant tissue compared to WT (Fig. 6.11 B, D). 
 
These results strengthen the previous data with E-cadherin, suggesting that the 
combined loss of Lgl and Dscam function leads to a mild disruption to junction 
integrity and apicobasal polarity. 
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Figure 6.11 Reduced Baz and aPKC levels in Dscam21; Lgl KD mutant 
clones 
(A-B) Positively marked clones from Drosophila nota were fixed and stained for (A) E-
cadherin, (A’) Baz and (B) aPKC in WT (left side of dotted line) and Dscam21; Lgl KD 
mutant tissue (right side of dotted line). (A-B) Disruption to junction integrity in 
mutant tissue highlighted by arrows. Scale bars represent 10µm. (C-D) Quantification 
of Baz and aPKC fluorescence intensity. (n ≥40 from 4 animals for aPKC and 2 animals 
for Baz). Mean and SEM plotted. 
  
227 
 
6.3 Discussion 
Due to its drastic effect on tumour progression the complex molecule Dscam was 
identified as a hit from a genetic screen carried out in Chapter 4. Dscam has been 
widely researched with regards to its well-characterised roles in the nervous system 
including self-avoidance and axon guidance (Schmucker et al., 2000). However, with 
regards to cancer development and progression Dscam remains extremely novel and 
uncharacterised. This chapter suggests that Dscam may also act in a tumour 
suppressive manner in the Drosophila epithelium.  
 
In the Drosophila notum, Dscam1 was shown to cooperate with Lgl in a tumour 
suppressive manner, affecting several cancer-associated processes. Additionally, 
Dscam2 and Dscam4 produced similar phenotypes. For example, down regulating 
Dscam1, Dscam2 or Dscam4 in lgl homozygous mutant tissue resulted in aberrant 
tissue multi-layering, developmental defects, elongated dynamic basal filopodia and 
apical constriction. These phenotypes were however more severe in lgl-/-; Dscam1 
KD clones. This suggests that a combined loss of Dscam1 and lgl function could lead 
to a disruption of cell-cell adhesion and/or the apical actomyosin cytoskeleton, which 
regulates cell shape and contractility. To further analyse the role of Dscam in cell-cell 
adhesion, Dscam mutant and Dscam KD tissue could be fixed and stained for 
adhesion molecules such as α- and β-catenin along with integrins such as 
myospheroid (β-integrin). Moreover, to look in more detail at the effects Dscam has 
on the actin cytoskeleton, a Life-actin fused protein could be expressed, allowing the 
actin cytoskeleton to be studied in the living epithelium of Dscam mutants. 
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During developmental processes such as gastrulation Rho family members and 
actomyosin contractility has been shown to regulate apical constriction (Barrett, 
Leptin, & Settleman, 1997; Dawes-Hoang et al., 2005). Therefore it could be 
hypothesised that the apical constriction seen in Dscam KD clones could be due to 
Dscam regulating actin filaments and signalling through the Rho-kinase pathway. In 
support of this claim, in 2000, Schmucker et al, identified Dscam as a regulator of 
axon guidance in the nervous system through its interactions with Dock and Pak 
which have been shown previously to regulate the actin cytoskeleton through 
interactions with Rho family GTPases; RhoA, Rac and cdc42 (Hing, Xiao, Harden, Lim, 
& Zipursky, 1999; Nobes & Hall, 1995).  
 
Similarly, the significant elongation of basal filopodia seen suggests that Dscam 
cooperates with Lgl to directly or indirectly regulate the actin cytoskeleton. Filopodia 
are extensions of the plasma membrane encompassing bundles of actin filaments 
which serve many functions in epithelial cells, including adhesion and probing 
environmental signals (Vignjevic, Peloquin, & Borisy, 2006). These actin-rich 
protrusions are regulated directly by small Rho-GTPases and polarity protein 
complexes as well as indirectly via signalling pathways including Wnt/β-catenin which 
in turn regulate the filopodial binding protein fascin. In cancer, filopodia are linked to 
invasive tumours whereby changes in the actin cytoskeleton, typically driven by 
localised changes in Rho family GTPases, produces actin-rich protrusions which drive 
front-rear polarity and increase cell motility (Etienne-Manneville & Hall, 2002; Nobes 
& Hall, 1995; Vignjevic et al., 2007). Dscam could therefore regulate basal protrusions 
by directly affecting the actin cytoskeleton or indirectly by regulating Rho-GTPases. 
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Additionally, in the nervous system Dscam is important in the regulation of self-
avoidance and in recent loss-of-function studies in the mouse retina resulted in 
elongated dendritic processes, crossing over and generation of dendrite bundles (Li 
et al., 2015).  
 
Within the last 5 years, two genetic techniques; Flybow (Hadjieconomou et al., 2011) 
and LOLLIbow (Boulina, Samarajeewa, Baker, Kim, & Chiba, 2013); have been 
developed which enable multi-colour labelling of sub-populations of cells in 
Drosophila. In this way both Flybow and LOLLIbow could be used to visualise 
protrusions in Dscam mutants and Dscam KD animals in real time. This would enable 
us to look more closely at protrusion morphology and dynamics in Dscam mutants 
and how protrusions from neighbouring cells interact with one another. 
 
Immunofluorescent analysis of both Dscam21 and Dscam21; Lgl KD mutant tissue 
showed decreased levels of E-cadherin, Baz and aPKC at AJs. In Dscam21 mutant 
animals a decrease in E-cadherin levels was seen along the mutant/WT boundary, 
however this was not reproduced when using the live-cadherin. As the live-cadherin 
construct drives GFP-tagged E-cadherin expression, this could result in excess E-
cadherin levels in the cell, which may account for the difference seen at the 
mutant/WT boundary. The Dscam21; Lgl KD genotype was also sufficient to reduce E-
cadherin levels along the mutant/WT clone boundary. Additionally, ectopic E-
cadherin rich puncta and junction extensions, along with junction breaks were also 
observed. Ectopic E-cadherin puncta were only observed in animals with Dscam21 
mutant clones and labelled with an antibody against E-cadherin. Moreover these 
230 
 
puncta were also observed in WT tissue, which suggests that the observed puncta are 
simply an artefact of the antibody staining. As it is unlikely that the effects on 
junction integrity are a major contributor to the overall cancer phenotype, future 
experiments would involve looking at other possible explanations. For example, in 
the nervous system Dscam has been shown to regulate JNK signalling through its 
interactions with Pak and Dock, therefore it may be enhancing the cancer phenotype 
in our system through JNK signalling (Qu et al., 2013; Schmucker et al., 2000). 
Additionally FRET-probes could be used to analyse changes in Rho GTPase activity in 
Dscam mutant animals.  
 
Altogether, these data suggest that in the epithelium a loss of Dscam1 function could 
affect cell adhesion, junction integrity and apicobasal polarity, which could contribute 
to the phenotypes observed when Dscam1 and lgl function is lost (e.g. multi-layering 
and apical constriction) as these phenotypes are associated with the deregulation of 
these processes. Additionally, elongated dynamic filopodia are associated with a 
front-rear polarity which requires a loss of apicobasal polarity within columnar 
epithelial cells. All of this together suggests that Dscam may be important in the 
regulation of cell polarity and the localisation of polarity determinants within the cell.  
However, it should be stressed that the effects on junction integrity and cell polarity 
are relatively mild and are unlikely to be the underlying cause of the extreme 
phenotypes observed in lgl-/-; Dscam1 KD clones. 
 
Although a much more detailed analysis is required, this chapter outlines some 
preliminary experiments which show that loss of Dscam promotes tumour 
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progression in the epithelium. These results suggest that Dscam function is not 
limited to the nervous system, however has a novel cooperative role in preventing 
tumour progression in the epithelium.  
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Discussion 
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Chapter 7 Discussion 
 
Tumour invasion and metastasis is a complex process that is poorly understood yet 
accounts for more than 90% of cancer related deaths. By improving our knowledge of 
the complex processes and genetic determinants involved in tumour progression, 
targeted cancer therapy could be advanced and improved. Drosophila has become an 
increasingly popular model organism with which to characterise the cell biological 
events that underlie tumour progression. These events are usually associated with 
aberrant changes in cell polarity and adhesion through the concomitant 
misexpression of various genes. During my PhD I carried out a pilot screen to 
optimise conditions for a large-scale genetic screen in the Drosophila notum. From 
the full genetic screen I then identified novel genes which affect tumour progression.   
 
7.1 Optimisation and screening  
The aim of the pilot screen was to (i) optimise conditions for the full screen by 
identifying a suitable genetic background for the enhancer/suppressor screen. (ii) 
Carry out cooperative experiments with Notch. (iii) Verify RNAi KD was working as 
expected and independent RNAi lines produce similar phenotypes and (iv) to 
generate a database and scoring system for qualitative analysis of animals.  
 
My preliminary studies showed that by inducing mutant clones which were 
homozygous mutant for the lgl tumour suppressor gene, neoplastic tumours could be 
generated on the back of the fly. These tumours covered approximately 15-35% of 
the notum and were mildly multi-layered and invasive. In contrast, clones of cells 
234 
 
homozygous mutant for dlg and scrib were invariably small. A possible explanation 
for this is that dlg and scrib mutant cells were being eliminated through JNK-
mediated apoptosis as a result of cell competition (as described in Section 3.3). This 
theory has been demonstrated by other researchers who show that mutations in 
these tumour suppressor genes require cooperation with oncogenic Ras or Notch in 
order to preferentially grow and not be out competed by surrounding wild-type cells 
(Brumby & Richardson, 2003; C. L. Chen et al., 2012; Pagliarini & Xu, 2003). Unlike 
these other systems, my data showed that clones homozygous mutant for lgl were 
sufficient to grow and survive.  One possible explanation for this is that unlike Dlg and 
Scrib, Lgl interacts with the Salvador/warts/hippo pathway such that loss of Lgl 
results in the mislocalisation of hippo and subsequent activation of the transcription 
factor Yki. Yki in turn transcriptionally activates genes involved in cell growth and 
survival (Grzeschik et al., 2010). In other Drosophila tissues such as the imaginal discs, 
lgl mutant clones are small and outcompeted by WT cells like those seen with dlg and 
scrib mutant clones in our system. To my knowledge, this is the first demonstration of 
a tissue in the fly where large lgl mutant clones can be generated, implying that these 
lgl clones have not been outcompeted by wild type tissue. One possible explanation 
for this is that in other studied tissues, such as the imaginal discs, mutant clones find 
themselves in a highly proliferative environment; however in the notum the tissue is 
not so proliferative.  From these results, it was determined that lgl mutant clones 
would make an ideal genetic background with which to carry out an 
enhancer/suppressor screen. In addition, I showed that when combined with an 
activated allele of Notch, the tumour phenotype was enhanced, mimicking the 
cooperative effect seen in other systems (Brumby & Richardson, 2003).  
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By carrying out a pilot screen on more than 40 well-characterised cancer-related 
genes we demonstrated that it was possible to replicate expected phenotypes with 
known genes in our system and RNAi lines for the same gene were giving similar 
phenotypes. Analysis of all the genes screened during the pilot led the way to the 
generation of a database for large data-sets. Using this database all genes, animals 
and phenotypes could be qualitatively analysed. Moreover, this way of recording 
data allowed me to quickly identify genes which appeared to drastically enhance or 
suppress the tumour phenotype. By the end of the pilot screen, our data provided 
evidence that our system was working efficiently, and could be used for the high-
throughput screening of a host of candidate genes.  
 
The main aim of the full candidate screen was to identify novel genes that promote 
or inhibit the tumour phenotype. These genes were selected using various online 
tools and databases, identifying genes that were previously found to be commonly 
mutated or down regulated in a range of human epithelial cancers (Lawrence et al., 
2014). Identified genes were then checked for their suitability for the screen, i.e. that 
they had Drosophila orthologues and available RNAi constructs on the correct 
chromosomes. For some of these genes the fly gene and/or the human orthologue 
were well characterised, while others were completely unknown. These 
uncharacterised genes had only been implicated in human cancer from 
genetic/epigenetic analyses of human tumours. This range of well-characterised and 
unknown genes was selected to help make sense of gene clustering based on 
phenotype. In 3 years, over 418 genes (610 RNAi lines) were screened and 
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qualitatively analysed using the database generated from the pilot screen. Using our 
method of subjective analysis, genes that generated strong phenotypes when 
knocked-down could be easily identified. For example, approximately 200 genes 
increased tumour multi-layering and 80 genes increased tumour invasiveness. From 
this screen I selected 3 genes with interesting phenotypes to characterise further, 
these were: CG7379, CG10600 and Dscam. 
 
7.2 Characterisation of identified hits 
We are now in the process of completing this large-scale screen and have identified 
numerous novel conserved genes that affect tumour progression in this Drosophila 
system. To take this further, (i) interesting hits will be characterised in the fly, with 
the aim of understanding the molecular basis of their effect on tumour progression, 
and (ii) the role of homologous genes will be tested in mammalian cell culture models 
of metastasis and, potentially, in other in vivo cancer models. In this way, we may 
identify promising targets for the development of anti-cancer therapies. The three 
genes I chose to characterise, in addition to providing promising results, also 
illustrate many of the techniques that will be used to characterise these genes in the 
future. 
 
7.2.1 CG7379 has anti-invasive properties and regulates junction 
integrity and cell-adhesion 
I selected the Drosophila gene CG7379 to characterise further as KD in the lgl mutant 
background significantly enhanced the invasive phenotype. While CG7379 remained 
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uncharacterised in Drosophila, its human orthologue ING1 is a well-characterised 
gene implicated in human cancer; however its known role is in the regulation of 
apoptosis (Garkavtsev et al., 1998; Helbing et al., 1997; Tsang et al., 2003). By 
overexpressing p35 my data shows that the invasive phenotype observed in CG7379 
mutant clones is not due to reduced apoptosis – rather my results suggest that 
CG7379 function is important to maintain cell-cell junction integrity. To verify this, 
further experiments would involve testing the level of apoptosis is WT, lgl -/- alone, 
CG7379-/- alone and lgl-/-; CG7379 KD using TUNEL staining, or live constructs such 
as apoliner. Analysis of E-cadherin and Arm (β-catenin) in CG7379 KD clones with and 
without an accompanying lgl mutation showed that junction integrity was 
compromised, with reduced E-cadherin and Arm at AJs, junctional breaks and ectopic 
E-cadherin rich junction extensions. To maintain cell-cell adhesion, E-cadherin and 
Arm form a cadherin-catenin complex that is at the core of the adherens junction. 
These essential components of the AJ are often misregulated in human cancers to 
allow tumour cells to break cell contacts and invade. Therefore by affecting AJ 
protein localisation and regulation in cells, this may explain why CG7379 KD 
promotes tumour invasion. Researchers have shown that deregulation of endocytosis 
mediated junctional turnover of E-cadherin results in E-cadherin ectopic structures, 
similar to those seen in my results (Georgiou et al., 2008). Therefore I propose that 
CG7379 maintains junction integrity and cell adhesion by regulating the turnover of 
junction material required during important processes such as cell division. In 
support of my hypothesis, the human orthologue ING1 has been shown to regulate 
senescence by mediating expression of intersectin-2 which is a member of endocytic 
machinery (Rajarajacholan et al., 2013). My data suggests that by regulating 
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expression of genes involved in endocytosis, CG7379 might be acting in a tumour 
suppressive manner to maintain junction integrity. My work also demonstrated that 
CG7379 KD impaired integrity of the septate junctions as well as the adherens 
junctions, as FasIII localisation was also disrupted. On the other hand my data 
showed that CG7379 KD did not affect the localisation/expression of key players in 
apicobasal polarity. Future experiments would involve looking at cell-cell junctions in 
mammalian cells in vitro, including non-transformed epithelial cell lines such as 
MDCK cells. For this ING1 would be knocked down in MDCK cells to test whether the 
same effect is observed on junctions in mammalian cells. If these junction defects are 
mimicked in mammalian cells, this would reveal a new aspect of ING1 function that 
has not been demonstrated before and is relevant to its role in cancer.  
 
By carrying out in vitro experiments on ING1, I showed that the human orthologue 
also has anti-invasive properties in different mammalian tissues and KD was sufficient 
to promote invasion in both glioblastoma and adenocarcinoma cells. This suggests 
that this gene doesn’t act in a tissue specific manner and is likely to be involved in 
pathways common to both tissue types.  
 
In summary my data characterising CG7379 strongly suggests that this gene has 
important anti-invasive properties by regulating junction integrity and cell adhesion. 
Previous research on ING1 has suggested that this gene may function in a tumour 
suppressive manner by regulating apoptotic machinery, p53 and the cell cycle. 
However, I propose that this gene might also be involved in endocytosis mediated 
recycling of E-cadherin and junctional material in order to regulate dynamic junction 
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stability and adhesion. In order for research to progress I suggest that experiments 
should be carried out which test whether CG7379 is directly involved in the 
expression/regulation of endocytosis-mediated E-cadherin junctional turnover. 
Additionally, I would investigate further the effects CG7379 KD has on junction 
dynamics using FRAP, and study junction integrity and adhesion in vitro. Once it is 
fully understood how CG7379/ING1 KD promotes invasion, this gene could 
potentially become a therapeutic target.  
 
7.2.2 CG10600 regulates cell adhesion and junction integrity 
The second gene that I chose to characterise further was CG10600 (human 
orthologue: RSBN1L). This gene was completely novel and remained uncharacterised 
in both Drosophila and humans making it an extremely interesting and novel gene to 
characterise. I chose this gene as it affected a wide range of phenotypes from 
developmental defects, apical constriction, multi-layering, invasion and basal 
filopodia. Similar to CG7379, my data showed that E-cadherin levels were reduced 
with CG10600 KD, however this was only seen when combined with the lgl[4] 
mutation. Therefore I suggest that while CG7379 KD is sufficient to impair junction 
integrity and adhesion, CG10600 requires cooperation with additional tumour 
suppressors. In comparison to the E-cadherin phenotype observed with CG7379 KD, 
CG10600 KD did not result in ectopic E-cadherin structures or puncta, suggesting that 
the process of endocytosis is not being impaired in these mutants.  
 
While I was able to demonstrate that CG10600 has a potential tumour suppressive 
function by regulating junction integrity and adhesion through E-cadherin, 
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unfortunately I did not investigate the effect of CG10600 KD on apicobasal polarity. 
My in vitro invasion assay demonstrated that RSBN1L (CG10600) has anti-invasive 
functions in a tissue specific manner, able to promote invasion in the 
adenocarcinoma cell line. While RSBN1L did not promote invasion in U87 cells, as 
metastasis precedes invasion in glioblastomas, this data does not preclude RSBN1L 
from being involved in metastasis in these tumours. To answer this question an assay 
for cell migration should be carried out, such as classic Boydon chamber or scratch 
assays. With cell adhesion being impaired in Drosophila, it would worth looking at 
adhesion, junction integrity, cell polarity and cytoskeletal regulators in both 
glioblastomas and adenocarcinomas in vitro.  
 
Due to the lack of genetic tools available for studying this gene, I used CRISPR/cas 
technology to generate a mutant. While I was able to identify many single nucleotide 
changes in the mutant, I was not able to fully sequence the entire mutant to the 
end/new stop codon. Therefore for research to progress further, I suggest that 
current lab members finish sequencing the mutant and determine how these 
nucleotide changes might affect protein structure and function.  
 
While my data on CG10600 is limited, it is clear that this gene is important for cell 
adhesion and may have clinical relevance due to its anti-invasive function in 
adenocarcinomas. Still, there are many unanswered questions, such as what is the 
extent of tissue specificity? Does this gene regulate apicobasal polarity? How does 
this gene regulate cell adhesion? One of the advantages of investigating a completely 
novel gene is its novelty; however the major disadvantage is the lack of tools 
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available for its study. Therefore, uncovering the molecular mechanisms by which 
this gene affects tumour progression will be a more long-term project. 
 
7.2.3 Dscam regulates the actin cytoskeleton, cell adhesion and 
apicobasal polarity. 
The final gene that I chose to characterise further was Dscam.  I showed that Dscam1, 
Dscam2 and Dscam4 all cooperate with lgl in our system to promote tumour 
progression. However, KD of Dscam1 produced more severe phenotypes compared 
to the other two homologues. KD of Dscam in the lgl mutant background produced 
similar phenotypes to that seen with CG10600 KD including developmental defects, 
apical constriction and multi-layering. The most striking phenotype observed 
however, was long basal filopodia.   When studied in the nervous system, Dscam has 
been shown to regulate axon guidance as well as the length and spacing of dendritic 
processes (Li et al., 2015; Schmucker et al., 2000). Taking this into consideration, it is 
unsurprising that in the epithelium we saw a phenotype associated with actin rich 
protrusions. I therefore propose that while in the nervous system Dscam is important 
in regulating the actin cytoskeleton in dendrites and axons, similarly in the epithelium 
Dscam is important in regulating the actin cytoskeleton in epithelial cells, thereby 
affecting protrusion morphology. Moreover, based on current literature I believe that 
it is highly likely to do this via interactions with Rho GTPases. In the nervous system 
the current model shows that Dscam interacts with Pak and Dock which in turn 
regulate Rac, Rho and cdc42 during axon guidance (Schmucker et al., 2000). 
Therefore I suggest that in epithelial cells, Dscam may function in a similar manner to 
mediate actin filaments associated with filopodia. Dynamic filopodia are associated 
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with EMT and front-rear polarity enabling epithelial cells to become motile and 
invade/metastasis. Therefore if Dscam is important in the regulation of these 
dynamic processes it may have clinical relevance in invasive/metastatic human 
cancers.  
 
Analysis of E-cadherin in lgl-/-; Dscam1 KD animals showed that loss of both Dscam1 
and Lgl together is sufficient to impair junction integrity.  Moreover junction breaks 
were also observed with this genotype. Additionally, my data showed that in 
combination with the lgl[4] mutation Dscam KD affected apicobasal polarity as 
demonstrated by staining for aPKC and Baz.  
 
Taking into consideration all of my data on Dscam and its known role in the nervous 
system, I suggest that Dscam regulates the actin cytoskeleton in the epithelium, and 
is important in regulating filopodial morphology. Additionally, I propose that Dscam 
plays a novel role in regulating cell-adhesion, junction integrity and apicobasal 
polarity in an epithelium. To verify this, Dscam mutant tissue could be fixed and 
stained for actin cytoskeletal proteins (e.g. phalloidin), or a live-actin construct could 
be expressed in the living epithelium. Additionally, genetic tools like Flybow or 
LOLLIbow could be used to more closely look at protrusion dynamics and 
morphology.  Moreover, this would allow us to look at the how protrusions from 
different cells interact with each other.   
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7.3 Future work 
Future work will not be limited to the characterisation of individual genes but will 
hope to determine whether genes that promote invasion in our in vivo Drosophila 
model also mediate cellular invasion in malignant human cancers. Moreover we hope 
to identify how tumour genetic background and the extent of tumour progression 
may affect gene transcription. Hits for invasion could also be used in a secondary 
screen using 3-D invasion assays. Human orthologues of these genes could be 
knocked down in human cancer cell lines to see if they promote invasion in the same 
way. Similarly, this work could be studied further using mouse models, looking at 
specific cancer types (dependant on which cell types were affected in vitro).  
 
To improve our understanding of the effects candidate genes have on the 
transcriptome future work will involve extracting RNA from cells of the notum and 
carrying out RNA Seq analysis. RNA Seq enables complete transcriptome profiling to 
quantitate precise expression levels of isoforms and transcripts within a cell (Z. Wang, 
Gerstein, & Snyder, 2009).  These experiments will involve generating GFP-positive 
tumours with different genetic backgrounds; then dissecting and fixing the tissue 
prior to dissociation. FACS could then be used to sort GFP positive and negative 
nuclei before performing whole transcriptome sequencing on total RNA from 
transformed cells together with control RNA derived from non-transformed cells. This 
will allow us to study genotypes that form neoplastic (invasive) tumours and compare 
those to hyperplastic (non-invasive) tumours. Once this protocol is established, the 
lab will possess a combination of tools (fly genetics, live cell imaging and 
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transcriptome sequencing) that would allow the genetic dissection of tumour 
progression in a living animal. 
 
7.4 Conclusions 
There is still much to learn about the genetic determinants involved in tumour 
progression, invasion and metastasis. By optimising a novel system in the Drosophila 
notum I have shown how novel genes involved in a variety of cancer-related and cell 
biological processes can be identified and characterised. I have further investigated 3 
genes that I propose play a role in tumour progression. I have proposed that CG7379 
acts in a tumour suppressive manner, affecting junction integrity and cell adhesion, 
potentially through endocytosis-mediated recycling of junction material. Moreover I 
have provided evidence that this gene’s tumour suppressive function may not be 
limited to epithelial derived cancers. CG10600 on the other hand appeared to be 
more tissue specific and affect junction integrity and cell adhesion via alternate 
mechanisms to endocytosis. Finally, I suggested that Dscam has a novel role outside 
of the nervous system in regulating the actin cytoskeleton, adhesion and apicobasal 
polarity. My research emphasises the complexity of tumour progression and the 
multitude of genetic determinants involved, and it is hoped that future experiments 
can provide a molecular mechanism of how these genes function. In this way my 
research and continued work in the Georgiou lab may have clinical relevance.  
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APPENDIX 
Appendix A: Plasmid map for pCFD3 
pCFD3-dU6:3gRNA was a gift from Simon Bullock (Addgene plasmid # 49410) (Port et al., 
2014). 
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Appendix B: Pilot genes 
 
Gene RNAi Source GO Terms 
Abi 36142-GD (III) VDRC 
actin cytoskeleton regulation, adhesion; 
lamellipodium assembly 
APC 
51469-GD (III) VDRC 
Polarity. Adhesion 
1451R-1 (III) NIG 
Apc2 22290-GD (X) VDRC Cell adhesion; cell cycle. polarity; 
Archipelago 15010R-3 (III) NIG Cell cycle. Regulation of hypoxic reaction 
Arm 11579R-1 (III) NIG Polarity and adhesion 
Baz-IR058 5055R-1 (III) NIG Polarity and adhesion 
Bcl2 
47515-GD (III) VDRC 
apoptosis  
12397R-1 (III) NIG 
Beclin-1 
(Atg6) 
22122-GD (III) VDRC Autophagy.  
cdc42 12530R-2 (III) NIG GTPase/Polarity/actin.cell migration 
CDK5-IR 8203R-3 (III) NIG adult behavior;centrosome localization;  
Cytochrome c 17128-GD (III) VDRC Apoptosis 
dE2f2 
45743-GD (X) VDRC 
Cell cycle.  
1071R-1 (III) NIG 
Death 
caspase  
5370R-2 (III) NIG organelle organization; autophagy 
Dig 
41136-GD (III) VDRC 
Polarity.  
1725R-1 (III) NIG 
E2F-IR15886 
15886-GD (III) VDRC 
Cell cycle. Growth; proliferation; apoptosis. 
15887-GD (III) VDRC 
fas 42237-GD (III) VDRC 
Morphogenesis of an epithelium; polarity of 
embryonic epithelium; dorsal closure. 
if (aPS2) 
Integrin 
44885-GD  VDRC 
Cell migration. regulation of glucose 
metabolic process;  
lgl-IR 
51247-GD (III) VDRC 
Polarity. Cell cycle 
51249-GD (III) VDRC 
Mad 
12399R-1 (III) NIG 
Cell cycle. Dorsal closure 
12399R-2 (III) NIG 
Merlin 7161-GD (III) VDRC Proliferation 
mew (aPS1) 
Integrin 
1771R-1 (III) NIG cell migration irrespective of tissue type 
Mnt 
10971-GD (III) VDRC  regulation of glucose metabolic 
process;  growth;  cell cycle;  2856R-2 (X) NIG 
Moesin 
10701R-1 (III) NIG 
Differentiation. cell polarity; 
10701R-3 (X) NIG 
Myospheroid 
(bPS) 
1560R-1 (III) NIG 
Protrusion-matrix adhesion; proliferation. 
cell adhesion;  
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NF1 
35877-GD (III) VDRC response to stress; growth; metabolic 
process; 8318R-1 (III) NIG 
p53 
10692-GD (III) VDRC 
Response to DNA damage. Apoptosis 
14873R-1 (III) NIG 
PAK3 
39843-GD (III) VDRC 
Actin regulation.  
14895R-1 (III) NIG 
pTEN 
35731-GD (III) VDRC 
cell cycle;  extracellular matrix organization;  
5671R-1 (III) NIG 
Puc 3019-GD (X) VDRC Actin regulation; apoptosis.  cell cycle 
Ral 2849R-1 (III) NIG 
Actin regulation.  JNK cascade; Notch 
signalling pathway;  Ras protein signal 
transduction; dorsal closure;  
Rbf1 10696-GD (III) VDRC 
cell proliferation;  response to DNA 
damage; cell cycle, Apoptosis 
salvador 13831R-2 (III) NIG Growth. regulation of cell death;  
Scrib 
5462R-2 (III) NIG Polarity. cell-cell junction organization; 
polarity;  45556-GD (III)  VDRC 
SLIK 
4527R-2 (III) NIG establishment of mitotic spindle 
orientation; actin cytoskeleton organization;  
4527R-3 (III) NIG 
TIMP1 6281R-2 (III) NIG Wing disc morphogenesis; delamination. 
tkv 
14026R-1 (III) NIG Cell fate determination; cell-cell 
adhesion; organ growth. 14026R-3 (III) NIG 
TOR 5092R-1 (III) NIG Growth. cell fate determination; 
TSC1 
22252-GD (III) VDRC growth; epithelium development; 
autophagy;  6147R-1 (III) NIG 
upd-IR3282 5993R-2 (III) NIG Jak/STAT. 
WASp 
13757-GD (III)  VDRC 
Actin regulation.  
1520R-2 (III) nIG 
α-catenin 20123-GD (III) VDRC 
cell adhesion; AJ organization; epithelium 
development; establishment or maintenance 
of cell polarity 
Kirre 
6695-GD (III) VDRC Negative control – muscle precursor cells, 
embryo 6696-GD (III) VDRC 
Otu 
47431-GD (III) VDRC Negative control – expressed in female 
germline only 12743R-3 NIG 
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Appendix C: Screen genes 
 
Gene RNAi Source Main GO Terms 
18w 
8896R3 (III) NIG 
immune response;  cell adhesion 
30498 (III) Bloomington 
Ac78C 55312 (III) Bloomington Response to stimulus in sensory perception 
Actn 
4376R1 (III) NIG 
actin regulation 
7760 (III) VDRC 
Adar 
7763 (III) VDRC 
locomotor behaviour 
28311 (III) Bloomington 
Ago 15010R-3 (III) NIG cell cycle; response to hypoxia;  
Akt1 
2902 (III) VDRC 
cell death 
4006R-3 (III) NIG 
Alk 11446 (X) VDRC neurogenesis 
alpha-spec 31209 (III) Bloomington cell adhesion; neurogenesis 
Ank 25945 (III) VDRC signal transduction; cytoskeletal regulation 
Ank2 
26121 (III) VDRC structural constituent of 
cytoskeleton; cytoskeletal protein binding 5115 (III) VDRC 
Apoltp 51937 (III) Bloomington regulation of lipid transport 
Arm 11579R-1 (III) NIG cell adhesion; cell morphogenesis; 
Asp 
2910 (III) VDRC actin regulation; establishment of mitotic 
spindle 28741 (III) Bloomington 
AstC-R2 
50000 (III) VDRC G-protein coupled receptor signalling 
pathway. 25940 (III) Bloomington 
Asx 31192 (III) Bloomington mitotic cell cycle, histone modifications 
ATP7 31083 (III) Bloomington ion transport and homeostasis 
ATPsyn-beta 
11154R-1 (III) NIG 
regulation of glucose metabolic process 
37812 (X) VDRC 
Atx-1 21870 (III) VDRC Photoreceptor cell maintenance. 
Aub 30124 (III) VDRC 
regulation of nuclear-transcribed mRNA 
catabolic process 
babo 
3825 (III) VDRC 
metabolic process and signalling 
853 (III) VDRC 
Bap170 
3274R-2 (III) NIG 
regulation of transcription 
34582 (III) VDRC 
Bbg 15974 (III) VDRC cell migration; innate immune response 
Bdl 31974 (III) Bloomington cell adhesion 
Bel 6299 (III) VDRC 
mitotic sister chromatid segregation; 
autophagy 
bent 46252 (III) VDRC filament assembly, sarcomere organization 
Blimp-1 
5249R-2 (III) NIG 
regulation of transcription 
34978 (III) VDRC 
bmm 37880 (III) VDRC lipid homeostasis 
Bnk 1480R-3 (III) VDRC actin filament organization 
Brm 
37720 (III) VDRC 
transport; metabolic process 
37721 (III) VDRC 
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Bro 13679 (X) VDRC regulation of transcription 
brv2 31670 (III) Bloomington calcium ion transport,  
Btl 
32134R-1 (III) NIG 
epithelium migration, metabolic process 
27108 (X) VDRC 
Bun 28322 (III) Bloomington Apoptosis 
Bx 29454 (III) Bloomington morphogenesis of an epithelium 
Ca-alpa1T 26251 (III) Bloomington Calcium ion transport. 
ca-alpha1D 
51491 (III) VDRC 
Calcium ion transport. 
52644 (III) VDRC 
Cac 48093 (X) VDRC calcium ion transport 
Calx 28306 (III) Bloomington Response to stress, transport 
calypso 
47743 (III) VDRC 
Histone modifications for ubiquitination 
28904 (X) VDRC 
Cap 39207 (III) VDRC 
Chromatid cohesion, DNA repair, 
neurogenesis 
Capt 
5061R-4 (III) VDRC 
regulation of cell morphogenesis 
21995 (III) VDRC 
Capu 32922 (III) Bloomington actin filament organization 
CcapR 
14767 (III) VDRC G-protein coupled receptor signalling 
pathway 31490 (III) Bloomington 
cdep 
2008R3 (III) NIG regulation of Rho and Race signal 
transduction 31168 (III) Bloomington 
CG10186 
30767 (III) VDRC Sensory perception of pain. 
 10186R-1 (III) NIG 
CG10211 12352 (III) VDRC response to oxidative stress 
CG10274 
10274R-2 (X) VDRC 
Unknown 
52407 (III) VDRC 
CG10348 10348R1 (III) NIG Sensory perception of pain. 
CG10585 
31272 (III) VDRC 
Isoprenoid biosynthetic process. 
31273 (III) VDRC 
CG10600 
10600R-2 (III) NIG Unknown 
 31276 (III) VDRC 
CG10621 31291 (III) VDRC Unknown 
CG10623 
10623R-3 (III) NIG 
Unknown 
10623R-4 (X) NIG 
CG10669 
10669R-1 (III) NIG 
Unknown 
10669R-4 (III) NIG 
CG10702 
3691 (III) VDRC transmembrane receptor protein tyrosine 
kinase signalling pathway 27052 (III) VDRC 
CG10916 31379 (III) VDRC 
intracellular signal transduction, protein 
ubiquitination 
CG10931 52107 (X) VDRC Histone modifications 
CG11180 28629 (III) Bloomington Neurogenesis. 
CG11247 52116 (III) VDRC Neurogenesis. 
CG11318 
 
11318R1 (III) NIG G-protein coupled receptor signalling 
pathway. 51792 (III) Bloomington 
CG11444 
11444R-1 (III) VDRC 
Unknown 
31501 (III) VDRC 
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CG11593 11593R2 (III) NIG Unknown 
CG11836 43308 (III) Bloomington Proteolysis. 
CG12268 
12268R1 (III) NIG 
Unknown 
1166 (III) VDRC 
CG12484 
12484R1 (III) NIG 
lateral inhibition 
12484R2 (III) NIG 
CG12950 
12950R1 (III) NIG 
Unknown 
10011 (III) VDRC 
CG1311 12242 (III) VDRC Unknown 
CG13185 18782 (III) VDRC 
Ribosomal large subunit assembly; cellular 
response to starvation. 
CG13579 
13579R1 (III) NIG G-protein coupled receptor signalling 
pathway. 9366 (III) VDRC 
CG13597 
13597R-4 (X) VDRC 
mRNA splicing 
32225 (III) VDRC 
CG14446 
14446R2 (III) NIG 
Unknown 
32487 (III) Bloomington 
CG14838 14838R3 (III) NIG Unknown 
CG15117 47530 (III) VDRC metabolic process; 
CG15269 51506 (III) Bloomington Unknown 
CG15395 
15395R-3 (III) VDRC 
Unknown 
39929 (III) VDRC 
CG15556 1791 (III) VDRC 
G-protein coupled receptor signalling 
pathway 
CG15744 28516 (III) Bloomington 
G-protein coupled receptor signalling 
pathway 
CG16721 25201 (III) VDRC CAMP-mediated signalling. 
CG16868 
 
16868R1 (III) NIG 
Unknown 
29617 (III) Bloomington 
CG17002 17002R-2 (III) VDRC Unknown 
CG1724 
30315 (III) VDRC Protein transport; protein targeting to 
mitochondrion. 30317 (III) VDRC 
CG17739 36542 (III) VDRC Unknown 
CG18335 
18335R-1 (III) VDRC 
Unknown 
52471 (III) VDRC 
CG18476 
6527 (III) VDRC 
Unknown 
17822R-1 (III) VDRC 
CG2135 16625 (III) VDRC Carbohydrate metabolic process. 
CG25C 28369 (III) VDRC Morphogenesis, dorsal closure 
CG30268 42705 (III) VDRC Oxidation-reduction process. 
CG30280 
34743 (III) VDRC G-protein coupled receptor signalling 
pathway. 34744 (III) VDRC 
CG30417 
25619 (III) VDRC 
Unknown 
48182 (X) VDRC 
CG31626 1975R-2 (III) VDRC Unknown 
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11082 (X) VDRC 
CG31731 31731R-2 (III) VDRC Transport. 
CG31999 
31999R1 (III) NIG 
Cell adhesion. 
31587 (III) Bloomington 
CG32066 44825 (III) VDRC Unknown 
CG32238 29424 (III) VDRC Protein polyglutamylation. 
CG32333 26118 (III) VDRC Sensory perception of pain. 
CG32373 32373R-1 (III) VDRC synaptic target recognition 
CG33288 
51189 (X) VDRC 
Unknown 
51190 (III) VDRC 
CG3339 
41917 (III) VDRC 
microtubule-based movement 
41918 (III) VDRC 
CG34113 
10989R2 (III) NIG 
Unknown 
22742 (III) VDRC 
CG34120 
11673 (III) VDRC 
Transport. 
1819R-1 (III) VDRC 
CG34380 39446 (III) VDRC tyrosine kinase receptor signalling pathway 
CG34422 40440 (III) VDRC phagocytosis 
CG4096 44522 (III) Bloomington 
Epidermal growth factor receptor signalling 
pathway; proteolysis. 
CG42255 32092R-3 (III) VDRC Unknown 
CG42342 28648 (III) Bloomington Unknown 
CG42672 31737 (III) Bloomington Unknown 
CG42817 
3849 (III) VDRC 
Unknown 
25882 (III) Bloomington 
CG4360 
4360R2 (III) NIG 
Unknown 
51813 (III) Bloomington 
CG4393 
4393R1 (III) NIG 
Unknown 
4393R4 (III) NIG 
CG4438 50033 (III) VDRC Unknown 
CG4587 
4587R2 (III) NIG sensory perception of pain, voltage-gated 
calcium channel activity 3839 (III) VDRC 
CG4887 
4887R-3 (III) VDRC 
sensory perception of pain,  mRNA splicing,  
21970 (III) VDRC 
CG4896 
26652 (III) VDRC 
mRNA splicing 
48197 (III) VDRC 
CG5037 
42787 (III) VDRC 
Heme biosynthetic process. 
31169 (III) Bloomington 
CG5155 31568 (III) Bloomington Sperm individualization. 
CG5245 27381 (X) VDRC Unknown 
CG5389 
5389R-3 (X) VDRC 
ATP synthesis regulation of proton transport. 
22111 (III) VDRC 
CG5550 
31000 (III) VDRC 
Unknown 
31001 (III) VDRC 
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CG5645 9289 (X) VDRC Unknown 
CG5984 52489 (X) VDRC Unknown 
CG6153 22257 (III) VDRC Cellular response to DNA damage stimulus. 
CG6272 
34156 (III) VDRC 
neurogenesis; regulation of transcription,  
34158 (III) VDRC 
CG6480 23447 (III) VDRC Histone modification, chromatin silencing. 
CG7229 37671 (III) VDRC spermatogenesis 
CG7379 
27988 (III) VDRC 
Chromatin modifications 
27989 (III) VDRC 
CG7394 9210 (III) VDRC 
neurogenesis; protein import into 
mitochondrial matrix 
CG7420 
46316 (III) VDRC 
negative regulation of protein secretion 
7420R-1 (III) VDRC 
CG7607 7607R1 (III) NIG Unknown 
CG7708 28613 (III) Bloomington Unknown 
CG7911 23075 (III) VDRC chromatin remodelling;  
CG8027 8027R-3 (III) VDRC Unknown 
CG9095 23159 (III) VDRC Unknown 
CG9279 45052 (III) VDRC microtubule-based movement;  
CG9492 51725 (III) Bloomington microtubule-based movement 
CG9572 44802 (III) VDRC Unknown 
CG9701 9701R-2 (III) VDRC Carbohydrate metabolic process. 
CG9784 
9784R-1 (III) VDRC 
dephosphorylating;  
30098 (III) VDRC 
Chd3 13636 (III) VDRC Chromatin/DNA binding;  
cheer 3937R2 (III) NIG  axon development; mitotic cell cycle  
CIC-c 
6466 (III) VDRC 
transmembrane transport. 
27034 (III) Bloomington 
Cirl 
8639R1 (III) NIG G-protein coupled receptor signalling 
pathway. 34821 (III) Bloomington 
Cnc 
17894R-3 (X) NIG response to stress; metabolic process, 
nervous system development 37674 (III) VDRC 
Cnn 4832R1 (III) NIG 
nervous system development,  chromosome 
segregation 
Cont 
40613 (III) VDRC septate junction assembly; axon 
ensheathment; cell adhesion; 28923 (III) Bloomington 
Cora 9788 (III) VDRC embryonic morphogenesis; cell polarity;  
Crb 
6383R2 (III) NIG 
Polarity; Notch signalling pathway. 
40869 (III) Bloomington 
CSN8 50566 (X) VDRC 
Mitotic G2 DNA damage checkpoint; cell 
cycle. 
CTCF 30713 (III) VDRC regulation of transcription,  
Cubn 
14613 (III) VDRC 
renal protein absorption; 
14614 (III) VDRC 
cv-c 
14847R2 (X) NIG actin cytoskeleton organization; Rho protein 
signal transduction; 32329 (III) VDRC 
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CycD 29024 (III) VDRC JAK-STAT cascade; regulation of cell growth 
Cype 33878 (III) Bloomington 
sensory perception of pain; mitochondrial 
electron transport,  
Ddr 55906 (III) Bloomington 
transmembrane receptor protein tyrosine 
kinase signalling pathway;  
Dgk 
29459 (III) Bloomington G-protein coupled receptor signalling 
pathway 36745 (III) Bloomington 
Dhc36C 
27451 (III) VDRC microtubule-based movement; glycerol-3-
phosphate metabolic process 5526R-1 (III) NIG 
Dhc62B 15804R-1 (III) NIG Microtubule movement. 
Dhc93AB 
41947 (III) VDRC 
microtubule-based movement;  
3723R-2 (III) NIG 
Dia 1768R-1 (III) NIG actin cytoskeleton reorganization; cell cycle;  
Dis3 
6413R-2 (III) NIG 
regulation of gene expression;  
35090 (III) VDRC 
Dlt 41876 (III) VDRC 
lateral inhibition; morphogenesis of an 
epithelium; cell proliferation 
DNApol-
epsilon 
6768R-2 (III) NIG cell cycle;  response to DNA damage  
Dob 14814 (III) VDRC Triglyceride catabolic process. 
Dom 
7787 (III) VDRC regulation of immune system process; 
metabolic process;  41674 (III) Bloomington 
Dp 
7836 (III) VDRC  regulation of transcription, lateral 
inhibition;  15637R-2 (III) NIG 
Ds 4313 (III) VDRC  cell adhesion; polarity 
Dscam1 
25622 (III) VDRC 
axon guidance 
36233 (III) VDRC 
Dscam2 
1003 (III) VDRC 
cell adhesion 
41890 (X) VDRC 
Dscam3 
6685 (III) VDRC 
cell adhesion 
31190R-1 (III) NIG 
Dscam4 
25366 (III) VDRC 
cell adhesion 
42882 (III) VDRC 
Dsor2 40026 (III) VDRC 
migration; mitotic G2 DNA damage 
checkpoint (cell cycle);  
Dys 19230 (III) VDRC cell polarity;  
E(z) 
6502R-4 (III) NIG 
regulation of gene expression; cell cycle 
27646 (III) VDRC 
Eaat1 3747R-2 (III) NIG L-glutamate transport;  
Ebi 
40862 (III) VDRC regulation of gene expression; neuron 
differentiation; response to oxidative stress; 4063R-2 (III) NIG 
Egfr 
43267 (III) VDRC  peripheral nervous system 
development; cell proliferation  10079R-2 (III) NIG 
Egg 
12196R-1 (III) NIG 
 regulation of DNA metabolic process;  
21172 (III) VDRC 
Ehbp1 31143 (III) Bloomington Regulation of Notch signalling pathway. 
eIF-2beta 9416 (III) VDRC translational initiation; response to stress;  
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Elongin-C 15302 (III) VDRC 
ubiquitin-dependent protein catabolic 
process; dendrite morphogenesis;  
Emb 
31353 (III) Bloomington Protein transport; regulation of response to 
hypoxia. 34021 (III) Bloomington 
Ent1 11907R2 (III) NIG Nucleoside transport. 
Eph 
1511R-1 (III) NIG regulation of glucose metabolic 
process; nervous system development;  4771 (III) VDRC 
Ephrin 
1862R2 (III) NIG 
 axon guidance;  
27039 (III) Bloomington 
Exn 33373 (III) Bloomington cell-cell adhesion;  
fd102C 11152R-2 (III) NIG regulation of transcription 
Fkh 
37062 (III) VDRC 
Apoptosis;   
49960 (III) VDRC 
Fra 
6557 (III) VDRC 
axon guidance;  cell migration;  
29909 (III) VDRC 
Frac 
31577 (III) Bloomington 
axon target recognition 
31578 (III) Bloomington 
Fred 
46180 (III) VDRC 
cell-cell adhesion 
42621 (III) Bloomington 
Ft 
29566 (III) Bloomington 
adhesion;  
34970 (III) Bloomington 
Fw 39575 (III) VDRC planar polarity; cell adhesion  
Gbeta13F 
10545R-2 (III) NIG polarity, G-protein coupled receptor 
signalling pathway; cell adhesion 31257 (III) VDRC 
Grk 
17610R2 (III) NIG 
tissue migration;  
4331 (III) VDRC 
Grn 
33746 (III) Bloomington 
regulation of transcription; axon guidance; 
34578 (III) Bloomington 
Gtp-bp 14877 (III) VDRC GTP binding 
Gug 13687 (III) VDRC epithelium development; 
Ham 
15907R1 (III) NIG  Regulation of transcription, sensory organ 
development; cell proliferation. 32470 (III) Bloomington 
Hbs 7449R1 (III) NIG 
cell-cell adhesion 
 
Hig 
13266 (X) VDRC 
cell adhesion; synaptic target recognition 
2040R-1 (III) NIG 
Hiw 
26998 (III) VDRC 
regulation of cellular component biogenesis;  
28031 (III) Bloomington 
Hml 
37005 (III) VDRC 
metabolic process;  
37006 (III) VDRC 
How 10293R-1 (III) NIG 
cell development; cell migration; cell 
adhesion;  
hppy 7097R-1 (III) NIG Apoptosis 
Hsp83 7716 (III) VDRC  metabolic process;  
IA-2 
11344R3 (III) NIG Protein dephosphorylating; regulation of 
secretion. 7560 (III) VDRC 
Idh 42915 (III) VDRC  metabolic process. 
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42916 (III) VDRC 
Ih 
35836 (III) VDRC 
circadian cycle; transport;  
29574 (III) Bloomington 
IP3K2 12724R-2 (III) NIG autophagy cell death; 
Ir8a 25813 (III) Bloomington 
 transmission of nerve impulse; transport; 
calcium-mediated signaling. 
Irp-1B (2) 30153 (III) VDRC regulation of translational initiation  
Iz 27985 (III) Bloomington 
cell death; response to stress; regulation of 
transcription  
Jbug 
11605R2 (III) NIG 
planar polarity;  
39070 (III) Bloomington 
Jim 
11352R2 (III) NIG  Regulation of chromatin silencing; dendrite 
morphogenesis. 11352R3 (III) NIG 
Jub 30806 (III) bloomington Hippo signalling; mitotic nuclear division. 
Kirre 6695 (III) VDRC cell-cell adhesion  
Kis 18326R-1 (III) NIG developmental growth;  
kl-2 19181 (III) VDRC Cilium movement. 
kl-3 53317 (III) Bloomington Cilium movement. 
Klg 
39515 (III) VDRC 
cell adhesion  
28746 (III) Bloomington 
Klu 
12296R-2 (III) NIG Regulation of Raps protein signal 
transduction; neurogenesis; proliferation. 12296R-3 (III) NIG 
Kon 10275R-1 (III) NIG 
epithelium development; filo podium 
assembly;  
Krn 8056R4 (III) NIG 
 epidermal growth factor receptor signalling 
pathway; cell proliferation; cell migration 
Kst 33933 (III) Bloomington zonula adherents assembly;  cell cycle  
Kto 
8491R-1 (III) NIG transcription; autophagy cell death;  Wnt 
signalling pathway; 23142 (III) VDRC 
Kug 
5098 (III) VDRC adhesion; polarity; actin cytoskeleton 
organization;  7749R-1 (III) NIG 
LanB1 
23119 (III) VDRC  tissue development;  
 23121 (III) VDRC 
Lap1 
10255R1 (III) NIG 
Protein transport; cell polarity. 
27036 (III) Bloomington 
Lar 36270 (X) VDRC adhesion; axon extension  
Lea 
5574R2 (III) NIG 
brain development; cell-cell adhesion;  
34589 (III) Bloomington 
lectin-22C 
15378R1 (III) NIG 
carbohydrate metabolic process 
15378R6 (III) NIG 
Lid 
42203 (III) VDRC 
JAK-STAT cascade; histone modifications  
42204 (III) VDRC 
Lilli 
13081 (III) VDRC 
lipid transport; transcription regulation 
8817R-4 (III) NIG 
ln-R 991 (III) VDRC 
regulation of developmental growth; cell 
proliferation; response to stress; 
Lpt 22171 (III) VDRC 
histone modification; transcription; 
phagocytosis; 
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lr25a 15627R2 (III) NIG 
Detection of chemical stimulus involved in 
sensory perception; transmission of nerve 
impulse; ion transport. 
LRP1 
8397 (III) VDRC 
calcium ion binding 
44579 (III) Bloomington 
Mbc 51446 (III) Bloomington cytoskeleton organization; 
Mbt 29379 (III) Bloomington cell-cell adhesion;  
MED23 
28361 (III) VDRC 
transcription  
28363 (III) VDRC 
mei-38 51805 (III) VDRC mitotic spindle organization; 
Mes-4 10837 (III) VDRC histone modifications 
mesh 
40940 (X) VDRC Cell-matrix adhesion; septate junction 
assembly. 12074R-1 (III) NIG 
mfas 37889 (III) VDRC axonogenesis;  
Mgl 
29324 (III) Bloomington 
regulation of endocytosis;  
33940 (III) Bloomington 
mGluRA 
11144R3 (III) NIG regulation of synaptic transmission, G-
protein coupled receptor signalling pathway;  1793 (III) VDRC 
Mhc 
17927R4 (III) NIG 
epithelial cell migration  
7164 (III) VDRC 
Mkk4 
26929 (III) VDRC 
neurogenesis;  JNK cascade; 
9738R-1 (III) NIG 
Mrtf 34503 (III) VDRC 
cell cycle; cellular response to 
hypoxia; regulation of transcription, cell 
migration; actin cytoskeleton organization;  
Msk 38963 (III) VDRC cell development;  
Msp-300 
25906 (III) VDRC 
actin cytoskeleton organization;  
18252R-2 (III) NIG 
Mtt 32376 (III) Bloomington 
G-protein coupled receptor signalling 
pathway 
Mub 34870 (III) Bloomington mRNA splicing,  
mus205 24472 (III) VDRC 
DNA replication; double-strand break repair 
via homologous recombination (DNA repair). 
My 
37710 (III) VDRC 
cell cycle; glucose metabolic process;  
9045R-1 (III) VDRC 
Myd88 25399 (III) VDRC development; regulation metabolic process; 
Mys 1560R-1 (III) NIG cell adhesion;  
Na 3306 (III) VDRC circadian rhythm;  
nAcrbeta-64 
39421 (X) VDRC 
synaptic transmission, ion transport. 
31883 (III) Bloomington 
Ndae1 
4675R-1 (III) NIG 
transport 
3664 (III) VDRC 
NetA 18657R-2 (III) NIG axon guidance; cell migration. 
Net 
17302 (III) VDRC 
cell cycle; lateral inhibition;   
19594 (X) VDRC 
NGI2 28331 (III) Bloomington synaptic growth at neuromuscular junction 
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Nipped-A 2905R3 (III) NIG 
histone modifications; phagocytosis; 
regulation of transcription,  Notch signaling 
pathway; cell cycle;  
Nlg3 1062R1 (III) NIG 
histone modifications, phagocytosis; 
regulation of transcription, Notch signaling 
pathway; cell cycle; 
Nmdar2 
14794R1 (III) NIG 
sensory perception of touch; ion transport; 
3196 (III) VDRC 
nompC 31512 (III) Bloomington  sensory perception of touch;   transport;  
nopo 22013 (III) VDRC 
Cell death; mitotic cell cycle, protein 
ubiquitination. 
Nos 
6713R3 (III) NIG synapse assembly; DNA replication; nervous 
system development; 50675 (III) Bloomington 
Nrg 
27201 (III) VDRC 
brain development;  adhesion; 
27202 (III) VDRC 
Nrm 979 (III) VDRC Synaptic target recognition; cell adhesion. 
Nrx-1 36326 (III) VDRC synapse assembly; transport; 
Nrx-IV 28715 (III) Bloomington cell junction assembly;  adhesion;  
Nub 
6217 (III) VDRC dendrite morphogenesis; regulation of 
transcription  43678 (X) VDRC 
Nup62 
44806 (III) VDRC 
phagocytosis. 
6251R-1 (III) NIG 
Or33a 
1461 (III) VDRC 
Sensory perception of smell. 
1462 (III) VDRC 
Or59b 
43808 (III) VDRC 
sensory perception of smell  
43809 (III) VDRC 
Osa 
7467R-1 (III) NIG 
Wnt signalling;   
7810 (III) VDRC 
Otk 8967R4 (III) NIG cell adhesion 
p120ctn 51729 (III) Bloomington 
Cell adhesion; regulation of actin 
cytoskeleton organization. 
Pak 12553 (X) VDRC 
cell morphogenesis; adhesion; cell junction 
organization 
Pan 3014 (III) VDRC 
morphogenesis of an epithelium; cell 
proliferation; 
Para 
6131 (III) VDRC 
mechanosensory behaviour; 
6132 (III) VDRC 
Patj 
31620 (III) VDRC 
homeostatic process; 
12021R-4 (III) NIG 
Pdk2 
31296 (III) Bloomington 
ion transport; spermatogenesis; 
51502 (III) Bloomington 
pdm2 
30708 (III) VDRC 
neurogenesis; regulation of transcription,  
52272 (III) VDRC 
Pex13 
39544 (III) VDRC 
unknown 
50697 (III) Bloomington 
phI 31038 (III) Bloomington 
regulation of small GTPase mediated signal 
transduction; cell cycle;  
Pi3K21B 33556 (III) VDRC cell proliferation;  
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Pi3K92E 
38985 (III) VDRC epithelium development; homeostatic 
process;  4141R-1 (III) NIG 
Piwi 6122R-1 (III) NIG cell fate determination;  
Plc21C 
4574R2 (III) NIG regulation of neuromuscular synaptic 
transmission;  33719 (III) Bloomington 
plexA 11081R2 (III) NIG axon guidance; sensory perception of pain; 
plexB 6873 (III) VDRC 
axon guidance; regulation of Rho protein 
signal transduction 
PMCA 31572 (III) Bloomington  calcium ion transmembrane transport 
Pp2A-29B 
23886 (III) VDRC 
Transport; metabolic process; autophagy. 
49671 (III) VDRC 
Pp2C1 40827 (III) Bloomington 
Protein dephosphorylating; oxidation-
reduction process. 
PpV 31690 (III) VDRC Protein dephosphorylating; mitotic cell cycle. 
Prestin 
5485R-1 (III) NIG 
transport 
5485R-3 (III) NIG 
Ptp10D 
1817R1 (III) NIG dephosphorylating; axon guidance; central 
nervous system development;   1101 (III) VDRC 
Ptp36E 
34369 (III) VDRC 
protein dephosphorylating 
34368 (III) VDRC 
Ptp4E 
1012 (II) VDRC Protein dephosphorylating; axon guidance; 
CNS development. 38369 (III) Bloomington 
ptp52F 3116 (III) VDRC axon guidance;  
Put 
7904R-2 (III) VDRC 
cell cycle; dorsal closure; metabolic process 
37279 (III) VDRC 
Pvr 
8222R-2 (X) VDRC response to stress; actin cytoskeleton 
organization;  13502 (III) VDRC 
Pxn 
15276 (III) VDRC Phagocytosis; response to oxidative stress; 
ECM organization. 15277 (X) VDRC 
Pyx 
31297 (III) Bloomington 
ion transport; 
51836 (III) Bloomington 
R 33437 (III) VDRC 
adhesion; cell-cell junction assembly; cell 
migration;  
Rab40 
1900R-1 (III) VDRC 
Rab protein signal transduction;  
29259 (III) VDRC 
Rac1 49247 (X) VDRC 
cell proliferation; metabolic process; cell 
migration; cell adhesion; 
Rac2 
8556R-3 (III)  NIG actin cytoskeleton organization; metabolic 
process; cell junction maintenance;  50349 (III)  VDRC 
Ras85D 28129 (III) VDRC   cell proliferation; mitotic cell cycle 
Rdx 9924R-2 (X) NIG polarity; apoptosis 
ref(2)P 10360R-1 (III) NIG Mitochondrion organization. 
Rfabg 6879 (III) VDRC Wnt signaling pathway;  
RhoGAP19D 
43955 (X) VDRC 
Rho protein signal transduction;  
32361 (III) Bloomington 
RhoGAPp19
0 
28877 (III) VDRC Rho protein signal transduction;  
278 
 
RhoGEF3 31581 (III) Bloomington regulation of Rho protein signal transduction; 
Ric 
8418R-3 (III)  NIG small GBase mediated signal 
transduction; response to oxidative stress;  35930 (X)  VDRC 
Rim 
7305R2 (III) NIG 
 vesicle-mediated transport;  
39385 (III) VDRC 
Rm62 
10279R-2 (X)  NIG 
mRNA splicing,  
46908 (III) VDRC 
Robo 35768 (III) Bloomington cell-cell adhesion;  epithelial cell migration, 
robo3 29398 (III) Bloomington axon guidance 
RpL5 
38929 (III) 
 
VDRC 
 ribosomal large subunit 
assembly; translation 
Rst 
951 (III) VDRC 
axon genesis; apoptosis;  cell adhesion  
28672 (III) Bloomington 
Run 
28673 (III) Bloomington  tissue development; regulation of 
transcription,   34707 (III) Bloomington 
RunxA 33353 (III) Bloomington 
dendrite morphogenesis; regulation of 
transcription,  
S6k 
10539R-2 (III)  NIG Developmental growth; axon 
genesis; response to stress. 18126 (X)  VDRC 
S6kII 17596R-1 (III)  NIG circadian behaviour;  metabolic process;  
SA 
3423R-2 (III)  NIG neurogenesis; mitotic sister chromatid 
cohesion 3423R-3 (III) NIG 
Salm 33714 (III) Bloomington 
neuron differentiation; instar larval or pupal 
development; epithelial cell migration 
Salr 4881R3 (III) NIG 
regulation of transcription,  sensory organ 
development;  neurogenesis; 
Sax 
1891R-1 (III)  NIG response to stress; morphogenesis of an 
epithelium; 42457 (III) VDRC 
Scox 
8885R2 (III) NIG regulation of transcription, sensory organ 
development; neurogenesis; 7861 (III) VDRC 
Sdk 33412 (III) Bloomington Eye development 
Sdr 
3837R1 (III) NIG Transmembrane receptor protein tyrosine 
kinase signalling pathway. 44575 (III) VDRC 
Sei 3606 (III)  VDRC ion transport; sensory perception of sound; 
sema-1a 18405R1 (III) NIG  Organ morphogenesis; brain development. 
Sema-1b 
6446R3 (III) NIG 
axon guidance; embryonic morphogenesis 
28588 (III) Bloomington 
Sema-2a 15810 (III) VDRC axon guidance; synaptic target inhibition;  
Sema-2b 
48057 (III) VDRC axon guidance;  response to DNA damage 
stimulus;  28932 (III) Bloomington 
Sema-5c 
5661R1 (III) NIG 
 axon guidance; brain development 
1052 (X) VDRC 
sens-2 21386 (III) VDRC  nucleic acid binding;  
Sep2 26413 (III) VDRC  
Cell cycle; regulation of glucose metabolic 
process. 
Ser 27174 (X)  VDRC morphogenesis of an epithelium;  
Shn 34689 (III) Bloomington Cell morphogenesis;  cell proliferation;  
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Shot 28336 (III) Bloomington cytoskeleton organization;  
Sick 53315 (III) Bloomington  axon genesis; actin filament organization;  
Side 
31062R2 (III) NIG 
Motor neuron axon guidance. 
1284 (III) VDRC 
Sif 5406R3 (III) NIG 
actin cytoskeleton organization; regulation of 
Rho protein signal transduction; 
Sirt4 40295 (X) VDRC  histone modifications 
SK 
24597 (III) VDRC Regulation of membrane potential in 
photoreceptor cell. 27238 (III) Bloomington 
Sl 
4200R-3 (III)  NIG 
cell migration; signal transduction;   
7173 (III) VDRC  
Slbo 
27043 (III) Bloomington regulation of transcription, cell 
migration; regulation of glucose metabolic 
process;  JAK-STAT cascade;  
53309 (III) Bloomington 
Sli 31467 (III) Bloomington 
Adhesion; epithelium development; cell 
migration. 
SMC1 6532 (III) VDRC  
regulation of gene expression; mitotic sister 
chromatid cohesion; 
Smox 2262R-1 (III)  NIG 
cell cycle; brain development;  regulation of 
cellular metabolic process;  
Smr 
27068 (III) Bloomington transcription, mitotic cell cycle;  glucose 
metabolic process;  Notch signalling 
pathway;  
34087 (III) Bloomington 
Snr1 12645 (III)  VDRC cell proliferation; chromatin remodelling;  
Sox15 45482 (III)  VDRC 
regulation of transcription, apoptosis; cell 
proliferation;  
spen 48846 (III) VDRC tyrosine kinase signalling pathway; 
Spn38F 9334R-3 (III) NIG proteolysis;  
Spp 7247 (III) VDRC cellular response to unfolded protein 
Ss 
10715 (III) VDRC 
metabolic process; 
33415 (III) Bloomington 
Stj 25807 (III) Bloomington 
synaptic transmission; sensory perception of 
pain; 
su(Hw) 34006 (III) Bloomington negative regulation of transcription,  
Su(var)2-HP2 
25972 (III) Bloomington 
neurogenesis; cell cycle;  
31346 (III) Bloomington 
Syx1A 
5448R-4 (III) NIG 
Metabolic processes 
33112 (III) VDRC 
Taf1 
41099 (III) VDRC 
  cell cycle;  histone modifications 
32421 (III) Bloomington 
Tefu 
6535R-1 (III) NIG mitotic G2 DNA damage checkpoint (cell 
cycle); regulation of immune response; 
regulation of transcription,  
22502 (III) VDRC 
Tehao 
17903 (III) VDRC  Innate immune response; signal 
transduction. 7121R-3 (III) NIG 
Ten-a 11270R1 (III) NIG adhesion;  synaptic growth at neuromuscular 
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32482 (III) VDRC junction; 
Tep1 
30873 (III) VDRC 
Humoral response. 
32856 (III) Bloomington 
Tep2 18589R1 (III) NIG humoral response; phagocytosis;  
Tep4 13466 (III) VDRC humoral response 
Tep5 31866 (III) VDRC Metabolic processes 
Tg 
7356R1 (III) NIG 
innate immune response;  
26100 (III) VDRC 
Tim17B1 9455 (III) VDRC Protein import into mitochondrion. 
Tim17B2 3838 (III) VDRC protein import into mitochondrion;  
Tkv 
14026R-1 (III) NIG 
embryonic morphogenesis;   
14026R-3 (III) NIG 
Tol 2656 (III) VDRC axon guidance;  
Toll-7 30488 (III) Bloomington Axon guidance; autophagy. 
Tollo 
9430 (III) VDRC innate immune response; regulation of 
glucose metabolic process; 27098 (III) VDRC 
Traf-like 34836 (III) VDRC signal transduction; defence response 
Traf4 3048R-3 (III) NIG sister chromatid cohesion;  
Trax 49383 (III) VDRC Metabolic processes 
Trf4-1 41096 (III) VDRC 
apical constriction; adherents junction 
organization; dorsal closure;  
Trf4-2 
19801 (III) VDRC 
Sister chromatid cohesion. 
19799 (III) VDRC 
Trim9 21405 (III) VDRC axon guidance 
Trio 
18214R1 (III) NIG 
actin cytoskeleton reorganization 
40137 (III) VDRC 
Troll 
22642 (X) VDRC Maintenance of epithelial cell apical/basal 
polarity; axon guidance. 29440 (III) Bloomington 
Trp1 
8894 (III) VDRC posttranslational protein targeting to 
membrane, 8895 (III) VDRC 
Trr 10749 (X) VDRC hippo signalling; regulation of transcription,  
Trx 31092 (III) Bloomington 
Regulation of response to DNA damage 
stimulus; cell migration; axon guidance. 
Trx-2 36298 (III) VDRC Disulphide oxidoreductase activity. 
TTLL3B 31456 (X) VDRC 
sperm individualization; protein 
polyglycylation 
tweek 
19306 (III) VDRC 
endocytosis 
26645 (III) VDRC 
U2af38 3582R-2 (III) NIG Cellular homeostasis; cell fate determination 
Uif 38365 (III) Bloomington 
Cellular homeostasis; Notch signalling 
pathway. 
unc-13 
2999R3 (III) NIG synaptic vesicle 
exocytosis;  neurotransmitter secretion;  33606 (III) VDRC 
unc-5 
8166R1 (III) NIG 
cell migration; axon guidance;  
8137 (III) VDRC 
unc79 51471 (III) Bloomington locomotor behaviour 
Unc-89 
29412 (III) VDRC regulation of Rho protein signal transduction; 
sarcomere organization;  29413 (III) VDRC 
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Usp 
4380R-3 (III) NIG glucose metabolic process; response to 
starvation; 16893 (III) VDRC 
Utx 5640R-2 (III) NIG metabolic process; signal transduction;  
Vap 44638 (III) VDRC Endocytosis; regulation of ATPase activity. 
Vav 39059 (III) Bloomington 
 cell morphogenesis; cell junction 
organization; adhesion;  
Vhl 50727 (III) Bloomington 
cell migration; mitotic cell 
cycle; morphogenesis of an epithelium; 
Vkg 
16858R-3 (III) NIG 
Skeletal muscle tissue development. 
16986 (III) NIG 
Vn 
10491R2 (III) NIG brain development; notum 
development; apoptosis 50358 (III) VDRC 
Wb 
3141 (III) VDRC 
Imaginal disc-derived wing morphogenesis. 
15288R-3 (III) NIG 
Wit 
10776R-2 (III) NIG 
signal transduction; synaptic growth  
42244 (III) VDRC 
Wnt2 38077 (III) VDRC Axon extension; Wnt signalling pathway. 
wrapper 
10382R3 (III) NIG 
apoptotic process; axon development;  
29561 (III) Bloomington 
Wry 8021 (III) VDRC Notch signalling pathway. 
X11L-beta 1852R-3 (III) NIG protein localization  
Xpd 41021 (X) VDRC 
regulation of chromosome segregation; cell 
division; 
zfh2 13305 (III) VDRC 
wing disc development; CNS development; 
regulation of transcription, 
Zir 28005 (III) Bloomington 
Phagocytosis; regulation of Rho protein 
signal transduction. 
zormin 17563 (III) VDRC sensory perception of pain 
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Appendix D: Expression levels of ING1 and RSBN1L in MDA-
MB231 and U87 cells 
 
 
RT-PCR on cells harvested from (A) MDA-MB-231 and (B) U87 cell lines using RSBN1L, 
GAPDH and ING1 specific primers to check expression levels.  
Table D1: CT values  
 U87 MDA-MB-231 
ING1 27.36 25.7 
RSBN1L 29.59 28.57 
GAPDH 18.22 19.26 
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Appendix E: CG10600 sequence 
CRISPR target region highlighted. 
 
CACATCTGAAGACTAGAGTTGAAAAACGACAGTGCGAGACGGCTTCTAGAACAAAAAAAAAAACTAT
TCGCGAATCGCTGAAAACGCCGCTGCGGAAATTCTGCCAGTCGAATGAAAATCGAGTGGAAGAGGG
CGCGGGTGAATTGCAAACGGAGCGTAAGATAAAAGACACGGCTAGCTGAGAGGCGTCACGTAGACG
GCCGACTGATCGATATTCAATACAGGCGTAGGGCAACACGCACACACACCCATACGCGCGTGTGTGT
GCCACTGCACACACAAACACATGGAGAACACTCGAGGTGGCGAAAATAATGTAGAATTGGCCAACG
GCGGCAAGGAATCCACGGGAAATGTACGAAAACCGGAGAAGAAGCCACTGGAAGGAGCGGTCGGG
GCTTCCAAGCAGCGGGAGACGCCTGAAAAGGGCGTAAACAAAGCGTCGGCAGTGGAAAACAACAAC
GCAAATGCCCGCGGAAATGCCAGTCCAACAACTACAAGCGCACAGCGAGAAGCAACAACAACAATTA
CGCCAGTGGAACCAACAGCAGCAGCAACAACTACAAACGGCAACACTTTACCCACACAACAGCAACA
ACAACTGCAGTCAGGCGATGGCAACGCAAATAACCCAACAACAAATGCACGTATAATGCTAGCTGCA
GCTGAAGAGGAACAGGCAGTAGCATCGTCGGTGGCAACAACTGCAGGGGCACCCACAGCCGCAACA
ACAACTGCAACAACAACCGCGTTGGCAGACACAACAAAAACAAGCACAAGTACGGACGAGAAGACA
GGTAAAGTAAAGCGAAATTCGCAGAACACGAATCCAATGTCAACTAATGTGATTTGCACACCCACCC
ACTCGCCAACGCCGCCCACAGAAGAGCGCAACCACAAAAGGAAGAAGAGAGACAGGGAGCGGGAT
GAAGACAAGAATCGGCGCAGCAACAACCACAACAGCAGCAGCAAGGATCGGGACAAGGATAGGGA
TCGGGACAAAGAGCGGGACAAGGAGCGCGATAGGGAGCGGGAGCGCGACAGGAATCGCGAGAGC
AGCTCCAAATCCTCCAAGGAGGCCGAACACAAGTCCAGCTCATCGCGCAGCAAGGAGAAGTATCATC
GCAGTGATAGGGACCGCGAACGGGAGAAGGAGCGCGATCGGGAGAAGGTGAGCCCAGGAACCGTT
TCGAAAGTGCAGAACGCATACAGAAACGTTGATTTATTGTAAACTCTGATCTGATTTCCAGAACATAC
ATTTCTTTAATAAGTAAATGTCAATTTCTAGTAAAACTAACAAACAAAAGTATTGTCAGGGTCTTACCA
CCCATTTACTACGAATAAGCAAGACACGTGATCTTAAATACAGCGAGTCATAATTCTCAGAACCTTTTA
TTTTTGATGCGCTACATGTTTATAGTATACTTTCCAGTTTACATAGTGCTAAGTAAACCTCTACAAGATT
GCACAGCTGTCCATCAAAGTAGAAATAATGAAGCACTACAAATTTATATTTTCCAGATTCCTTCCTCGT
CGTCCAGCTCATCCTCGCACTCGAATCGAAGGAGAAGTTCCGACAGCAGCCGGAGCAGTCAGAACAG
CTCCTTCAAGTCGAAGGATCCAGGGGCAGATCCTGTTTTGCCTCAGGCGGTTGTTGCTGCTCTCGAAA
AGCAGATTAAGGTGGAGGAGGTCATCAAAAAAGAACCAGTAGAAACCAAACAAGAAGTGGATACAG
AACCTACACCAGTACTTAGTAACCTCATTAAAACTGAAGCGGAAATCAAAACGGAATCGACGGAGAA
GCCAAACAAACCTCTAGTAAATGGCGAGGCGATAGCGAAAACCCGAGATGAGGTTTCCAGACAGCT
AAATTTCGGAGACAAGGTCTCCAATTCCAAGTTAATGCCTTCGCCGGCACCGAAATCCAGTTCGGGAT
CGAACTCCACGGCCAGCAATCATTCCTCCAGCCAAAGTAGCAGCAGCCGCAAATCCTACTTATCGTCT
TCGTCCTCTTCATCCTCCAGCAACCATCACAAGAGTTCCTCTTCGTCATCGTCTCGCCACTCCTCATCTA
CATCTCGGGAGTGCTCCAAGTGCTACAAGCGCTCCAAAATTCGGCGAACCAGCGTGGGCGTCCAGTG
CTTACAGCATGCACCAGCAACTGGACCCTGGCAAACCGTTCAGAGCCTGCCGCCTAGGCCTAACCGA
AAACCACCGGCTGGCTTGGAGAACTTAAAGTACGGCTGCTACTTTCAGGTGGAGCAATATCCAAATG
GCGGGGCCTCCATTGTTCACCTGTATCAACATGAAATCGACGCATTGTCGCCAGATGAAATGGAGGA
GCTGGTGGATGAGTTCTTTGAGGTGTGCTTTGCCGAGGATGAGCAAGGGTATGCCCACCATGTGATG
GGTATTGTCCACGATGCCGCGAGGTATTTACCCGATCTACTCGAGCACATGGCCGAGAACTACTCAAC
GCTGACGGTAAAGGCGGGAGTTCTTGGACGAAACTCCGATATCGAGACCTGTACAATGTCGCAATAC
AACGAGCAGGTAAATCCATATATAAAGCAGTGCTAGCAAGAAAAATATGTAACAATTCTTGTTCGTTT
CTCACCTTTAGGTGGTTCGCAACTATTGCCAAGGAACCTTTCGATATGGACCACTGCATCAGATCAGT
TTGGTTGGCAAAGTGCATGAAGAGGTGGGCGGATACTTCCCAGATCTGTTGGGTCGTATTGAAATGA
ATCCATTTTTACGAAAGGTAAGCACACTCAAATGCTAAAAACACTTGACTAATTTAACTCTCTTATCTC
AGACCATGCCTTGGGCTTGTAATTCTATACTCCAAACGGATCCTCGTCAGTCGAACGATGGCCCCATT
CTCTGGATCCGTGCTGGGGAGCAGTTGGTCCCCACAGCAGAGTTGAATAGCAAGACCCCACTGAAAA
GGCAAAGGTAAGTAGCATTTGGAGCAATATTCTTAAAAACCATTAATTAACTTACACAATTCACATGC
AGGACTCGTATTAATGAATTGAGGAACCTTCAATATTTGCCGCGTTTGTCTGAGGCACGGGAGACGA
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TGATCGAGGATCGGACCAAGGCGCATGCGGATCACGTGGGCCATGGCCACGAACGCATCACCACCG
CAGCAGTTGGTGAGATGCCTCTCATTGAAAAGCTGCTCCGAAATCGACTAATCGGCGTAATGTTTCTA
TTATCCGTCCTGCAGGCATACTGAAAGCTGTACACTGTGGTCAAACTTACTCGCAGAACCGCATCACC
AAAGACGTGGTCGCTTTTGCCGCCCAGGACTTTAACACAATGGTGGAAATGCTGCAGCTGGACCTGC
ACGAGCCGCCAATCTCACAGTGCGTACAGTGGATCGAGGACGCCAAACTTAACCAGCTGCGCCGCGA
GGGCGTCCGTTACGCTCGTATTCAGCTGTGCGACAATGACATATACTTCTTACCCCGCAACATAATCCA
CCAGTTTCGCACAGTGACAGCGGTAACGAGCGTAGGTAAGGGATCGAATGCAATTTTTCTCTTCATCG
TTCGATTAACCTACAAATTTTTACTCTGCAGCTTGGCACCTGCGACTAAGACAGTATTATCCCGGCCAG
GAAGTGATTAACGAGAAGAATAACCCTGTGCTAGCCGAAACACCTCACTACAAGGAAAAGCAAACGA
TCCTGCCAAACCCAATTAGCCACGACGAATGCGGCAAAAAGACACCATCAAAGCGTGCACACGATGG
CAGGACCAAGAAGAAACTTATTGACCTCGATGGCAAGGAGCGTCGATCTAGTGAGAGCAGCATAGA
CGAGCACCCAGCTGCAGGAAGTTCCTCGCCTAGCCAAAATCAGGAAAACAACAGCAACAGCAGCAGT
CAGAGCGGAGCTAGTGGGGTTAGCACACCCAAAAAGAAGAGCAGCAAGGAGGACTCCAAGATAGA
TATGCGGAAAATGGTTCTGGAGCACAAATATAAGCTGACCAAAGCAGCGGTAACTGAAACCCCTGAG
AAGGAGAAGCTCAAAAAGGATAAGGACAAGGAAAAGTCTAGGGGGAAGGATAGAGATAAGGAAA
AGGAACGAGGCAAGGAAAAGGAAAAGGAAAAAGAAAAGAAAAACGATACTCCTAAAAAACATGCA
ACGCCAGCAAAGAGCTCTTTGAGTGAGCCCTCGCCCGCCAAAATTCCCAAATTAAATAATGACACAGC
TCCTGCAACTGCACTTCCACTGAAATCTACACCCTCCTCTGCGCCACCTACGTGCACTCTTCCTGTAGCT
GCGCCGCCTATCCTGTCAGGACTGCCACCGCCACTCGTGCCTCAGACGCCTTTCATTGATCGTCTAAAT
CAAAAGGAGCCCGAGATCAAGATCGAAGTAAAGATTGTCTCCGACAGTAAAAGTGATATCAGTACCT
CCAATCCAGTTGTGTCAACAACAGCCCCACCACCGCCGCCACCTCCGGATCCGGTTGAAGATGTGGGT
AACGAGCTAATTGTGGAGAGCACACCCCAATTGATCGTTGACCACGAAGAGGAGGTCTCTGAAGTGT
GTTCCGAGGAGATTGTCGAAATGGATATACCGATACCCAAAGAACCAGTCCCAGCTGCTGCTTTTACA
TCATTGCCTAATACTCCGTCACCACTTATTAGTGCTCACTCCACTCTGGCTACTGCGCCCATACCAAAAT
CTTTTCTCCATCCACCAGTACCAATTGTAGCTGCACCCGCTCCTCCGCCACCCAGTCAAATTGTGAAAG
TGGTACTCCCAGGCTCTTTGACGCCTCTTACCAGAATGTCAGTGGTTTTGCCACCCTTGCCGCCATTAC
CACCATCACGGACATCTGCACCGCCACCGCCGCCGCCTCCTCCGAGCACCAAAAGCAGTGCTATCACA
ATGCCCATATCAGCCCCAGTTTCCACGTTGAAACCCACCTACAAAACCATTAATTTGCCCTCCCACAAG
ATTATCATCGCAGGCTCCGCGGCGGGAAGTCGAGTCTCGATGGCAAAGGGCACGTCGAAGAGACCT
GATTTATTGGGATCCATCATAGCCAGCATGGACAAGCCAGCGGGAAGTGGACCCAATAGCAACTCCT
CATCATCGACATCCTCGGCAACAACGAATAGTTCGCTCTCCTCTTACGCCGGTTCCAACAATAGCTTTT
GAAACTGGGAAAAGAAATGGACGGAAAGCGAGAGTAGAGGCTCCTATTTGGACTTTATGTGAAACT
ATATATTTTGTAAATTTAAAAGCACTCGTTATTACGTTAAACGGATTTCGAGTAGCTGAATCCTTTAAA
GGAAGATCTCAACTCTGAAAGGGATTTCAATACTTACTGAAGGTTGGCCATACAATTATATATTTTTAA
GTGGTGCGCCAAACTTCCGTATATCATGTTTTACATTCTGCAGGAGTCGCTATTATACCATTTATTTTG
AAAATTGTTATTCCTTGTTCTGCGATATTGAGCAGCCACAGTTTTGTGCGAACTGAGTGAAATCTCATC
CAGTGCCCAGAGATCTTCCTTTGTATATAGCCAAAAGCTTATATGTAGTCCTAAACTTCACATACAAAC
ACCCTTATATTTGATAACGAAACATAGGTTTATAAGCTAAATATGCGGCACTTGATAGAAATGTAGTT
TTTTAATTTATTTACACCACCAACCACACCGCAAGCACTTTTTAGATACAACAATTGAAAGTTTTTTAAT
GCAGGCTGGTACACTGAGCTGTTATAGTGTGTATTTTTAAAAGGCATGCACCTATTGGCCAGAGACAC
TCGTTCTCCTTATAACAATACATTTAAAGGTCCCAGTTTGATTTCCTTCTCAACAACTTTTTTGAAAAGT
GTTTTAAAAGTGCGTAGAACAATACACACATTGATAATTACTATATATATATATACCATATATAACTTT
AGGACTAAGACAGCTTACACGTTGAAGAAACAAT 
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Appendix F: CG10600 amino acid sequence 
 
Aligned CG10600 WT and CG10600 mutant amino acid sequence 
Red amino acids indicate changes in the mutant polypeptide compared to WT 
 
WT  MENTRGGENNVELANGGKESTGNVRKPEKKPLEGAVGASKQRETPEKGVNKASAVENNNANARG 
*   MENTRGGENNVELANGGKESTGNVRKPEKKPLEGAVGASKQRETPEKGVNKASAVENNNANARG 
 
WT  NASPTTTSAQREATTTITPVEPTAAATTTNGNTLPTQQQQQLQSGDGNANNPTTNARIMLAAAE 
*   NASPTTTSAQREATTTITPVEPTAAATTTNGNTLPTQQQQQLQSGDGNANNPTTNARIMLAAAE 
 
WT  EEQAVASSVATTAGAPTAATTTATTTALADTTKTSTSTDEKTERNHKRKKRDRERDEDKNRRSN 
*   EEQAVASSVATTAGAPTAATTTATTTALADTTKTSTSTDEKTERNHKRKKRDRERDEDKNRRSN 
 
WT  NHNSSSKDRDKDRDRDKERDKERDRERERDRNRESSSKSSKEAEHKSSSSRSKEKYHRSDRDRE 
*   NHNSSSKDRDKDRDRERDRDRDRDRERDRNRNRRSKSSSDAEAESSSSSSRDKYHHHDRDRERE 
 
WT  REKERDREKIPSSSSSSSSHSNRRRSSDSSRSSQNSSFKSKDPGADPVLPQAVVAALEKQIKVE 
*   KESDRDKVNIPSSSSSSSSHSNRRRSSDSSRSSQNSSFKSKDPGADPVLPQAVVAALEKQIKVE 
 
WT  EVIKKEPVETKQEVDTEPTPVLSNLIKTEAEIKTESTEKPNKPLVNGEAIAKTRDEVSRQLNFG 
*   EVIKKEPVETKQEVDTEPTPVLSNLIKTEAEIKTESTEKPNKPLVNGEAIAKTRDEVSRQLNFG 
 
WT  DKVSNSKLMPSPAPKSSSGSNSTASNHSSSQSSSSRKSYLSSSSSSSSSNHHKSSSSSSSRHSS 
*   DKVSNSKLMPSPAPKSSSGSNSTASNHSSSQSSSSRKSYLSSSSSSSSSNHHKSSSSSSSRHSS 
 
WT  STSRECSKCYKRSKIRRTSVGVQCLQHAPATGPWQTVQSLPPRPNRKPPAGLENLKYGCYFQVE 
*   STSRECSKCYKRSKIRRTSVGVQCLQHAPATGPWQTVQSLPPRPNRKPPAGLENLKYGCYFQVE 
 
WT  QYPNGGASIVHLYQHEIDALSPDEMEELVDEFFEVCFAEDEQGYAHHVMGIVHDAARYLPDLLE 
*   QYPNGGASIVHLYQHEIDALSPDEMEELVDEFFEVCFAEDEQGYAHHVMGIVHDAARYLPDLLE 
 
WT  HMAENYSTLTVKAGVLGRNSDIETCTMSQYNEQVVRNYCQGTFRYGPLHQISLVGKVHEEVGGY 
*   HMAENYSTLTVKAGVLGRNSDIETCTMSQYNEQVVRNYCQGTFRYGPLHQISLVGKVHEEVGGY 
 
WT  FPDLLGRIEMNPFLRKTMPWACNSILQTDPRQSNDGPILWIRAGEQLVPTAELNSKTPLKRQRT 
*   FPDLLGRIEMNPFLRKTMPWACNSILQTDPRQSNDGPILWIRAGEQLVPTAELNSKTPLKRQRT 
 
WT  RINELRNLQYLPRLSEARETMIEDRTKAHADHVGHGHERITTAAVGILKAVHCGQTYSQNRITK 
*   RINELRNLQYLPRLSEARETMIEDRTKAHADHVGHGHERITTAAVGILKAVHCGQTYSQNRITK 
 
WT  DVVAFAAQDFNTMVEMLQLDLHEPPISQCVQWIEDAKLNQLRREGVRYARIQLCDNDIYFLPRN 
*   DVVAFAAQDFNTMVEMLQLDLHEPPISQCVQWIEDAKLNQLRREGVRYARIQLCDNDIYFLPRN 
 
WT  IIHQFRTVTAVTSVAWHLRLRQYYPGQEVINEKNNPVLAETPHYKEKQTILPNPISHDECGKKT 
*   IIHQFRTVTAVTSVAWHLRLRQYYPGQEVINEKNNPVLAETPHYKEKQTILPNPISHDECGKKT 
 
WT  PSKRAHDGRTKKKLIDLDGKERRSSESSIDEHPAAGSSSPSQNQENNSNSSSQSGASGVSTPKK 
*   PSKRAHDGRTKKKLIDLDGKERRSSESSIDEHPAAGSSSPSQNQENNSNSSSQSGASGVSTPKK 
 
WT  KSSKEDSKIDMRKMVLEHKYKLTKAAVTETPEKEKLKKDKDKEKSRGKDRDKEKERGKEKEKEK 
*   KSSKEDSKIDMRKMVLEHKYKLTKAAVTETPEKEKLKKDKDKEKSRGKDRDKEKERGKEKEKEK 
 
WT  EKKNDTPKKHATPAKSSLSEPSPAKIPKLNNDTAPATALPLKSTPSSAPPTCTLPVAAPPILSG 
*   EKKNDTPKKHATPAKSSLSEPSPAKIPKLNNDTAPATALPLKSTPSSAPPTCTLPVAAPPILSG 
 
WT  LPPPLVPQTPFIDRLNQKEPEIKIEVKIVSDSKSDISTSNPVVSTTAPPPPPPPDPVEDVGNEL 
*   LPPPLVPQTPFIDRLNQKEPEIKIEVKIVSDSKSDISTSNPVVSTTAPPPPPPPDPVEDVGNEL 
286 
 
WT  IVESTPQLIVDHEEEVSEVCSEEIVEMDIPIPKEPVPAAAFTSLPNTPSPLISAHSTLATAPI 
*   IVESTPQLIVDHEEEVSEVCSEEIVEMDIPIPKEPVPAAAFTSLPNTPSPLISAHSTLATAPI 
 
WT  PKSFLHPPVPIVAAPAPPPPSQIVKVVLPGSLTPLTRMSVVLPPLPPLPPSRTSAPPPPPPPP 
*   PKSFLHPPVPIVAAPAPPPPSQIVKVVLPGSLTPLTRMSVVLPPLPPLPPSRTSAPPPPPPPP 
 
WT  STKSSAITMPISAPVSTLKPTYKTINLPSHKIIIAGSAAGSRVSMAKGTSKRPDLLGSIIASM 
*   STKSSAITMPISAPVSTLKPTYKTINLPSHKIIIAGSAAGSRVSMAKGTSKRPDLLGSIIASM 
 
WT  DKPAGSGPNSNSSSSTSSATTNSSLSSYAGSNNSF 
*   DKPAGSGPNSNSSSSTSSATTNSSLSSYAGSNNSF 
 
  
